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A B S T R A C T
Background
Cryptococcal meningitis is a severe fungal infection that occurs primarily in the setting of advanced immunodeficiency and remains
a major cause of HIV-related deaths worldwide. The best induction therapy to reduce mortality from HIV-associated cryptococcal
meningitis is unclear, particularly in resource-limited settings where management of drug-related toxicities associated with more potent
antifungal drugs is a challenge.
Objectives
To evaluate the best induction therapy to reduce mortality fromHIV-associated cryptococcal meningitis; to compare side effect profiles
of different therapies.
Search methods
We searched theCochrane InfectiousDiseasesGroupSpecializedRegister, CENTRAL,MEDLINE (PubMed), Embase (Ovid), LILACS
(BIREME), African IndexMedicus, and IndexMedicus for the South-East Asia Region (IMSEAR) from 1 January 1980 to 9 July 2018.
We also searched the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), ClinicalTrials.gov,
and the ISRCTN registry; and abstracts of select conferences published between 1 July 2014 and 9 July 2018.
Selection criteria
We included randomized controlled trials that compared antifungal induction therapies used for the first episode of HIV-associated
cryptococcal meningitis. Comparisons could include different individual or combination therapies, or the same antifungal therapies
with differing durations of induction (less than two weeks or two or more weeks, the latter being the current standard of care). We
included data regardless of age, geographical region, or drug dosage. We specified no language restriction.
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Data collection and analysis
Two review authors independently screened titles and abstracts identified by the search strategy. We obtained the full texts of potentially
eligible studies to assess eligibility and extracted data using standardized forms. The main outcomes included mortality at 2 weeks,
10 weeks, and 6 months; mean rate of cerebrospinal fluid fungal clearance in the first two weeks of treatment; and Division of AIDS
(DAIDS) grade three or four laboratory events. Using random-effects models we determined pooled risk ratio (RR) and 95% confidence
interval (CI) for dichotomous outcomes andmean differences (MD) and 95%CI for continuous outcomes. For the direct comparison of
10-week mortality, we assessed the certainty of the evidence using the GRADE approach. We performed a network meta-analysis using
multivariate meta-regression. We modelled treatment differences (RR and 95% CI) and determined treatment rankings for two-week
and 10-week mortality outcomes using surface under the cumulative ranking curve (SUCRA). We assessed transitivity by comparing
distribution of effect modifiers between studies, local inconsistency through a node-splitting approach, and global inconsistency using
design-by-treatment interaction modelling. For the network meta-analysis, we applied a modified GRADE approach for assessing the
certainty of the evidence for 10-week mortality.
Main results
We included 13 eligible studies that enrolled 2426 participants and compared 21 interventions. All studies were carried out in adults,
and all but two studies were conducted in resource-limited settings, including 11 of 12 studies with 10-week mortality data.
In the direct pairwise comparisons evaluating 10-week mortality, one study from four sub-Saharan African countries contributed data
to several key comparisons. At 10 weeks these data showed that those on the regimen of one-week amphotericin B deoxycholate (AmBd)
and flucytosine (5FC) followed by fluconazole (FLU) on days 8 to 14 had lower mortality when compared to (i) two weeks of AmBd
and 5FC (RR 0.62, 95% CI 0.42 to 0.93; 228 participants, 1 study), (ii) two weeks of AmBd and FLU (RR 0.58, 95% CI 0.39 to
0.86; 227 participants, 1 study), (iii) one week of AmBd with two weeks of FLU (RR 0.49, 95% CI 0.34 to 0.72; 224 participants,
1 study), and (iv) two weeks of 5FC and FLU (RR 0.68, 95% CI 0.47 to 0.99; 338 participants, 1 study). The evidence for each of
these comparisons was of moderate certainty. For other outcomes, this shortened one-week AmBd and 5FC regimen had similar fungal
clearance (MD 0.05 log10 CFU/mL/day, 95% CI -0.02 to 0.12; 186 participants, 1 study) as well as lower risk of grade three or four
anaemia (RR 0.31, 95% CI 0.16 to 0.60; 228 participants, 1 study) compared to the two-week regimen of AmBd and 5FC.
For 10-week mortality, the comparison of two weeks of 5FC and FLU with two weeks of AmBd and 5FC (RR 0.92, 95% CI 0.69 to
1.23; 340 participants, 1 study) or two weeks of AmBd and FLU (RR 0.85, 95% CI 0.64 to 1.13; 339 participants, 1 study) did not
show a difference in mortality, with moderate-certainty evidence for both comparisons.
When two weeks of combination AmBd and 5FC was compared with AmBd alone, pooled data showed lower mortality at 10 weeks
(RR 0.66, 95% CI 0.46 to 0.95; 231 participants, 2 studies, moderate-certainty evidence).
When two weeks of AmBd and FLU was compared to AmBd alone, there was no difference in 10-week mortality in pooled data (RR
0.94, 95% CI 0.55 to 1.62; 371 participants, 3 studies, low-certainty evidence).
One week of AmBd and 5FC followed by FLU on days 8 to 14 was the best induction therapy regimen after comparison with 11 other
regimens for 10-week mortality in the network meta-analysis, with an overall SUCRA ranking of 88%.
Authors’ conclusions
In resource-limited settings, one-week AmBd- and 5FC-based therapy is probably superior to other regimens for treatment of HIV-
associated cryptococcal meningitis. An all-oral regimen of two weeks 5FC and FLU may be an alternative in settings where AmBd is
unavailable or intravenous therapy cannot be safely administered. We found no mortality benefit of combination two weeks AmBd
and FLU compared to AmBd alone. Given the absence of data from studies in children, and limited data from high-income countries,
our findings provide limited guidance for treatment in these patients and settings.
P L A I N L A N G U A G E S U M M A R Y
Treatment for HIV-associated cryptococcal meningitis
What is the aim of this review?
The aim of this Cochrane Review was to find the best therapy to reduce the risk of death from cryptococcal meningitis in HIV-positive
individuals. The Cochrane review authors analysed data from relevant clinical trials to answer this question and found 13 relevant
studies.
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Key messages
Shorter initial treatment with one week of combined amphotericin B deoxycholate and flucytosine probably results in lower risk of
death than longer treatment with two weeks of combination amphotericin B deoxycholate and flucytosine that has traditionally been
recommended in treatment guidelines. The shorter treatment likely results in similar clearance of the infection with less toxicity from
the drugs used for treatment.Where amphotericin B deoxycholate cannot be given, two weeks of combined flucytosine with fluconazole
is likely a good treatment option. Given the absence of data from studies in children, and limited data from high-income countries,
our findings provide limited guidance for treatment in these patients and settings.
What was studied in this review?
HIV-associated cryptococcal meningitis is a severe fungal infection of the brain and surrounding membranes that causes about 15%
of HIV-related deaths worldwide. Infection occurs mostly in people with advanced HIV/AIDS and most deaths from cryptococcal
meningitis occur in resource-limited countries. Treatment includes initial antifungal therapy followed by continuation treatment with
oral fluconazole. Previous guidelines have recommended two weeks of combination intravenous amphotericin B and oral flucytosine as
the best available treatment. However, due to the high cost of treatment and limited availability of these potent antifungal drugs as well
as challenges in managing common drug toxicities, resource-limited countries often use less effective therapies such as oral fluconazole
alone.
The review authors compared different antifungal drugs used for initial therapy of HIV-associated cryptococcal meningitis to determine
the best treatment to reduce the risk of death. Several recent clinical trials included in this review studied shorter initial treatment
courses or all-oral treatments for cryptococcal meningitis to reduce drug toxicity and improve affordability in resource-limited countries
where most infections occur.
What are the main results of the review?
The 13 studies included 2426 people and directly compared 21 different therapies. All studies were carried out in adults, and all but
two studies were conducted in resource-limited settings, including 11 of 12 studies with 10-week mortality data. One recent large
study conducted in adults from four countries in Africa contributed to 10 of these comparisons. This study found that one week of
combination intravenous amphotericin B deoxycholate and oral flucytosine followed by fluconazole probably resulted in a lower risk
of death within 10 weeks than two weeks of combination amphotericin B deoxycholate and flucytosine (moderate-certainty evidence).
The rate of fungal reduction measured in cerebrospinal fluid did not differ between the treatment groups but a shorter duration of
amphotericin B deoxycholate and flucytosine was associated with lower risk of life-threatening toxicities measured through blood
testing. These results suggest that shorter one week treatment with amphotericin B deoxycholate and flucytosine is probably better
than two weeks of amphotericin B deoxycholate and flucytosine.
In this same study, one week of amphotericin B deoxycholate and flucytosine probably resulted in a lower risk of death than a
combination of oral flucytosine and fluconazole (moderate-certainty evidence). However, risk of death was similar between oral
flucytosine and fluconazole and two weeks of amphotericin B deoxycholate and flucytosine (moderate-certainty evidence). Where
intravenous amphotericin B therapy is not available or cannot be safely given to patients, this suggests that combination therapy with
oral flucytosine and fluconazole is a good alternative treatment.
Due to the lack of data from studies in children, and limited data from high-income countries, our findings provide limited guidance
for treatment in these patients and settings.
How up-to-date is this review?
The review authors initially searched for studies up to 9 July 2018.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
One week of AmBd + 5FC compared to two weeks of AmBd + 5FC for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 1 week of AmBd + 5FC
Comparison: 2 weeks of AmBd + 5FC
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ 5FC
Risk with 1 week of AmBd
+ 5FC
Mortality: 10 weeks 383 per 1000 237 per 1000
(161 to 356)
RR 0.62
(0.42 to 0.93)
228
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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B A C K G R O U N D
Description of the condition
Cryptococcal meningitis is a severe fungal infection primarily seen
in people with compromised cell-mediated immunity. Most cases
occur in the context of advancedHIV disease (defined as cluster of
differentiation 4 (CD4) cell count < 200 cells/mm3), with the risk
increasing with decreasing CD4 cell count. Rollout of combined
antiretroviral therapy (ART) in the 1990s led to a large decline in
incident HIV-associated cryptococcal meningitis in high-income
countries, but a large burden of disease still exists in resource-
limited settings (Dromer 2004; Pyrgos 2013; Rajasingham 2017).
This reflects, in part, an enduring high proportion of HIV-posi-
tive individuals who present late for care due to delays in HIV di-
agnosis and linkage to care (Anderegg 2017). However, a growing
proportion of cases (approximately 50%) are now seen in ART-
experienced individuals, reflectingARTdefault and treatment fail-
ure (Beardsley 2016; Rhein 2016; Scriven 2016). In 2014, an esti-
mated 223,100 incident cases and 181,100 deaths occurred glob-
ally, and cryptococcal meningitis is estimated to cause up to 15%
of HIV-related deaths (Rajasingham 2017). Approximately 73%
of cases are estimated to occur in sub-Saharan Africa.
Cryptococccal meningitis is caused by environmental yeast species
Cryptococcus neoformans and Cryptococcus gattii. C neoformans has
a worldwide distribution and causes clinical disease in immuno-
compromised individuals, whereas C gattii has a more limited ge-
ographical distribution and is also associated with disease in im-
munocompetent hosts (Chen 2000). A typically asymptomatic
primary pulmonary infection occurs after inhalation of fungal
spores or desiccated yeast. In the absence of an effective immune
response to clear or contain infection, yeast can spread to the cen-
tral nervous system (CNS) to cause a severe meningoencephalitis.
Clinical presentation is subacute, and commonly includes fever,
headache, neck stiffness, altered mental status, vomiting, and neu-
rological deficits such as cranial nerve palsies (Moosa 1997; Day
2013).
Diagnostic confirmation of cryptococcal meningitis relies on lum-
bar puncture (LP), which is also an essential part of management
to lower raised intracranial pressure. Use of India ink stain to de-
tect yeast in cerebrospinal fluid (CSF) is commonly performed in
resource-limited settings. Testing is cheap, rapid, and requires lim-
ited laboratory infrastructure, but has poor sensitivity (Boulware
2014a). Culture, considered the gold standard for diagnosis, is
more sensitive but is more expensive, requires additional labo-
ratory infrastructure and expertise, and results are delayed while
yeast grow in culture media. Various cryptococcal antigen (CrAg)
assays are available that provide rapid results, and CrAg testing of
CSF by latex agglutination or, preferably, lateral flow assay is rec-
ommended by the World Health Organization (WHO) (WHO
2018). Cryptococcal antigen testing can also be performed on
serum or plasma. Although a positive test from a blood sample
is not specific for CNS disease, initiation of treatment for cryp-
tococcal meningitis based on a positive test of serum or plasma
is recommended if LP cannot be performed or is clinically con-
traindicated (WHO 2018).
Description of the intervention
Polyenes, azoles, and the pyrimidine analog flucytosine (5FC),
are the mainstays of treatment for cryptococcal meningitis. Per
WHO guidelines (issued in 2011) and Infectious Disease Society
of America guidelines (issued in 2010), the preferred induction
therapy for adults includes intravenous (IV) amphotericin deoxy-
cholate (AmBd) (0.7 to 1 mg/kg daily) and oral 5FC (100 mg/
kg daily in four divided doses) for a minimum of two weeks, fol-
lowed bymaintenance oral fluconazole (400 to 800 mg daily) for a
minimum of eight additional weeks (Perfect 2010; WHO 2011).
Liposomal amphotericin (AmB) is less nephrotoxic but more ex-
pensive than AmBd, and IV liposomal AmB (3 to 4 mg/kg daily)
or IV AmB lipid complex (5 mg/kg daily) may be substituted for
AmBd during the induction phase of treatment (Perfect 2010). A
phase three clinical trial conducted in Vietnam comparing AmBd
1 mg/kg daily and 5FC 100 mg/kg daily to AmBd 1 mg/kg daily
alone found a statistically significant mortality benefit of combina-
tion therapy, providing evidence for these recommendations (Day
2013). Treatment guidelines provide tiered recommendations for
alternative regimens if first-line therapy cannot be administered.
Intravenous amphotericin has strong fungicidal activity, and treat-
ment for at least 14 days has been considered first-line therapy
(Perfect 2010; WHO 2011). Major drug-related adverse effects
include nephrotoxicity, hypokalaemia, and anaemia, and ther-
apy should include IV fluid hydration, potassium supplementa-
tion, and regular laboratory monitoring for haematological and
metabolic toxicities (Bicanic 2015). The relatively high cost of
treatment, requirement of IV administration, and limited ability
to monitor for drug-related toxicities in many settings often re-
sult in the use of alternative oral antifungal regimens, primarily
fluconazole. To reduce the cost of treatment and promote greater
use in resource-limited settings, recent trials have evaluated the ef-
ficacy of AmB-based induction therapy for a duration of less than
14 days (Muzoora 2012; Jarvis 2018; Molloy 2018).
Flucytosine, available orally or intravenously, is recommended
in combination with amphotericin as first-line therapy (Perfect
2010). Themost serious drug-related adverse effect of 5FC is bone
marrow suppression. Hepatotoxicity is also a drug-related toxic-
ity, and patients commonly experience gastrointestinal symptoms
(Vermes 2000). These serious adverse effects are uncommon with
current dosing recommendations (Loyse 2013a). Flucytosine is
practical because of oral availability but is expensive and unavail-
able in most high-burden, resource-limited settings and unregis-
tered throughout Africa (Loyse 2013b).
Fluconazole, an azole drug, is recommended as maintenance ther-
apy for cryptococcal meningitis. However, it is often used for in-
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duction therapy in resource-limited settings due to its low cost
(including through a donation programme) and oral formulation.
Fluconazole monotherapy is associated with very high mortality
compared to amphotericin-based regimens (Bicanic 2006; Schaars
2006; Rothe 2013). Fluconazole demonstrates weak Cryptococcus
spp. killing activity compared to amphotericin, although dose esca-
lation studies show improved fungal killing at high doses without
a significant increase in drug-related side effects (Bicanic 2007;
Longley 2008; Milefchik 2008).
Several adjunctive drugs have also been evaluated for the treat-
ment of cryptococcal meningitis in combination with traditional
antifungal therapies. These include therapies with immunomod-
ulatory functions such as dexamethasone and interferon-gamma,
acetazolamide to lower intracranial pressure, and sertraline, an
antidepressant that also demonstrates antifungal activity against
Cryptococcus spp. in in vitro and in animal models (Jarvis 2012;
Zhai 2012; Beardsley 2016; Rhein 2016).
In addition to the choice and dose of drug therapy, a number
of other factors influence outcomes of treatment for HIV-associ-
ated cryptococcal meningitis. The accumulation of yeast or shed
capsular polysaccharides may obstruct CSF reabsorption at arach-
noid granulations, leading to elevated intracranial pressure (Loyse
2010). Elevated intracranial pressure is independently associated
with mortality, and therapeutic LP after initial diagnostic LP may
decrease the risk of death (Bicanic 2009;Meda 2014; Rolfes 2014).
Standard electrolyte supplementation and IV fluids with ampho-
tericin therapy may also decrease mortality (Bahr 2014). Further-
more, several randomized controlled trials (RCTs) have demon-
strated reduced mortality when ART is delayed for several weeks
with either amphotericin- or fluconazole-based regimens, which
is possibly explained by early immune reconstitution with ART
causing deleterious inflammation in response to living or dead
yeast components within the contained CNS space (Makadzange
2010; Bisson 2013; Boulware 2014b).
How the intervention might work
Antifungal therapies with activity against Cryptococcus spp. act by
various mechanisms (Table 1). Fluconazole and other azoles in-
hibit biosynthesis of ergosterol, which is essential in fungal cell
membranes; polyenes bind to fungalmembrane sterols and disrupt
cell membranes; and flucytosine is a pyrimidine analog that blocks
fungal ribonucleic acid (RNA) and protein biosynthesis. Among
adjunctive treatments, sertraline is fungicidal against Cryptococcus
spp. in in vitro and animal studies, although the mechanism of ac-
tion is unclear. Other adjunctive therapies may improve outcomes
through modulation of the immune response or by lowering ele-
vated intracranial pressure.
Why it is important to do this review
HIV-associated cryptococcal meningitis is a significant cause of
mortality in HIV-positive individuals, particularly people with
advanced HIV disease in resource-limited settings, and results
in up to 15% of HIV-related deaths (Rajasingham 2017). Al-
though guidelines exist for the antifungal management of cryp-
tococcal meningitis, recommendations are based on limited data
from RCTs, and in clinical practice treatment is highly variable
due to drug costs, availability, and ability to monitor and man-
age drug-related toxicities (Perfect 2010). A Cochrane Review on
treatment for HIV-associated cryptococcal meningitis was pub-
lished in 2008, but a number of clinical trials comparing new in-
duction regimens as well as several novel therapies have since been
published (Sloan 2008).
Evaluationofmultiple treatment regimens in predominately small,
phase two clinical trials, and a large number of potential inde-
pendent pairwise comparisons provides a rationale for including
a network meta-analysis (NMA) in a systematic review of these
treatment regimens. Furthermore, given the lack of availability or
affordability of widely accepted first-line two-week AmB and 5FC
combination therapy inmost resource-limited settings, which have
the overwhelming burden of disease, a ranking of alternative reg-
imens by NMA will support the development of evidence-based
guidance of best treatment options in the context of common re-
source constraints.
A previous systematic review and NMA on the treatment of
HIV-associated cryptococcal meningitis was published (Campbell
2015). However, the review combined data from RCTs with co-
hort and other non-randomized trials, and included re-treatment
cases. Additionally, several RCTs evaluating short-course induc-
tion regimens and novel adjunctive therapies have since been pub-
lished. This Cochrane Review and NMA therefore incorporates
new evidence to inform the best antifungal regimens for the treat-
ment of HIV-associated cryptococcal meningitis.
O B J E C T I V E S
• To evaluate the best induction therapy to reduce mortality
from HIV-associated cryptococcal meningitis
• To compare side effect profiles of different therapies
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We included RCTs that included participants assigned to different
induction regimens. We excluded non-randomized studies.
Types of participants
Inclusion criteria
We included studies limited to HIV-positive individuals with first
episode of cryptococcal meningitis, diagnosed by positive CSF
India ink stain, fungal culture, or cryptococcal antigen (CrAg)
test. Inclusion was not limited by ART status at enrolment (ART
naive or experienced). Studies could be unblinded, single-blinded,
or double-blinded.
Exclusion criteria
We excluded studies that had re-treatment cases, as these may
be associated with antifungal resistance or may represent partially
treated cases (Bicanic 2006). As a serum and plasma CrAg test-
ing is not specific for CNS cryptococcal infection, we excluded
any studies that included participants based on a positive blood
test or clinical suspicion without microbiological confirmation of
CSF. We also excluded cryptococcal antigen screening studies for
cryptococcal meningitis prevention. We assessed the amount of
and reasons for missing data in studies. We excluded studies with
significant (> 20%) loss to follow-up. We also excluded studies
with significant imbalances between groups in clinically relevant
parameters (such as baseline severity of disease or CD4 count).
Types of interventions
Interventions
Interventions included the following antifungal drugs or drug
classes used for induction therapy: amphotericin B deoxycholate,
liposomal/lipid formation amphotericin B, flucytosine, azole
drugs, and adjunctive therapies (including but not limited to ac-
etazolamide, dexamethasone, interferon-gamma, and sertraline).
We did not limit study inclusion by duration of induction therapy
or by drug dosage.
Comparisons
We considered studies comparing any combination of the follow-
ing interventions.
• AmB deoxycholate for at least two weeks
• AmB deoxycholate for less than two weeks
• Liposomal/lipid complex AmB for at least two weeks
• Liposomal/lipid complex AmB for less than two weeks
• Azole drugs
• 5FC
• Adjunctive therapies (for example, sertraline,
dexamethasone, acetazolamide, interferon-gamma (IFNg))
Types of outcome measures
Our primary treatment outcome was mortality. Our secondary
outcomeswere drug-related adverse events and rate of fungal clear-
ance. Early fungicidal activity (EFA), or mean rate of fungal clear-
ance in the first two weeks of antifungal therapy, has been shown
to correlate with mortality and is frequently reported in phase two
studies that are not powered to detect mortality differences and to
inform larger studies (Bicanic 2009).
Primary outcomes
• Mortality, subdivided into:
◦ short term (within two weeks)
◦ medium term (within 10 weeks)
◦ long term (up to six months)
Secondary outcomes
• Mean rate of fungal clearance (early fungicidal activity) in
the first two weeks of antifungal therapy.
• Serious adverse events related to therapy: we described
grade three (severe) and grade four (potentially life-threatening)
laboratory events according to Division of AIDS (DAIDS)
definitions for main laboratory abnormalities associated with
antifungal drugs (DAIDS 2014). We limited comparisons to
anaemia, neutropenia, nephrotoxicity, hepatotoxicity (alanine
aminotransferase (ALT) elevation), and hypokalaemia.
Search methods for identification of studies
We attempted to identify all potential studies regardless of lan-
guage or publication status (published, unpublished, in press, and
in progress). We restricted searches to studies published since 1
January 1980. We did not initially include search filters for study
design.
Electronic searches
We searched the Cochrane Infectious Diseases Group Specialized
Register, CENTRAL, MEDLINE (PubMed), Embase (Ovid),
LILACS (BIREME), African Index Medicus, and Index Medi-
cus for the South-East Asia Region (IMSEAR) using the search
strategy detailed in Appendix 1, including HIV-related search
terms, search terms for cryptococcal meningitis, and search terms
for antifungal and adjunctive therapies. We also searched the
World Health Organization International Clinical Trials Reg-
istry Platform (WHO ICTRP) ( www.who.int/ictrp/search/en/),
ClinicalTrials.gov ( clinicaltrials.gov), and the ISRCTN registry (
www.isrctn.com/) to identify ongoing trials, using ‘HIV’, ‘AIDS’,
‘cryptococcal meningitis’, and ‘antifungal agents’ as search terms.
We searched from 1 January 1980 up to 9 July 2018 without lan-
guage restriction.
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Searching other resources
We searched for recent studies (1 July 2014 to 9 July 2018) of
HIV-associated cryptococcal meningitis from select conferences:
• Conference on Retroviruses and Opportunistic Infections
(CROI);
• all conferences of the International AIDS Society (IAS);
• International Conference on Cryptococcus and
Cryptococcosis (ICCC);
• Infectious Diseases Society of America (IDSA) IDWeek.
We checked the reference lists of all included studies.We contacted
leading researchers to identify any unpublished data.
Data collection and analysis
Selection of studies
We aggregated articles that we had obtained from the electronic
database via the search strategy and de-duplicated in EndNote
(EndNote 2013). Two review authors (MWT and AES) indepen-
dently screened the titles and abstracts of these articles for po-
tential eligibility. Two review authors (MWT and AES) obtained
and assessed the full-texts of potentially eligible articles, and both
completed study eligibility forms (Appendix 2). Both review au-
thors evaluated articles for possible duplicated reporting, and one
review author (MWT) contacted study authors for additional in-
formation as needed. We resolved any discrepancies regarding el-
igibility of individual studies through discussion or through ad-
judication by additional review authors (NF and JNJ) when nec-
essary. We documented search results using a flow diagram fol-
lowing PRISMA recommendations, including unique articles re-
trieved from the initial search, number of titles excluded by review
of title and abstract, and number of articles retrieved in full text
(Moher 2009). We listed excluded RCTs, with a brief justification
for exclusion, in the ‘Characteristics of excluded studies’ table.We
did not exclude any studies based on language.
Data extraction and management
Two review authors (MWT and AES) independently used a stan-
dardized data extraction form to obtain study information, includ-
ing data outlined in Appendix 3.
Assessment of risk of bias in included studies
We assessed risk of bias with the Cochrane ‘Risk of bias’ tool
(Higgins 2011). We graded studies as at either ‘low’, ‘high’, or
‘unclear risk’ within seven domains: random sequence generation,
allocation concealment, blinding of participants and personnel,
blinding of outcome assessment, incomplete outcome data, selec-
tive reporting, and bias due to problems not covered elsewhere.
We generated a ‘Risk of bias’ summary figure for included studies.
Measures of treatment effect
In the analysis of RCTs, we displayed mortality at each mortal-
ity endpoint for interventions using forest plots. In each pair-
wise comparison, for dichotomous outcome measures (for exam-
ple, two-week mortality) we obtained risk ratios (RRs) with 95%
confidence interval (CI). For continuous outcomes (for example,
rate of fungal clearance), we calculated pairwise mean differences
(MDs) with 95% CI.
Relative ranking
We generated ranking probabilities for each intervention, taking
into account each possible rank and cumulative ranking probabil-
ities. We summarized the cumulative ranking probabilities using
the surface under the cumulative ranking area (SUCRA) values
(Salanti 2011). The SUCRA value represents the probability that
a treatment will present the best outcome with no uncertainty and
was used to develop a hierarchy of treatments for HIV-associated
cryptococcal meningitis.
Unit of analysis issues
Our unit of analysis was HIV-positive individuals treated for an
initial episode of cryptococcal meningitis.
Cluster-randomized trials
Cluster-randomised trials were eligible for inclusion if methods
were used that adjusted for clustering of data to analyse effect
estimates at the level of the individual. We did not find studies
with cluster-randomized designs.
Cross-over randomized clinical trials
We excluded any cross-over randomized clinical trials.
Repeated observations on participants
We assessed individual-level mortality outcomes for different peri-
ods of follow-up including short-term (two-week), medium-term
(up to 10 weeks), and long-term (up to six months) time frames.
Multiple treatment events
We excluded studies that included re-treatment cases of HIV-
associated cryptococcal meningitis.
Trials with multiple treatment groups
Cryptococcal meningitis trials may compare more than two treat-
ment groups. We collected data for all comparator arms and anal-
ysed multi-arm trials as multiple separate two-arm trials in pair-
wisemeta-analysis.We accounted for the correlationwithinmulti-
arm trials in the NMA (see Data synthesis).
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Dealing with missing data
Wedescribed missing participant, intervention, and outcome data
within included studies. We contacted original investigators to
request relevant missing data. For binary outcomes, we performed
intention-to-treat analyses. We considered participants who were
lost to follow-up as alive after loss to follow-up. Given the severity
of the primary outcome (death) and high risk of bias, we excluded
studies that had a significant loss to follow-up within six months
(> 20%). Loss to follow-up for the 13 studies included in our
analysis was very low (median < 1%) and believed to be unlikely
to significantly bias results.
Assessment of heterogeneity
We considered the following potential causes of clinical and
methodological heterogeneity: ART status, timing of ART, study
settings (resource-limited country versus high-income country),
inclusion of participants with abnormal mental status (for exam-
ple, Glasgow coma score less than 15), one or more LP after diag-
nostic LP (lowering of intracranial pressure), dosing of antifungal
therapy, risk of bias (assessed by ‘Risk of bias’ tool).
We evaluated statistical heterogeneity using the tau2 and I2 values
in both comparison-specific and common heterogeneity pairwise
meta-analyses (see Data synthesis). We could not evaluate statis-
tical heterogeneity through visual inspection of forest plots, sub-
grouping, or meta-regression, as there were few studies contribut-
ing to each comparison.
Assessment of transitivity and inconsistency
The validity of NMA relies on the assumption of transitivity -
that the sets of trials in each comparison are similar other than the
intervention, allowing meaningful indirect comparisons of inter-
ventions that were not evaluated in the same study. We evaluated
transitivity by assessing the distribution of effect modifiers across
studies. We also examined inconsistency, the statistical agreement
between direct and indirect estimates.
We evaluated local consistency between direct and indirect com-
parisons using the node-splitting and loop-specific approaches,
and global consistency using design-by-treatment interaction
modelling, which integrates loop inconsistencywith consideration
of design inconsistency (Dias 2010; Higgins 2012). If we identi-
fied inconsistency, we more closely examined the potential effect
modifiers in inconsistent loops and conducted a sensitivity analy-
sis excluding studies that may be sources of inconsistency.
Potential effect modifiers included the following.
• ART status
• Timing of ART
• Study settings (resource-limited country versus high-
income country)
• Inclusion of participants with abnormal mental status (for
example, Glasgow coma score less than 15)
• One or more LP after diagnostic LP (lowering of
intracranial pressure)
• Dosing of antifungal therapies
Assessment of reporting biases
We planned to assess reporting bias by examining asymmetry in
funnel plots of pairwise comparisons that had a sufficient number
of studies (at least 10), however there were too few studies for this
analysis. We planned to assess reporting bias across the network
using comparison-adjusted funnel plots (Chaimani 2013). As we
were not able to identify a meaningful treatment order and there
were too few studies per comparison, we did not carry out this
analysis.
Data synthesis
We first conducted pairwise meta-analyses for all direct compar-
isons using random-effects models. We conducted these analyses
assuming both comparison-specific heterogeneity (that is, each di-
rect comparison has a separate heterogeneity estimate) and a com-
mon heterogeneity across comparisons to determine tau2 and I
2 values. We performed pairwise meta-analyses using the ‘metan’
(for the comparison-specific heterogeneity analysis) and ‘mvmeta’
(for the common heterogeneity analysis) commands in Stata (Ver-
sion 13) (Stata 2013) and tools in Review Manager 5 (RevMan
2014).
We thenperformedNMA, combiningdirect outcomes datawithin
studies and indirect data across studies, to compare primary and
secondary outcomes from multiple interventions. We performed
NMA following themultivariatemeta-regression approach (White
2011; White 2012). We used random-effects models that account
for within-study correlation of multi-arm trials (Lu 2006). We
modelled treatment differences (log risk ratios for binary outcomes
and mean differences for continuous outcomes) and treatment
rankings. We performed network meta-analyses using the ‘net-
work’ suite of commands in Stata (Version 13) (White 2015).
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis to examine sources of
heterogeneity in studies when sufficient data were available, in-
cluding: ART status, timing of ART, study settings (resource-lim-
ited country versus high-income country), inclusion of partici-
pants with abnormal mental status (for example, Glasgow coma
score less than 15), one or more LP after diagnostic LP (lowering
of intracranial pressure), dosing of amphotericin, and dosing of
azole drug.
These analyses were limited due to the small number of included
studies and general lack of heterogeneity in the above factors.
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Sensitivity analysis
For studies with missing data or reporting of per-protocol results
on mortality, we planned to perform sensitivity analyses imputing
missing data under the best and worst cases (no missing partici-
pants experience the event or all missing participants experience
the event, respectively), but did not perform these analyses as the
amount of missing data was minimal in most included studies.
We excluded studies with > 20% missing mortality outcome data
within six months.
Presentation of results
We presented both a pairwise comparison analysis to show pooled
effect estimates and certainty of the evidence for all the direct com-
parisons, and a NMA to demonstrate the relative ranking of each
comparison. We reported pairwise estimates of treatment effects
in tables (for example, RRs and 95% CI for mortality and culture
clearance outcomes and MDs and 95% CI for rate of fungal clear-
ance) from both pairwise meta-analyses and network meta-analy-
ses along with a table of probability rankings based on SUCRA.
We generated a ‘Summary of findings’ table with mortality out-
comes by intervention group (absolute risk and risk ratio) along
with the number of studies and participants assigned to inter-
vention arm, certainty of the evidence (GRADE), and additional
comments as indicated. We also presented a GRADE assessment
using the CINeMA tool, which is based on modified approach
for NMA (Salanti 2014; CINeMA 2017). We limited GRADE
assessment to 10-week mortality for pairwise comparisons and the
NMA. The modified GRADE criteria we used were as follows.
GRADE assessment
Study limitations
• Serious limitations: comparison dominated by evidence at
unclear risk of bias. Downgraded by one level.
Imprecision
• Serious limitations: CI extends into clinically unimportant
effects. Downgraded by one level.
• Very serious limitations: CI extends into clinically
unimportant effects in both directions. Downgraded by two
levels.
Inconsistency
• Serious limitations: predictive interval for treatment effect
includes effects which change interpretation (neither
intervention favoured). Downgraded by one level.
Indirectness
• Serious limitations: insufficient evidence for the plausibility
of the transitivity assumption. Downgraded by one level. In the
presence of serious or very serious limitations due to
inconsistency, downgraded jointly with inconsistency.
R E S U L T S
Description of studies
Results of the search
We identified 1086 records of potentially eligible studies from the
electronic searches, and five records through additional sources.
From these, 13 were included in the review. The study selection
process is presented in Figure 1.
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Figure 1. Study flow diagram.
Included studies
Setting
We identified 13 RCTs that met our inclusion criteria. Most (11
of 13) were from resource-limited settings in sub-Saharan Africa
or Southeast Asia. One study was from North America (van der
Horst 1997), and one small study was from the Netherlands and
Australia (Leenders 1997). One study was conducted in the USA
and Thailand, with 70% of participants recruited from Thailand
(Pappas 2009). One study, conducted in Malawi, Zambia, Tanza-
nia, and Cameroon, contributed to 10 pairwise comparisons and
was the only study for nine of these comparisons (Molloy 2018).
Participants and study procedures
All studies were carried out in adults. Studies were similar with re-
spect to key characteristics that are known to influence mortality.
Early initiation of ART has been associated with higher mortal-
ity in HIV-positive patients with cryptococcal disease due to im-
mune reconstitution inflammatory syndrome (Boulware 2014b;
Makadzange 2010). In all studies that specified timing of ART ini-
tiation, ART was delayed for a minimum of two weeks. No study
excluded people with evidence of altered mental status, for exam-
ple depressed Glasgow coma scale score, which is associated with
worse outcomes (Jarvis 2014). In all but one study (Mayanja-Kizza
1998), patients were scheduled to receive at least one additional
LP after diagnostic LP during induction, an intervention that
reduces intracranial pressure and may improve survival (Bicanic
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2009; Meda 2014; Rolfes 2014). Use of combined ART at the
time of cryptococcal meningitis diagnosis was uncommon inmost
studies (< 10%); however, the threemost recently conducted stud-
ies found 32% to 59% of patients with reported ART exposure at
the time of enrolment. Loss to follow-up was uncommon in most
studies, ranging from 0 to 16% (median 2%) of participants.
Interventions
All studies evaluating amphotericin B deoxycholate-based therapy
(10 of 13 included studies) used the World Health Organization
recommended doses of 0.7 to 1.0 mg/kg/day (WHO 2011). Dose
of fluconazole ranged from 200 mg/day to 1200 mg/day. Flucy-
tosine dose was 100 mg/kg/day in four divided doses in all studies
that used this drug except one (Mayanja-Kizza 1998), which used
150 mg/kg/day in three divided doses. Details of the included
studies are presented in the Characteristics of included studies ta-
bles.
Outcomes
Mortality
Twenty-one direct comparisons for mortality were made in 13
studies. All studies that reported two-week mortality also followed
participants for a minimum of 10 weeks from enrolment. Four
studies reported six-month mortality.
Early fungicidal activity
Nine included studies provided mean early fungicidal activity
(EFA) values that compared 13 interventions.
DAIDS grade three/four laboratory toxicities
Eight of 13 studies reported laboratory toxicities according to the
DAIDS classification system: eight reported anaemia; eight re-
ported renal dysfunction; seven reported neutropenia; seven re-
ported hypokalaemia; and seven reported transaminase elevation.
Excluded studies
After de-duplication reduced the number of studies to 943, we
excluded 897 studies that were not RCTs and two studies that were
completed without results published in a peer-reviewed journal.
We excluded an additional 31 studies based on full-text review for
reasons described in the Characteristics of excluded studies table,
including four studies for significant baseline imbalances between
treatment groups and two for > 20% loss to follow-up.
Risk of bias in included studies
Risk of bias for the 13 included studies is summarized in Figure 2
and Figure 3.
Figure 2. ‘Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ‘Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All trials were randomized, but two studies did not state whether
random sequence generation was used and were therefore assessed
as at unclear risk of bias (van der Horst 1997; Mayanja-Kizza
1998). Similarly, five studies were at unclear bias for allocation
concealment because the method of allocation concealment was
not clearly stated (van der Horst 1997; Pappas 2009; Nussbaum
2010; Jackson 2012; Loyse 2012).
Blinding
Most studies did not blind participants, personnel, and outcome
assessors and were at high risk of bias for both domains. Only one
study was at low risk of bias for both domains (Beardsley 2016).
We did not downgrade GRADE assessments for performance or
detection bias for the other included studies, as we judged that
measurement of the primary outcome (mortality) was unlikely to
be biased due to lack of blinding.
Incomplete outcome data
All but one study was at low risk of attrition bias due to very low
loss to follow-up. One included study was at high risk of bias due
to 14% (8/58) loss to follow-up by six months (Mayanja-Kizza
1998).
Selective reporting
All but one study was at low risk of reporting bias and reported on
all prespecified primary and secondary outcomes. One study was
at unclear risk of reporting bias because primary and secondary
outcomes were not clearly stated, and the authors reported results
on multiple clinical and mycological outcomes (Leenders 1997).
Other potential sources of bias
Four studies had direct support from pharmaceutical manufactur-
ers of study drugs, or authors received research support fromman-
ufacturerswithout the role of the drug companies clearly stated and
were therefore assessed as at unclear risk of other potential sources
of bias (Leenders 1997; van der Horst 1997;Mayanja-Kizza 1998;
Pappas 2009).
Effects of interventions
See: Summary of findings for the main comparison One week
of AmBd + 5FC compared to two weeks of AmBd + 5FC for
HIV-associated cryptococcal meningitis; Summary of findings
2 One week of AmBd + 5FC compared to two weeks of AmBd
+ FLU for HIV-associated cryptococcal meningitis; Summary of
findings 3 One week of AmBd + 5FC compared to one week
of AmBd + FLU for HIV-associated cryptococcal meningitis;
Summary of findings 4 One week of AmBd + 5FC compared
to two weeks of 5FC + FLU for HIV-associated cryptococcal
meningitis; Summary of findings 5 Two weeks of 5FC + FLU
compared to two weeks of AmBd + 5FC for HIV-associated
cryptococcal meningitis; Summary of findings 6 Two weeks of
5FC + FLU compared to two weeks of AmBd + FLU for HIV-
associated cryptococcal meningitis; Summary of findings 7 Two
weeks of AmBd + 5FC compared to two weeks of AmBd for
HIV-associated cryptococcal meningitis; Summary of findings 8
Two weeks of AmBd + FLU compared to two weeks of AmBd for
HIV-associated cryptococcal meningitis; Summary of findings
9 Two weeks of AmBd + 5FC compared to two weeks of AmBd
+ FLU for HIV-associated cryptococcal meningitis; Summary of
findings 10 Two weeks of AmBd + FLU + steroids compared
to two weeks of AmBd + FLU for HIV-associated cryptococcal
meningitis; Summary of findings 11One week of AmBd + FLU
compared to two weeks of AmBd + FLU for HIV-associated
cryptococcal meningitis; Summary of findings 12 One week
of AmBd + FLU compared to two weeks of AmBd + 5FC for
HIV-associated cryptococcal meningitis; Summary of findings
13 One week of AmBd + FLU compared to two weeks of 5FC
+ FLU for HIV-associated cryptococcal meningitis; Summary of
findings 14 Two weeks of FLU compared to two weeks of 5FC
+ FLU for HIV-associated cryptococcal meningitis; Summary of
findings 15 Two weeks of L-AmB compared to two weeks of
AmBd for HIV-associated cryptococcal meningitis; Summary of
findings 16 Short-course L-AmB + FLU compared to two weeks
of L-AmB + FLU for HIV-associated cryptococcal meningitis;
Summary of findings 17 Two weeks of AmBd + 5FC + FLU
compared to two weeks of AmBd + 5FC for HIV-associated
cryptococcal meningitis; Summary of findings 18 Two weeks of
AmBd + 5FC + FLU compared to two weeks of AmBd + FLU for
HIV-associated cryptococcal meningitis; Summary of findings
19 Two weeks of AmBd + 5FC + FLU compared to two weeks
of AmBd for HIV-associated cryptococcal meningitis; Summary
of findings 20 One week of AmBd + 5FC + FLU compared
to one week of AmBd + FLU for HIV-associated cryptococcal
meningitis;Summaryoffindings 21Twoweeksof AmBd+5FC+
IFNg compared to two weeks of AmBd + 5FC for HIV-associated
cryptococcal meningitis
Pairwise comparisons
The results we present below for pairwise comparisons are derived
from our analysis assuming comparison-specific heterogeneity in
Review Manager 5. Our analyses in Stata assuming comparison-
specific and common heterogeneity produced similar results (re-
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sults not shown).
One week of amphotericin B deoxycholate with flucytosine
versus alternative regimens
One RCT conducted across nine centres inMalawi, Zambia, Tan-
zania, andCameroon provided data for these comparisons (Molloy
2018). This study was designed as a non-inferiority trial compar-
ing one-week amphotericin B deoxycholate (AmBd)-based regi-
mens, two-week AmBd-based regimens, and an all-oral regimen
of flucytosine (5FC) and fluconazole (FLU). Overall, 712 HIV-
positive adults with first episode of cryptococcal meningitis were
randomized 2:1:1:1:1 to (i) two weeks of 5FC 100 mg/kg/day and
FLU 1200 mg/day, (ii) two weeks of AmBd 1mg/kg/day and FLU
1200 mg/day, (iii) two weeks of AmBd 1 mg/kg/day and 5FC 100
mg/kg/day, (iv) one week of AmBd 1 mg/kg/day and FLU 1200
mg/day followed on days 8 to 14 by FLU 1200 mg/day, or (v) one
week of AmBd 1 mg/kg/day and 5FC 100 mg/kg/day followed by
FLU 1200 mg/day on days 8 to 14.
Mortality
At 10weeks, participants in the group receiving oneweek of AmBd
and 5FC followed by FLU on days 8 to 14 had lower mortality
than participants randomized to other induction therapies. At 10
weeks, there was a 38% reduced risk of death (risk ratio (RR)
0.62, 95% CI 0.42 to 0.93; 228 participants, 1 study, Analysis
1.1, Summary of findings for the main comparison: subgroup 2;
moderate-certainty evidence) compared to two weeks of AmBd
and 5FC; a 42% reduced risk of death (RR 0.58, 95% CI 0.39
to 0.86; 227 participants, 1 study, Analysis 2.1, Summary of
findings 2: subgroup 2; moderate-certainty evidence) compared
to two weeks of AmBd and FLU; a 51% reduced risk of death (RR
0.49, 95%CI 0.34 to 0.72; 224 participants, 1 study, Analysis 3.1,
Summary of findings 3: subgroup 2; moderate-certainty evidence)
compared to one week of AmB and FLU followed by FLU on
days 8 to 14; and a 32% reduced risk of death (RR 0.68, 95% CI
0.47 to 0.99; 338 participants, 1 study, Analysis 4.1, Summary of
findings 4: subgroup 2; moderate-certainty evidence) compared
to two weeks of 5FC and FLU.
All data were generated from a single trial with few overall events
(< 200). No direct comparisons were made to findings from high-
income settings, where mortality with two weeks of AmBd-based
induction regimens is observed to be lower (Saag 1991; van der
Horst 1997).
Early fungicidal activity
One week of AmBd and 5FC followed by FLU on days 8 to 14
did not result in significantly lower EFA compared to two weeks
of AmBd and 5FC (186 participants, 1 study, Analysis 1.2). The
mean rate of fungal clearance was higher with one week of AmBd
and 5FC followed by FLU on days 8 to 14 compared to two weeks
of AmBd and FLU (mean difference (MD) -0.07 log10 CFU/mL/
day, 95% CI -0.14 to 0.00; 192 participants, 1 study, Analysis
2.2); one week of AmBd and FLU followed by FLU on days 8 to
14 (MD -0.08 log10 CFU/mL/day, 95% CI -0.15 to -0.01; 179
participants, 1 study, Analysis 3.2); and two weeks of 5FC and
FLU (MD -0.18 log10 CFU/mL/day, 95% CI -0.24 to -0.12; 280
participants, 1 study, Analysis 4.2).
DAIDS grade three/four events
Compared to two weeks of AmBd and 5FC, a one-week regimen
of AmBd and 5FC was associated with a lower risk of grade three
or four anaemia (RR 0.31, 95% CI 0.16 to 0.60; 228 participants,
1 study, Analysis 1.3: subgroup 1). Compared to two weeks of
AmBd and FLU, a one-week regimen of AmBd and 5FC was
associated with a lower risk of grade three or four anaemia (RR
0.36, 95%CI 0.18 to 0.71; 227 participants, 1 study, Analysis 2.3:
subgroup 1) and renal toxicity (RR 0.29, 95% CI 0.10 to 0.85;
227 participants, 1 study, Analysis 2.3: subgroup 2). Compared
to one week of AmBd and FLU, a one-week regimen of AmBd
and 5FC was associated with a lower risk of grade three or four
anaemia (RR0.41, 95%CI 0.21 to 0.82; 224 participants, 1 study,
Analysis 3.3: subgroup 1). Compared to two weeks of 5FC and
FLU, a one-week regimen of AmBd and 5FCwas associated with a
higher risk of grade three or four hypokalaemia (RR 5.97, 95%CI
1.65 to 21.63; 338 participants, 1 study, Analysis 4.3: subgroup
4), but there was no difference with respect to other toxicities.
Two weeks of oral flucytosine and fluconazole versus
alternative regimens
One RCT from nine centres in Malawi, Zambia, Tanzania, and
Cameroon compared two weeks of an all-oral regimen of 5FC
100 mg/kg/day and FLU 1200 mg/day with several AmBd-based
induction regimens (Molloy 2018). This phase three study was
designed as a non-inferiority trial.
Mortality
At two weeks, there was no significant difference in mortality in
participants randomized to two weeks of 5FC and FLU compared
to participants randomized to two weeks of AmBd 1 mg/kg/day
and 5FC 100 mg/kg/day (340 participants, 1 study, Analysis
5.1: subgroup 1) or two weeks of AmBd 1 mg/kg/day and FLU
1200 mg/day (339 participants, 1 study, Analysis 6.1: subgroup
1). By 10 weeks, there was no difference in mortality in the 5FC
and FLU group compared to the group receiving two weeks of
AmBd and 5FC (340 participants, 1 study, Analysis 5.1, Summary
of findings 5: subgroup 2; moderate-certainty evidence) or the
group receiving two weeks of AmBd and FLU (339 participants, 1
study, Analysis 6.1, Summary of findings 6: subgroup 2;moderate-
certainty evidence).
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Early fungicidal activity
The mean rate of fungal clearance was lower with two weeks of
5FC and FLU than with two weeks of AmBd and 5FC (MD
0.23 log10 CFU/mL/day, 95% CI 0.17 to 0.29; 270 participants,
1 study, Analysis 5.2) as well as with two weeks of AmBd and
FLU (MD 0.11 log10 CFU/mL/day, 95% CI 0.05 to 0.17; 276
participants, 1 study, Analysis 6.2).
DAIDS grade three/four events
The risk of DAIDS grade three or four anaemia (RR 0.17, 95%
CI 0.09 to 0.32; 340 participants, 1 study, Analysis 5.3: subgroup
1) and hypokalaemia (RR 0.22, 95%CI 0.06 to 0.83; 340 partici-
pants, 1 study, Analysis 5.3: subgroup 4) was lower in the 5FC and
FLU arm compared with the arm receiving two weeks of AmBd
and 5FC. The risk of DAIDS anaemia (RR 0.20, 95% CI 0.10
to 0.39; 339 participants, 1 study, Analysis 6.3: subgroup 1) and
hypokalaemia (RR 0.17, 95% CI 0.05 to 0.61; 339 participants,
1 study, Analysis 6.3: subgroup 4) was lower in the 5FC and FLU
arm compared with the arm receiving two weeks of AmBd and
FLU. The risk of renal toxicity (RR 0.40, 95% CI 0.19 to 0.85;
339 participants, 1 study, Analysis 6.3: subgroup 2) was also lower
with 5FC and FLU compared to those receiving two weeks of
AmBd and FLU.
Two weeks of amphotericin B deoxycholate and flucytosine
versus two weeks of amphotericin B deoxycholate
Three studies compared induction with two weeks of AmBd and
5FC versus two or more weeks of AmBd alone. These included
a small trial from Thailand (Brouwer 2004), a large trial from
Vietnam (Day 2013), and a large trial from the USA (van der
Horst 1997). The trial from the USA reported similar and very
lowmortality by two weeks in both groups (6%). After two weeks,
investigators randomized participants who were clinically stable
or improving to fluconazole or itraconazole consolidation. Due to
risk of bias related to exclusion of participants who were not stable
or improving, we did not evaluate outcomes beyond two weeks
for this study. Amphotericin B deoxycholate alone was continued
for four weeks in the study from Vietnam, but for two weeks in
the other studies.
Mortality
At two weeks, there was a non-significant reduction inmortality in
participants who received combination AmBd and 5FC compared
toAmBd alone (612 participants, 3 studies, Analysis 7.1: subgroup
1; Figure 4) but a significant mortality reduction at 10 weeks (RR
0.66, 95% CI 0.46 to 0.95; 231 participants, 2 studies, Analysis
7.1, Summary of findings 7: subgroup 2; Figure 4; moderate-
certainty evidence). The study fromVietnam followedparticipants
up to six months and found a persistent survival benefit with
combined AmBd and 5FC (RR 0.64, 95% CI 0.46 to 0.88; 199
participants, 1 study, Analysis 7.1: subgroup 3).
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Figure 4. Forest plot of comparison: 7 Two weeks of AmBd + 5FC versus two weeks of AmBd, outcome: 7.1
Mortality.
Early fungicidal activity
Pooled data showed an improved rate of fungal clearance with
combined AmBd and 5FC compared to AmBd alone (MD -0.15
log10 CFU/mL/day, 95% CI -0.26 to -0.04; 225 participants, 2
studies, Analysis 7.2; Figure 5).
Figure 5. Forest plot of comparison: 7 Two weeks of AmBd + 5FC versus two weeks of AmBd, outcome: 7.2
Early fungicidal activity.
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DAIDS grade three/four events
In one study that evaluated DAIDS toxicity (Day 2013), neu-
tropenia was more common with combined AmBd and 5FC than
with AmBd alone (RR 4.46, 95% CI 0.99 to 20.10; 199 partic-
ipants, 1 study, Analysis 7.3: subgroup 3), but the risk of other
toxicities did not differ between groups. The study combined el-
evated transaminases as a safety outcome but did not report ab-
normal alanine aminotransferase individually. In the AmBd and
5FC group, 6/100 experienced transaminitis versus 11/99 in the
AmBd group.
Two weeks of amphotericin B deoxycholate and fluconazole
versus two weeks of amphotericin B deoxycholate
Three studies compared two weeks of AmBd and FLUwith at least
two weeks of AmBd alone, including a small study from Thailand
(Brouwer 2004), a large study from Vietnam (Day 2013), and a
small study from theUSA and Thailand (Pappas 2009). The study
from Thailand used a low dose of FLU (400 mg/day) combined
with AmBd, and the study from the USA and Thailand had one
intervention with a low dose (400 mg/day) and one with a higher
dose (800 mg/day) of FLU with AmBd. The study from Vietnam
administered FLU at 800 mg/day. Amphotericin B deoxycholate
alone was continued for four weeks in the Day 2013 study, but
for two weeks in the other studies.
Mortality
No significant difference in mortality was observed at two weeks
(371 participants, 3 studies, Analysis 8.1: subgroup 1; Figure 6) or
10 weeks (371 participants, 3 studies, Analysis 8.1, Summary of
findings 8: subgroup 2; Figure 6; low-certainty evidence) follow-
up. A single study found no significant improvement in survival
with combined therapy compared to AmBd alone (198 partici-
pants, 1 study, Analysis 8.1: subgroup 3) with follow-up to six
months (Day 2013). Considering only participants who received
AmBd with high-dose FLU (the currently recommended dose of
800 mg/day or higher) versus AmBd alone, again no significant
difference in mortality was observed at two weeks, 10 weeks, or
six months.
Figure 6. Forest plot of comparison: 8 Two weeks of AmBd + FLU versus two weeks of AmBd, outcome: 8.1
Mortality.
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Early fungicidal activity
Based on pooled data from two studies, rate of fungal clearance
did not differ between AmBd with FLU and AmBd arms (223
participants, 2 studies, Analysis 8.2; Figure 7).
Figure 7. Forest plot of comparison: 8 Two weeks of AmBd + FLU versus two weeks of AmBd, outcome: 8.2
Early fungicidal activity.
DAIDS grade three/four events
Based on one study (Day 2013), risk of anaemia was lower with
combined AmBd and FLU compared to AmBd alone (RR 0.63,
95% CI 0.43 to 0.91; 198 participants, 1 study, Analysis 8.3).
However, participants randomized to AmBd alone received a
longer dose of the drug compared to the combination AmBd and
FLU arm (four weeks versus two weeks), which is a plausible ex-
planation for this finding. The risk of other toxicities did not differ
between groups. The study reported elevated transaminases but
did not report abnormal alanine aminotransferase individually. In
the AmBd and FLU group, 14/99 experienced transaminitis ver-
sus 11/99 in the AmBd group.
Two weeks of amphotericin B deoxycholate and flucytosine
versus two weeks of amphotericin B deoxycholate and
fluconazole
FourRCTs compared twoweeks of AmBdand5FCwith twoweeks
of AmBd and FLU, including one small study from Thailand
(Brouwer 2004), one large study from Vietnam (Day 2013), one
small study from South Africa (Loyse 2012), and one large study
from nine centres in Malawi, Zambia, Tanzania, and Cameroon
(Molloy 2018). The South African study randomized participants
to receive FLU 800 mg/day (22 participants), FLU 1200 mg/day
(23 participants), or voriconazole 600 mg/day (13 participants)
combined with AmBd, with azole therapies combined in the anal-
ysis. The Vietnam and multisite studies used FLU doses of 800
mg/day and 1200 mg/day, respectively. The Thailand study ran-
domized some participants to low-dose FLU (400 mg/day).
Mortality
Two weeks of AmBd and 5FC had a non-significant survival ben-
efit compared to two weeks of AmBd and FLU at two weeks (538
participants, 4 studies, Analysis 9.1: subgroup 1; Figure 8); at
10 weeks (538 participants, 4 studies, Analysis 9.1, Summary of
findings 9: subgroup 2; Figure 8; low-certainty evidence); and at
six months (199 participants, 1 study, Analysis 9.1: subgroup 3;
Figure 8).
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Figure 8. Forest plot of comparison: 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU,
outcome: 9.1 Mortality.
Early fungicidal activity
The pooled mean rate of fungal clearance was better with two
weeks of AmBd and 5FC than with two weeks of AmBd and
FLU (MD -0.09 log10 CFU/mL/day, 95% CI -0.14 to -0.05; 474
participants, 4 studies, Analysis 9.2; Figure 9).
Figure 9. Forest plot of comparison: 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU,
outcome: 9.2 Early fungicidal activity.
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DAIDS grade three/four events
Based on combineddata from three studies, we foundnodifference
in DAIDS grade three or four laboratory events (507 participants,
3 studies, Analysis 9.3).
Adjunctive steroid therapy
One large study, a double-blinded RCT from Vietnam, Thailand,
Indonesia, Laos, Uganda, and Malawi, randomized 451 partici-
pants 1:1 to receive two weeks of AmBd and FLU with adjunctive
dexamethasone or two weeks of AmBd and FLU only (Beardsley
2016).
The investigators planned enrolment of 880 participants. How-
ever, interim analysis from the data and safety monitoring board
recommended study termination due to findings of harm associ-
ated with dexamethasone use across key outcomes, including rate
of fungal clearance, risk of adverse events, and patient disability.
Mortality
Investigators found non-significant increases in mortality in the
dexamethasone arm by 10 weeks (450 participants, 1 study,
Analysis 10.1, Summary of findings 10: subgroup2; high-certainty
evidence) and by six months (450 participants, 1 study, Analysis
10.1: subgroup 3).
Early fungicidal activity
Themean rate of fungal clearance was lower in the dexamethasone
arm than in the placebo arm (MD 0.10 log10 CFU/mL/day, 95%
CI 0.06 to 0.14; 450 participants, 1 study, Analysis 10.2).
DAIDS grade three/four events
The risk of grade three or four renal dysfunction was higher in the
dexamethasone arm than in the placebo arm (RR 1.59, 95% CI
1.18 to 2.16; 450 participants, 1 study, Analysis 10.3: subgroup
2), and the risk of hypokalaemia was lower in the dexamethasone
arm (RR 0.83, 95% CI 0.69 to 0.98; 450 participants, 1 study,
Analysis 10.3: subgroup 4).
One week of amphotericin B deoxycholate and fluconazole
versus alternative regimens
A large study from nine centres in Malawi, Zambia, Tanzania,
and Cameroon compared one week of AmBd 1 mg/kg/day and
FLU 1200 mg/day followed by FLU 1200 mg/day on days 8 to
14 to three additional interventions (Molloy 2018): (i) two weeks
of AmBd 1 mg/kg/day and 5FC 100 mg/kg/day; (ii) two weeks of
AmBd 1 mg/kg/day and FLU 1200 mg/day; and (iii) two weeks
of 5FC 100 mg/kg/day and FLU 1200 mg/day.
Mortality
Oneweek of AmBd and FLUwas associatedwith a non-significant
increase in mortality at two and 10 weeks compared to two weeks
of AmBd and FLU (225 participants, 1 study, Analysis 11.1,
Summary of findings 11: subgroup 1 and 2; moderate-certainty
evidence); mortality was significantly increased compared to two
weeks of AmBd and 5FC at two weeks (RR 1.55, 95% CI 1.00 to
2.43; 226 participants, 1 study; Analysis 12.1: subgroup 1) but not
at 10 weeks (226 participants, 1 study, Analysis 12.1, Summary of
findings 12: subgroup 2; moderate-certainty evidence). One week
of AmBd and FLU was also associated with a significant increase
in mortality at two and 10 weeks compared to two weeks of 5FC
and FLU (two weeks: RR 1.78, 95% CI 1.21 to 2.62; 10 weeks:
RR 1.39, 95% CI 1.07 to 1.80; 336 participants, 1 study, Analysis
13.1, Summary of findings 13: subgroups 1 and 2; moderate-
certainty evidence).
Early fungicidal activity
There was no difference in rate of fungal clearance comparing one
week of AmBd and FLU to two weeks of AmBd and FLU (175
participants, 1 study, Analysis 11.2). Oneweek of AmBd and FLU
was associated with lower mean fungal clearance rate compared to
two weeks of AmBd and 5FC (MD0.13 log10 CFU/mL/day, 95%
CI 0.06 to 0.20; 169 participants, 1 study, Analysis 12.2) and a
higher mean fungal clearance compared to two weeks of 5FC and
FLU (MD -0.10 log10 CFU/mL/day, 95% CI -0.16 to -0.04; 263
participants, 1 study, Analysis 13.2).
DAIDS grade three/four events
One week of AmBd and FLU was associated with no difference in
grade three or four toxicities compared to two weeks of AmBd and
5FC (225 participants, 1 study, Analysis 11.3) or AmBd and FLU
(226 participants, 1 study, Analysis 12.3). The risk of anaemia was
higher with one week of AmBd and FLU compared to two weeks
of 5FC and FLU (RR4.42, 95%CI 2.25 to 8.70; 336 participants,
1 study, Analysis 13.3: subgroup 1), but no difference was found
for other laboratory adverse events.
Fluconazole monotherapy
Two small trials compared two weeks of 5FC and FLU with FLU
monotherapy (Mayanja-Kizza 1998; Nussbaum 2010). One small
study at a single centre inMalawi compared two weeks of 5FC 100
mg/kg/day in four divided doses and FLU 1200 mg/day to two
weeks of FLU 1200 mg/day (Nussbaum 2010). A second study
from a single centre in Uganda compared two weeks of 5FC 150
mg/kg/day in three divided doses and FLU 200 mg/day for two
months with FLU 200mg/day for twomonths, a suboptimal FLU
dose (Mayanja-Kizza 1998; Bicanic 2007; Longley 2008). A high
proportion of participants were lost to follow-up in the Uganda
study (8/58) by 10 weeks.
Mortality
Mortality was higher with FLU monotherapy compared to com-
bination 5FC and FLU at two weeks (RR 3.04, 95% CI 1.31 to
7.06; 98 participants, 2 studies, Analysis 14.1: subgroup 1) and
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10 weeks (RR 1.46, 95% CI 0.96 to 2.23; 98 participants, 2 stud-
ies, Analysis 14.1, Summary of findings 14: subgroup 2; very low-
certainty evidence). Six-month mortality estimates were not avail-
able, as follow-up did not extend beyond 10 weeks.
Early fungicidal activity
One studymeasured EFA (Nussbaum 2010), and showed a signifi-
cantly lowermean rate of fungal clearance with FLUmonotherapy
compared to combination FLU and 5FC (MD 0.17 log10 CFU/
mL/day, 95% CI 0.08 to 0.26; 37 participants, 1 study, Analysis
14.2).
DAIDS grade three/four events
One small study found no significant difference in grade three
or four events between groups (40 participants, 1 study, Analysis
14.3) (Nussbaum 2010).
Liposomal amphotericin B regimens
Two studies evaluated induction therapy with liposomal AmB (L-
AmB) (Leenders 1997; Jarvis 2018). One small study from the
Netherlands and Australia randomized 28 participants to three
weeks of L-AmB 4mg/kg/day or three weeks of AmBd 0.7 mg/kg/
day followed by FLU 400 mg/day consolidation (Leenders 1997).
One recently completed trial in Botswana and Tanzania random-
ized participants to two weeks of L-AmB 3 mg/kg/day or one of
three short courses of high-dose L-AmB, a single dose of L-AmB
10 mg/kg on day one, L-AmB 10 mg/kg on day one and 5 mg/
kg on day three, or L-AmB 10 mg/kg on day one and 5 mg/kg on
days three and seven (Jarvis 2018). All participants received FLU
1200 mg/day for two weeks followed by 800 mg/day consolida-
tion. This phase two study was powered to detect a non-inferior
EFA with short course versus two weeks of L-AmB and was dis-
continued early when interim analysis found it had reached the
prespecified non-inferiority margin.
Mortality
No deaths were reported within two weeks in the study comparing
L-AmB to AmBd (Leenders 1997). Mortality up to 10 weeks and
at six months was low in both arms, with no significant difference
between groups (28 participants, 1 study, Analysis 15.1, Summary
of findings 15: subgroups 2 and 3; very low-certainty evidence).
In the study comparing two weeks of L-AmB and FLU with short-
course L-AmB with FLU, mortality up to two weeks and 10 weeks
(79 participants, 1 study, Analysis 16.1, Summary of findings 16:
subgroups 1 and 2; low-certainty evidence) did not differ between
groups. A larger phase three study is underway that will compare
a single 10 mg/kg dose of L-AmB and two weeks of 5FC 100 mg/
kg/day and FLU 1200 mg/day with one week of AmBd 1 mg/kg/
day and 5FC 100 mg/kg/day followed by FLU 1200 mg/day on
days 8 to 14.
Early fungicidal activity
The Leenders 1997 study did not compare EFA between treatment
regimens. A faster mean rate of fungal clearance was observed in
participants who received short-course L-AmB with FLU com-
pared to those who received two weeks of L-AmB with FLU in
the Jarvis 2018 study (MD -0.10 log10 CFU/mL/day, 95% CI -
0.21 to 0.01; 67 participants, 1 study, Analysis 16.2).
DAIDS grade three/four events
The Leenders 1997 study did not report DAIDS grade three or
four laboratory events. The risk of hypokalaemia was lower in
participantswho received short-course L-AmBandFLUcompared
to those who received two weeks of L-AmB and FLU in the Jarvis
2018 study (RR 0.07, 95% CI 0.01 to 0.58; 79 participants, 1
study, Analysis 16.3: subgroup 4).
Amphotericin B deoxycholate with flucytosine and
fluconazole
One small study conducted at a single centre in Thailand com-
pared a three-drug induction regimen of two weeks of AmBd 0.7
mg/kg/day, 5FC 100 mg/kg/day, and FLU 400 mg/kg/day with:
(i) two weeks of AmBd 0.7 mg/kg/day and 5FC 100 mg/kg/day,
(ii) two weeks of AmBd 0.7 mg/kg/day and FLU 400 mg/day, and
(iii) two weeks of AmBd 0.7 mg/kg/day (Brouwer 2004).
One small study conducted at a single centre in Malawi compared
a three-drug induction regimen of one week of AmBd 1 mg/kg/
day with two weeks of 5FC 100 mg/kg/day and FLU 1200 mg/
day, and one week of AmBd 1 mg/kg/day with two weeks of FLU
1200 mg/day (Jackson 2012). Both regimens were followed by
FLU 800 mg/day consolidation.
Mortality
In the Brouwer 2004 study, mortality was very low at two and
10 weeks in all arms with no significant difference in survival ob-
served between two weeks of AmBd and 5FC and FLU compared
to two weeks of AmBd and 5FC (31 participants, 1 study, Analysis
17.1, Summary of findings 17: subgroups 1 and 2; low-certainty
evidence), twoweeks of AmBdwith FLU (32 participants, 1 study,
Analysis 18.1, Summary of findings 18: subgroups 1 and 2; very
low-certainty evidence), and two weeks of AmBd alone (32 partic-
ipants, 1 study, Analysis 19.1, Summary of findings 19: subgroups
1 and 2; very low-certainty evidence).
In the Jackson 2012 study, no difference in mortality was observed
between groups within two weeks or 10 weeks (40 participants, 1
study, Analysis 20.1, Summary of findings 20: subgroups 1 and 2;
low-certainty evidence).
Early fungicidal activity
In theBrouwer 2004 study,mean rate of fungal clearancewas lower
in the AmBd and 5FC and FLU group compared to the AmBd
and 5FC group (MD 0.16 log10 CFU/mL/day, 95% CI 0.03 to
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0.29; 27 participants, 1 study, Analysis 17.2). No difference was
observed in mean EFA between the AmBd and 5FC and FLU
group and either the AmBd with FLU (26 participants, 1 study,
Analysis 18.2) or AmBd alone group (29 participants, 1 study,
Analysis 19.2).
In the Jackson 2012 study, mean rate of fungal clearance was
greater in the one week of AmBd and 5FC and FLU group com-
pared to the one week of AmBd and FLU group (MD -0.12 log10
CFU/mL/day, 95% CI -0.23 to -0.01; 37 participants, 1 study,
Analysis 20.2).
DAIDS grade three/four events
The Brouwer 2004 study did not report DAIDS grade three or
four events. The risk of events did not differ between the one week
of AmBd and 5FC and FLU group and the one week of AmBd and
FLU group in the Jackson 2012 study (40 participants, 1 study,
Analysis 20.3).
Adjunctive interferon-gamma therapy
One small study fromSouth Africa evaluated adjunctive interferon
gamma 1b (IFNg) with two weeks of AmBd 1 mg/kg/day and
5FC 100 mg/kg/day compared to two weeks of AmBd 1 mg/kg/
day and 5FC 100 mg/kg/day without IFNg (Jarvis 2012). The
study included two IFNg groups: one group received IFNg 100
µg subcutaneously on days 1 and 3, and one group received IFNg
100 µg subcutaneously on days 1, 3, 5, 8, 10, and 12. The study
was powered to evaluate improvement in EFA associated with
adjunctive IFNg rather than mortality benefit with IFNg.
Mortality
No difference was observed in mortality between groups at two
and 10 weeks (88 participants, 1 study, Analysis 21.1, Summary
of findings 21: subgroups 1 and 2; low-certainty evidence).
Early fungicidal activity
Themean EFA was greater for participants in the adjunctive IFNg
groups (MD -0.15 log10 CFU/mL/day, 95% CI -0.24 to -0.06;
88 participants, 1 study, Analysis 21.2).
DAIDS grade three/four events
Nodifference was observed between groups in DAIDS grade three
or four events (88 participants, 1 study, Analysis 21.3).
GRADE assessment for pairwise comparisons
We conducted GRADE assessment for 10-week mortality for all
comparisons.
Risk of bias
We downgraded few comparisons for risk of bias. We downgraded
one comparison (two weeks of FLU versus two weeks of 5FC and
FLU) due to high loss to follow-up in one of two studies included
in the comparison.We also downgraded a second comparison (two
weeks of AmBd versus two weeks of L-AmB) for risk of bias. The
single study for this comparison was sponsored by a study drug
manufacturer, with the role of the sponsor not stated. Additionally,
mortality was not stated as a primary outcome of interest.
Imprecision
We downgraded all but one comparison for imprecision due to in-
sufficient participants and events (fewer than 200 observed deaths
by 10 weeks).
Inconsistency
Due to the limited number of studies for most comparisons, there
was limited assessment of heterogeneity. Of those comparisons for
which heterogeneity could be assessed, no studies demonstrated
statistical heterogeneity.
Indirectness
We downgraded six comparisons for using lower doses of flu-
conazole than recommended in current treatment guidelines (two
weeks of AmBd and FLU versus two weeks of AmBd; two weeks of
AmBd and 5FC versus two weeks of AmBd and FLU; two weeks
of FLU versus two weeks of 5FC and FLU; two weeks of AmBd
and 5FC and FLU versus two weeks of AmBd and 5FC; two weeks
of AmBd and 5FC and FLU versus two weeks of AmBd and FLU;
and two weeks of AmBd and 5FC versus two weeks of AmBd).
Publication bias
We did not detect publication bias.
Ten-week mortality network meta-analysis
Overview
A network plot for 10-week mortality is shown in Figure 10. The
nodes (circles) represent the treatment combinations, while the
edges (lines) represent direct comparisons between treatment com-
binations. The size of the node is proportional to the number of
participants randomized to the treatment combination, and the
width of the edge is proportional to the number of trials compar-
ing the treatment combinations. We excluded a pair of treatment
combinations (two weeks of L-AmB with FLU and short-course
L-AmB with FLU from Jarvis 2018) from the network meta-anal-
yses, as these interventions were unconnected to the rest of the
network.
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Figure 10. Network plot for 10-week mortality.
Ten-week mortality was reported for 12 treatment combina-
tions in 11 trials involving 1961 participants (Leenders 1997;
Mayanja-Kizza 1998; Brouwer 2004; Pappas 2009; Nussbaum
2010; Jackson 2012; Jarvis 2012; Loyse 2012;Day 2013; Beardsley
2016;Molloy 2018). Trials assessed 20 direct comparisons with 16
comparisons (80%) based on one trial (Molloy 2018). The most
common comparators in the network were two weeks of AmBd
with FLU and AmBd with 5FC, with both examined in six trials
(55%). Eight trials (73%) were two-arm studies, one (9%) was a
three-arm trial, one (9%) was a four-arm trial, and one (9%) was
a five-arm trial. Due to the limited number of studies and par-
ticipants contributing to each node, the results of the NMA and
associated SUCRA rankings should be interpreted with caution.
Relative effects of treatment combinations derived from
network meta-analysis
The league table shows the relative effects of each treatment com-
bination derived from NMA (Figure 11). Treatment effects de-
rived from NMA were in general similar to those derived from
pairwise meta-analysis.
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Figure 11. Ten-week mortality treatment effect estimates. Values in the table are risk ratios (RRs) with 95%
confidence intervals. Bolded values represent statistically significant effects. The bottom half of the table
represents network meta-analysis-derived treatment effects, while the top half represents results from direct
comparisons alone. For network meta-analysis-derived effects, RR < 1 favours the treatment combination in
the column. For effects derived from pairwise meta-analysis, RR < 1 favours the treatment combination in the
row. Treatment combinations are ordered by surface under the cumulative ranking curve (SUCRA) rankings.
Most treatment effects had lowprecision for the 10-weekmortality
estimates. Using twoweeks of AmBd and FLU as reference, the RR
(95% CI) of 10-week mortality of each treatment combination in
order of SUCRA ranking is: one week of AmBd and 5FC 0.56
(0.38 to 0.82), two weeks of AmBd and 5FC and FLU 0.60 (0.19
to 1.85), two weeks of 5FC and FLU 0.83 (0.63 to 1.07), two
weeks of L-AmB 0.54 (0.05 to 5.35), two weeks of AmBd and
5FC and IFNg 0.82 (0.41 to 1.64), two weeks of AmBd and 5FC
0.89 (0.70 to 1.13), one week of AmBd and 5FC and FLU 0.98
(0.38 to 2.50), FLU 1.18 (0.72 to 1.94), one week of AmBd and
FLU 1.14 (0.87 to 1.50), AmBd and FLU and steroids 1.15 (0.93
to 1.42), and AmBd 1.24 (0.92 to 1.65) (Figure 12).
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Figure 12. Ten-week mortality risk for each treatment combination compared to reference of two weeks of
AmBd and FLU.
SUCRA rankings
The top three ranked treatment combinations (with SUCRA val-
ues) at 10 weeks were one week of AmBd and 5FC (88%), two
weeks of AmBd and 5FC and FLU (74%), and two weeks of 5FC
and FLU (67%), while the bottom three ranked treatment com-
binations were one week of AmBd and two weeks of FLU (26%),
two weeks of AmBd and FLU and steroids (26%), and two weeks
of AmBd (19%) (Figure 13). Of the top ranked treatment combi-
nations, both one week of AmBd and 5FC and two weeks of 5FC
and FLU show significant and clinically meaningful reductions in
10-week mortality risk compared to the bottom ranked treatment
combinations. The cumulative ranking probabilities for all treat-
ment combinations are presented in SUCRA plots below.
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Figure 13. Cumulative ranking probabilities for each treatment combination for 10-week mortality. The
SUCRA value represents the surface underneath the cumulative ranking curve and is the probabilities for each
treatment combination to be among the n-best options. The larger the SUCRA value, the higher the ranking
probability for the treatment combination in the network. The SUCRA values for each treatment
combination are as follows: AmBd (19%), AmBd + 5FC (59%), AmBd + 5FC + IFNg (59%), AmBd + FLU (45%),
AmBd + FLU + 5FC (74%), AmBd + FLU + St (26%), FLU (27%), FLU + 5FC (67%), L-Amb (67%), shortAmBd +
5FC (88%), shortAmBd + FLU (26%), shortAmBd + FLU + 5FC (45%).
Although the AmBd and 5FC and FLU node ranked highly in
the NMA, the direct evidence for this node consisted of a single
study that included only 16 participants in one arm of one study,
Brouwer 2004, with low mortality in all treatment groups and
no significant difference in 10-week mortality by direct, pairwise
comparisons. This result should be interpreted with caution due
to the very high likelihood of bias. Similarly, the L-AmB node
included 15 participants from one study in a high-income setting,
Leenders 1997, where mortality was low in both the three weeks
of L-AmB and three weeks of AmBd arms with no significant
difference inmortality between arms within 10 weeks in the direct
comparison.
Evaluation of transitivity and inconsistency
We did not find evidence that the assumption of transitivity was
violated. The distribution of prespecified potential effect modi-
fiers, including ART status, timing of ART, inclusion of partici-
pants with abnormal mental status, therapeutic lumbar puncture,
dosing of AmBd, and dosing of FLU, were generally similar across
comparisons. We examined study setting as a potential source of
intransitivity in a subgroup analysis excluding studies conducted
in high-income countries for 10-weekmortality. The findings were
similar to the primary analyses. However, our ability to thoroughly
examine transitivity was limited by the small number of studies
included per comparison, and therefore we cannot be entirely con-
fident that the assumption of transitivity is plausible in our net-
works.
We found no evidence of inconsistency for any outcome using the
design-by-treatment interaction modelling, node-splitting, and
loop-specific approaches. However, due to the limited amount of
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data available we are not able to draw firm conclusions regarding
the presence of inconsistency in our networks.
Modified GRADE for network meta-analysis
The certainty of the evidence for all comparisons using modified
GRADE for NMA was low or very low. Assessment for key com-
parisons is shown in Figure 14.
Figure 14. Modified GRADE for network meta-analysis
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
One week of AmBd + 5FC compared to two weeks of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 1 week of AmBd + 5FC
Comparison: 2 weeks of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ FLU
Risk with 1 week of AmBd
+ 5FC
Mortality: 10 weeks 412 per 1000 239 per 1000
(161 to 355)
RR 0.58
(0.39 to 0.86)
227
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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One week of AmBd + 5FC compared to one week of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 1 week of AmBd + 5FC
Comparison: 1 week of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 1 week of AmBd
+ FLU
Risk with 1 week of AmBd
+ 5FC
Mortality: 10 weeks 486 per 1000 238 per 1000
(165 to 350)
RR 0.49
(0.34 to 0.72)
224
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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One week of AmBd + 5FC compared to two weeks of 5FC + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: Randomized controlled trial
Intervention: 1 week of AmBd + 5 FC
Comparison: 2 weeks of 5FC + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of 5FC +
FLU
Risk with 1 week of AmBd
+ 5FC
Mortality: 10 weeks 351 per 1000 239 per 1000
(165 to 348)
RR 0.68
(0.47 to 0.99)
338
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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Two weeks of 5FC + FLU compared to two weeks of AmBd + 5FC for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of 5FC + FLU
Comparison: 2 weeks of AmBd + 5FC
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ 5FC
Risk with 2 weeks of 5FC +
FLU
Mortality: 10 weeks 383 per 1000 352 per 1000
(264 to 471)
RR 0.92
(0.69 to 1.23)
340
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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Two weeks of 5FC + FLU compared to two weeks of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of 5FC + FLU
Comparison: 2 weeks of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ FLU
Risk with 2 weeks of 5FC +
FLU
Mortality: 10 weeks 412 per 1000 350 per 1000
(264 to 466)
RR 0.85
(0.64 to 1.13)
339
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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Two weeks of AmBd + 5FC compared to two weeks of AmBd for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + 5FC
Comparison: 2 weeks of AmBd
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd Risk with 2 weeks of AmBd
+ 5FC
Mortality: 10 weeks 409 per 1000 270 per 1000
(188 to 388)
RR 0.66
(0.46 to 0.95)
231
(2 RCTs)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom two studies with few events.
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Two weeks of AmBd + FLU compared to two weeks of AmBd for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + FLU
Comparison: 2 weeks of AmBd
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd Risk with 2 weeks of AmBd
+ FLU
Mortality: 10 weeks 338 per 1000 317 per 1000
(186 to 547)
RR 0.94
(0.55 to 1.62)
371
(3 RCTs)
⊕⊕©©
LOW1,2
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for indirectness. Some part icipants received a lower dose of f luconazole than current ly recommended
in combinat ion with AmBd. Pappas 2009 excluded f rom enrolment pat ients who were not expected to survive two weeks,
so the study populat ion may not be representat ive of general pat ients with cryptococcal meningit is.
2Downgraded one level for imprecision. Few events with broad CI including appreciable benef it and appreciable harm.
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Two weeks of AmBd + 5FC compared to two weeks of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + 5FC
Comparison: 2 weeks of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ FLU
Risk with 2 weeks of AmBd
+ 5FC
Mortality: 10 weeks 355 per 1000 320 per 1000
(245 to 423)
RR 0.90
(0.69 to 1.19)
538
(4 RCTs)
⊕⊕©©
LOW1,2
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for indirectness. Some part icipants received a lower dose of f luconazole than is current ly recommended
in combinat ion with AmBd. A few part icipants in one study also received a dif ferent azole drug, voriconazole.
2Downgraded one level for imprecision. Few overall events.
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Two weeks of AmBd + FLU + steroids compared to two weeks of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + FLU + steroids
Comparison: 2 weeks of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ FLU
Risk with 2 weeks of AmBd
+ FLU + steroids
Mortality: 10 weeks 412 per 1000 473 per 1000
(383 to 584)
RR 1.15
(0.93 to 1.42)
450
(1 RCT)
⊕⊕⊕⊕
HIGH
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
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One week of AmBd + FLU compared to two weeks of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 1 week of AmBd + FLU
Comparison: 2 weeks of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ FLU
Risk with 1 week of AmBd
+ FLU
Mortality: 10 weeks 412 per 1000 486 per 1000
(363 to 651)
RR 1.18
(0.88 to 1.58)
225
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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One week of AmBd + FLU compared to two weeks of AmBd + 5FC for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 1 week of AmBd + FLU
Comparison: 2 weeks of AmBd + 5FC
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ 5FC
Risk with 1 week of AmBd
+ FLU
Mortality: 10 weeks 383 per 1000 486 per 1000
(360 to 658)
RR 1.27
(0.94 to 1.72)
226
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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One week of AmBd + FLU compared to two weeks of 5FC + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 1 week of AmBd + FLU
Comparison: 2 weeks of 5FC + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of 5FC +
FLU
Risk with 1 week of AmBd
+ FLU
Mortality: 10 weeks 351 per 1000 488 per 1000
(376 to 632)
RR 1.39
(1.07 to 1.80)
336
(1 RCT)
⊕⊕⊕©
MODERATE1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for imprecision. Data f rom a single study with few events.
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Two weeks of FLU compared to two weeks of 5FC + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of FLU
Comparison: 2 weeks of 5FC + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of 5FC +
FLU
Risk with 2 weeks of FLU
Mortality: 10 weeks 392 per 1000 573 per 1000
(376 to 875)
RR 1.46
(0.96 to 2.23)
98
(2 RCTs)
⊕©©©
VERY LOW1,2,3
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for risk of bias. High loss to follow-up by 10 weeks.
2Downgraded one level for indirectness. Part icipants in one study received a lower dose of f luconazole than is recommended
and a higher dose of f lucytosine.
3Downgraded two levels for imprecision. Data f rom two small studies with few events.
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Two weeks of L-AmB compared to two weeks of AmBd for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of L-AmB
Comparison: 2 weeks of AmBd
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd Risk with 2 weeks of L-AmB
Mortality: 10 weeks 154 per 1000 66 per 1000
(6 to 654)
RR 0.43
(0.04 to 4.25)
28
(1 RCT)
⊕©©©
VERY LOW1,2
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: AmBd: amphotericin B deoxycholate; CI: conf idence interval; L-AmB: l iposomal amphotericin B; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for risk of bias. Study sponsored by study drug manufacturer, and role of funder not stated. Mortality
also not stated as primary outcome of interest.
2Downgraded two levels for imprecision. Data f rom single small study with few events and broad CI including appreciable
benef it and appreciable harm.
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Short-course L-AmB + FLU compared to two weeks of L-AmB + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: short-course L-AmB + FLU
Comparison: 2 weeks of L-AmB + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of L-AmB
+ FLU
Risk with short-course L-
AmB + FLU
Mortality: 10 weeks 286 per 1000 294 per 1000
(134 to 643)
RR 1.03
(0.47 to 2.25)
79
(1 RCT)
⊕⊕©©
LOW1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: CI: conf idence interval; FLU: f luconazole; L-AmB: l iposomal amphotericin B; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded two levels for imprecision. Data f rom a single small study with few events and broad CI including appreciable
benef it and appreciable harm.
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Two weeks of AmBd + 5FC + FLU compared to two weeks of AmBd + 5FC for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + 5FC + FLU
Comparison: 2 weeks of AmBd + 5FC
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ 5FC
Risk with 2 weeks of AmBd
+ 5FC + FLU
Mortality: 10 weeks 67 per 1000 187 per 1000
(22 to 1000)
RR 2.81
(0.33 to 24.16)
31
(1 RCT)
⊕©©©
VERY LOW12
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for indirectness. Data generated f rom a single study that used a low dose of f luconazole.
2Downgraded two levels for imprecision. Data f rom a single small study with few events and broad CI including appreciable
benef it and appreciable harm.
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Two weeks of AmBd + 5FC + FLU compared to two weeks of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + 5FC + FLU
Comparison: 2 weeks of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ FLU
Risk with 2 weeks of AmBd
+ 5FC + FLU
Mortality: 10 weeks 438 per 1000 188 per 1000
(57 to 599)
RR 0.43
(0.13 to 1.37)
32
(1 RCT)
⊕©©©
VERY LOW1,2
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for indirectness. Data generated f rom a single small study that used a lower dose of f luconazole than
is current ly recommended.
2Downgraded two levels for imprecision. Data generated f rom a single small study with very few events.
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Two weeks of AmBd + 5FC + FLU compared to two weeks of AmBd for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + 5FC + FLU
Comparison: 2 weeks of AmBd
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd Risk with 2 weeks of AmBd
+ 5FC + FLU
Mortality: 10 weeks 188 per 1000 188 per 1000
(45 to 793)
RR 1.00
(0.24 to 4.23)
32
(1 RCT)
⊕©©©
VERY LOW1,2
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded one level for indirectness. Data generated f rom a single study that used a low dose of f luconazole.
2Downgraded two levels for imprecision. Data f rom a single small study with few events and broad CI including appreciable
benef it and appreciable harm.
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One week of AmBd + 5FC + FLU compared to one week of AmBd + FLU for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 1 week of AmBd + 5FC + FLU
Comparison: 1 week of AmBd + FLU
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 1 week of AmBd
+ FLU
Risk with 1 week of AmBd
+ 5FC + FLU
Mortality: 10 weeks 350 per 1000 301 per 1000
(122 to 735)
RR 0.86
(0.35 to 2.10)
40
(1 RCT)
⊕⊕©©
LOW1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; FLU: f luconazole; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded two levels for imprecision. Data f rom a single small study with few events and broad CI including appreciable
benef it and appreciable harm.
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Two weeks of AmBd + 5FC + IFNg compared to two weeks of AmBd + 5FC for HIV-associated cryptococcal meningitis
Patient or population: HIV-infected individual with f irst episode of cryptococcal meningit is
Setting: randomized controlled trial
Intervention: 2 weeks of AmBd + 5FC + IFNg
Comparison: 2 weeks of AmBd + 5FC
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with 2 weeks of AmBd
+ 5FC
Risk with 2 weeks of AmBd
+ 5FC + IFNg
Mortality: 10 weeks 323 per 1000 297 per 1000
(155 to 571)
RR 0.92
(0.48 to 1.77)
88
(1 RCT)
⊕⊕©©
LOW1
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
Abbreviations: 5FC: f lucytosine; AmBd: amphotericin B deoxycholate; CI: conf idence interval; IFNg: interferon gamma 1b; RCT: randomized controlled trial; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate certainty: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low certainty: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low certainty: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1Downgraded two levels for imprecision. Data generated f rom a single study with few events and broad CI that included
appreciable benef it and appreciable harm.
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D I S C U S S I O N
Summary of main results
This review included 13 studies of 2426 participants comparing
21 interventions used for induction therapy for first episode of
HIV-associated cryptococcal meningitis. Based on moderate-cer-
tainty evidence from one study, mortality within 10 weeks was
lower with shortened one week of AmBd and 5FC compared to
two weeks of AmBd and 5FC, which was previously considered
the gold standard, as well as compared to oral 5FC and FLU.
Based on moderate-certainty evidence, no difference in mortality
was observed with two weeks of oral 5FC and FLU compared
to two weeks of AmBd and 5FC. It is unclear if the addition of
FLU to AmBd improves mortality given the low certainty of the
evidence contributing to this comparison. Few studies provided
data on FLU monotherapy. Low-certainty evidence suggests that
FLU monotherapy may be inferior to the combination of 5FC
and FLU, and there were no direct comparisons with AmBd-based
regimens.
Results from the 10-week NMA complemented results from the
pairwise meta-analyses. Pairwise meta-analyses alone allowed us
to examine 21 treatment combination comparisons for 10-week
mortality, and with NMA we were able to estimate the relative
effects for an additional 46 comparisons. The NMA supports the
role of a short-course treatment combinationof oneweek of AmBd
and 5FC as an initial option in resource-limited settings due to
its high ranking in the network for mortality outcomes in the
context of its statistically and clinically significant effects compared
to some other combinations. All-oral induction therapy with 5FC
and FLU also performed well in the NMA. Two weeks of AmBd
and5FCandFLUperformedwell in the 10-weekNMA.However,
this treatment arm included only 16 participants from a single
study in which mortality was very low in all four treatment arms.
The SUCRA ranking for this treatment is highly likely to be biased
and should be interpreted cautiously.
With respect to early fungicidal activity, we found no difference
in the rate of CSF fungal clearance with short-course AmBd and
5FC compared to two weeks of AmBd and 5FC. Our findings
support improved fungal clearance of regimens with 5FC in ad-
dition to AmBd in comparison to induction regimens containing
AmBd with FLU or AmBd alone. Amphotericin B deoxycholate-
based regimens had greater fungal clearance than all-oral induc-
tion therapy with 5FC and FLU.
With respect to DAIDS grade three or four toxicities, traditional
two-week AmBd-based therapy was associated with higher occur-
rence of AmBd-related toxicities compared to short-course ther-
apy. All-oral 5FC and FLU therapy was associated with less tox-
icity (including anaemia, hypokalaemia, and renal dysfunction)
compared to several AmBd-containing regimens.
Regarding emerging adjunctive therapies, there is strong evidence
that adjunctive steroid therapy is harmful and should not be used
in clinical practice. One study found that adjunctive IFNg used in
combination with two weeks of AmBd and 5FC resulted in a faster
rate of CSF fungal clearance compared to AmBd and 5FC alone,
but this study was not adequately powered to assess differences in
mortality associated with the use of adjunctive IFNg.
Overall completeness and applicability of
evidence
The evidence provided in this review offers important and timely
insights into the best management to reduce mortality fromHIV-
associated cryptococcal meningitis in resource-limited settings
where the large majority of disease occurs (Rajasingham 2017). In
resource-limited settings, moderate-certainty evidence from one
study supports the use of one week of AmBd with 5FC fol-
lowed by high-dose fluconazole, with improvedmortality up to 10
weeks, similar CSF fungal clearance, and reduced treatment toxi-
city (Molloy 2018). These findings are consistent with non-RCT
data from animal studies demonstrating that near maximal anti-
fungal activity with AmBd therapy can be achieved within three
days (Livermore 2014). The findings in this review are widely ap-
plicable to the treatment of HIV-associated cryptococcal menin-
gitis in resource-limited settings.
This review has several important limitations, as follows.
First, 11 out of 13 studies were conducted in resource-limited
settings, and therefore our findings provide limited guidance for
management of HIV-associated cryptococcal meningitis in high-
income settings where mortality is significantly lower with tradi-
tional AmB-based induction therapy (Saag 1991; van der Horst
1997). No short-course (less than two weeks of AmB) or all-oral
(5FC and FLU) regimen was evaluated in high-income country
settings, although there is no reason to believe that these regimens
would be inferior in these settings. Furthermore, in high-income
settingsmore expensive but less toxic liposomal AmB is commonly
used instead of AmBd, and frequency of and ability to manage
treatment-related toxicities differs between high-income and re-
source-limited settings.
Second, we did not find any RCTs on treatment of HIV-associated
cryptococcal meningitis in children, for whom therapy is guided
by RCT evidence in adult populations. Nevertheless, there is no
reason to consider that these regimens would be inferior for the
treatment of cryptococcal meningitis in children.
Third, relatively few studies overall met the inclusion criteria for
this review, which was a limitation for both pairwise meta-analy-
sis and NMA. Importantly, we excluded observational studies as
well as studies with high loss to follow-up (> 20%) or significant
baseline imbalances between comparator groups.We also excluded
trials with any non-HIV-related cases of cryptococcal meningi-
tis or re-treatment cases, as these cases may be clinically distinct
fromHIV-associated disease with respect to patient comorbidities,
Cryptococcus spp. drug resistance, and disease severity, among other
factors. Few deaths were observed per treatment arm, and the cer-
tainty of evidence for most pairwise comparisons was downgraded
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for imprecision due to few events (< 200).
Fourth, our review provides limited insight into emerging adjunc-
tive therapies being evaluated for the treatment of HIV-associ-
ated cryptococcal meningitis. Interferon gamma 1b was associated
with improved early fungicidal activity with AmBd and 5FC in
one phase two RCT, but this study was underpowered to compare
differences in mortality up to 10 weeks (Jarvis 2012).
Fifth, the SUCRA rankings should be interpreted cautiously, espe-
cially when they are not accompanied by statistically or clinically
meaningful effects. Due to the imprecision of treatment effects on
mortality throughout the network, the rankings presented should
not be considered definitive.
Finally, although commonly used in resource-limited settings due
to low cost and oral administration, oral FLU was compared with
other regimens in few included studies. However, observational
studies and data from RCTs not meeting the inclusion criteria for
this review have consistently found very high mortality associated
with the use of FLU monotherapy (Makadzange 2010; Rothe
2013).
Certainty of the evidence
For pairwise comparisons, most comparisons had moderate- or
low-certainty evidence. We downgraded the evidence for all but
one comparison for imprecision due to few participants and events
within 10 weeks (< 200). We also downgraded the evidence for
several comparisons with therapies containing FLU for indirect-
ness due to evaluation of regimens containing doses of FLU lower
than currently recommended (< 800 mg/day).
For the NMA, the certainty of the evidence was low or very low,
due primarily to imprecision, heterogeneity (inconsistency), and
indirectness of comparisons.
Potential biases in the review process
We did not identify any major biases in the review process. One
author of this Cochrane Review (JNJ) was a principal investigator
or co-investigator in several trials, but did not participate in data
extraction or interpretation of results for these studies. We further
limited bias during the review process by conducting an extensive
search using a wide range of search terms and databases. Two
review authors reviewed the search outputs, evaluated eligibility,
and extracted data independently. Changes made to the study
protocol after publication and after the review process began are
detailed in the Differences between protocol and review section.
Agreements and disagreements with other
studies or reviews
Several influential studies in this review were recently completed
and not included in previous reviews of best treatment for HIV-
associated cryptococcal meningitis (Beardsley 2016; Jarvis 2018;
Molloy 2018). A previous NMA did not find evidence for mortal-
ity benefit with two weeks of AmBd and 5FC compared to AmBd
alone (Campbell 2015). This review had important methodolog-
ical differences, such as inclusion of both RCTs and observational
studies and inclusion of studies with re-treatment cases.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
This review has important implications for clinical practice in re-
source-limited settings.We found reduced 10-weekmortality with
shortened amphotericin B deoxycholate (AmBd) and flucytosine
(5FC) induction therapy compared to the current gold standard
of two weeks of AmBd and 5FC, based on moderate-certainty ev-
idence. Moderate-certainty evidence also indicated that an all-oral
regimen of two weeks of 5FC and fluconazole may be a good al-
ternative to two weeks of AmBd-based therapy, with no difference
in mortality observed between arms. This all-oral regimen may
be a good treatment option in settings where intravenous therapy
cannot be safely administered or AmBd is not available. There is
a need to expand access to 5FC in resource-limited settings where
HIV-associated cryptococcal meningitis is most common.
Implications for research
Our reviewhighlights that limitedRCTevidence exists comparing
treatment regimens for HIV-associated cryptococcal meningitis.
There is a lack of data on short-course regimens for the treatment of
HIV-associated cryptococcal meningitis in high-income settings,
where the lower mortality and low burden of disease compared
to resource-limited settings, as well as the positive findings from
low-income settings, will likely preclude such studies. Emerging
evidence, including from ongoing phase three studies, will provide
further evidence on the efficacy of adjunctive therapies as well
as short-course liposomal amphotericin regimens. Finally, there is
very limited evidence supporting treatment choice for children,
and as trials are unlikely, results can be extrapolated from adults,
albeit downgraded to a lower certainty of evidence.
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Characteristics of included studies [ordered by study ID]
Beardsley 2016
Methods Study type: blinded RCT
Setting: 13 hospitals in Vietnam, Thailand, Indonesia, Laos, Uganda, and Malawi
Participants Inclusion criteria:HIV infected;≥ 18 years of age; diagnosed with cryptococcal menin-
gitis by CSF India ink or CrAg or blood or CSF culture
Exclusion criteria: pregnant; more than 7 days of anticryptococcal therapy; renal fail-
ure; receiving glucocorticoids or glucocorticoids indicated for a pre-existing condition;
gastrointestinal bleeding
Number randomized: 451 (1 excluded after randomization due to administrative error)
Age: median 35 years
Gender: 62% male
CD4 T-cell count: median 18 cells/µL (AmBd and fluconazole with dexamethasone);
20 cells/µL (AmBd and fluconazole with placebo)
Baseline ART: 40% with prior ART use
Baseline GCS/AMS: GCS < 15 in 19% of participants
Interventions Intervention
1. AmBd 1 mg/kg/day and fluconazole 800 mg/day for 2 weeks with tapered
dexamethasone (0.3 mg/kg/day for 1 week, then 0.2 mg/kg/day for 1 week, then 0.1
mg/kg/day for 1 week, then 3 mg/day for 1 week, then 2 mg/day for 1 week, then 1
mg/day for 1 week)
2. AmBd 1 mg/kg/day and fluconazole 800 mg/day for 2 weeks with placebo
therapy for 6 weeks
Consolidation: Fluconazole 800 mg/day for 8 weeks then 200 mg/day maintenance
dose
Postdiagnosis ART:median time to ART 46 days (AmBd and fluconazole with dexam-
ethasone); 42 days (AmBd and fluconazole with placebo)
Lumbar puncture schedule: scheduled on days 1, 3, 7, and 14 and performed as
clinically indicated
Laboratory monitoring: haemoglobin, white blood cells, platelet count days 1, 7, and
14; Na, K, urea, Cr days 1, 3, 7, 11, and 14
Outcomes Primary outcome
• Mortality at 10 weeks
Secondary outcomes
• Mortality at 6 months
• Level of disability at 10 weeks and 6 months
• Visual acuity at 10 weeks
• Rate of decrease in cryptococcal counts in CSF during first 2 weeks
• Change in opening pressure during first 2 weeks
Outcome assessment schedule:Daily while hospitalized and scheduled assessments on
days 21, 28, 42, 80, and 182
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Beardsley 2016 (Continued)
Notes Date of study: 2013 to 2014 (study stopped early after data and safety monitoring
committee determined dexamethasone therapy was causing harm across key outcomes)
Funding: UK Department for International Development; The Wellcome Trust (UK);
Medical Research Council (UK) Joint Global Health Trials Scheme
Declaration of conflict of interest by authors: None reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1 randomization with variable block size
of 4 and 6 with computer-generated se-
quence, stratified by study site
Allocation concealment (selection bias) Low risk Computer-generated randomization acces-
sible only to central pharmacists
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and clinicians blinded to inter-
vention group.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors blinded to treatment
group.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6-month outcome available for all partici-
pants.
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk None noted.
Brouwer 2004
Methods Study type: Unblinded RCT
Setting: 1 hospital in Thailand
Participants Inclusion criteria: HIV infected; diagnosed by CSF India ink or CrAg test
Exclusion criteria: pregnant; previous cryptococcal meningitis; ALT > 5 times upper
limit of normal; ANC < 500 x 106/L; platelet count < 50 x 106/L; previous serious
reaction to study drugs
Number randomized: 64
Age: median 33 years
Gender: 60% male
CD4 T-cell count: median 9 cells/µL
Baseline ART: no
Baseline GCS/AMS: GCS < 15 or seizures in 19% of participants
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Brouwer 2004 (Continued)
Interventions Intervention
1. AmBd 0.7 mg/kg/day for 2 weeks
2. AmBd 0.7 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks
3. AmBd 0.7 mg/kg/day and fluconazole 400 mg/day for 2 weeks
4. AmBd 0.7 mg/kg/day and flucytosine 100 mg/kg/day and fluconazole 400 mg/
day for 2 weeks
Consolidation: fluconazole 400 mg/day for 8 weeks, then 200 mg/day maintenance
dose
Postdiagnosis ART: no participants started on ART within 10 weeks of follow-up
Lumbar puncture schedule: scheduled on days 3, 7, and 14 and as clinically indicated
Laboratory monitoring: not specified
Outcomes Primary outcome
• Rate of decrease in cryptococcal counts in CSF during first 2 weeks
Secondary outcome
• Mortality at 2 and 10 weeks
Outcome assessment schedule: daily while hospitalized and scheduled assessments on
days 21, 28, 42, 80, and 182
Notes Date of study: 2002
Funding:WellcomeTrust; Lancet international fellowship; StGeorge’sHospital;Nether-
lands Foundation for the Advancement of Tropical Medicine
Declaration of conflict of interest by authors: None reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1:1 randomization with blocks of 16
with pre-study generation of sealed en-
velopes prepared by an independent person
Allocation concealment (selection bias) Low risk Sealed envelopes prepared by independent
person
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes up to 10 weeks for all partici-
pants
Selective reporting (reporting bias) Low risk Authors reported all primary and secondary
outcomes.
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Brouwer 2004 (Continued)
Other bias Low risk None noted.
Day 2013
Methods Study type: unblinded RCT
Setting: 1 hospital in Vietnam
Participants Inclusion criteria: HIV infected; > 14 years of age; positive CSF India ink or CrAg,
CSF or blood culture, or blood CrAg with titre > 1:10
Exclusion criteria: pregnant; previous cryptococcosis; antifungal therapy for more than
3 days; renal or liver failure; receiving rifampicin; did not provide written informed
consent
Number randomized: 299
Age: median 28 years (AmBd); 28 years (AmBd and flucytosine); 27 years (AmBd and
fluconazole)
Gender: 82%male (AmBd); 80% male (AmBd and flucytosine); 85% male (AmBd and
fluconazole)
CD4 T-cell count: median 18 cells/µL (AmBd); 17 cells/µL (AmBd and flucytosine);
14 cells/µL (AmBd and fluconazole)
Baseline ART: 3% on ART at baseline
Baseline GCS/AMS: GCS < 15 in 28% of participants
Interventions Intervention
1. AmBd 1.0 mg/kg/day for 4 weeks
2. AmBd 1.0 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks
3. AmBd 1.0 mg/kg/day and fluconazole 800 mg/day for 2 weeks
Consolidation: fluconazole 400 mg/day up to 8 weeks, then 200 mg/day maintenance
dose
Postdiagnosis ART: ART initiation at discretion of physicians at follow-up (89/299 of
participants started ART within 6 months and 8/299 within 2 weeks of randomization)
Lumbar puncture schedule: scheduled weekly for 1 month and as clinically indicated
Laboratory monitoring: weekly CBC, urea, electrolytes, LFTs
Outcomes Primary outcome
• Mortality at 2 and 10 weeks
Secondary outcomes
• Mortality at 6 months
• Disability status at 10 weeks and 6 months
• Changes in CSF fungal counts in first 2 weeks
• Time to CSF sterilization
• Adverse events during first 10 weeks
Outcome assessment schedule:Daily while hospitalized, then monthly until 6 months
Notes Date of study: 2004 to 2010
Funding: Wellcome Trust and British Infection Society
Declaration of conflict of interest by authors: None reported.
Risk of bias
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Day 2013 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1 randomization with computer-gen-
erated sequence in blocks of 9
Allocation concealment (selection bias) Low risk Randomization list held securely at trial
centre
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Vital status at 6 months missing in few (7/
299) participants
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk None noted; pharmaceutical companies
supplied reduced study drug but had no
role in design or interpretation of study
Jackson 2012
Methods Study type: unblinded RCT
Setting: 1 referral hospital in Malawi
Participants Inclusion criteria: HIV infected; ART-naive; diagnosed by CSF India ink confirmed
by CrAg test or culture or by CSF CrAg test
Exclusion criteria: pregnant or breastfeeding; previous cryptococcal meningitis; ALT >
1200 IU/L; ANC < 500 x 106/L; platelets < 50 x 106/L; contraindication to any study
medication
Number randomized: 43 (3 excluded after randomization for false-positive India ink)
Age: median 35 years
Gender: 65% male
CD4 T-cell count: median 41 cells/µL
Baseline ART: none (excluded if prior ART)
Baseline GCS/AMS: GCS < 15 in 25% of participants
Interventions Intervention
1: AmBd 1.0 mg/kg/day for 1 week and fluconazole 1200 mg/day for 2 weeks
2: AmBd 1.0 mg/kg/day for 1 week and fluconazole 1200 mg/day and flucytosine 100
mg/kg/day for 2 weeks
Consolidation: fluconazole 800 mg/day for 2 weeks, then 400 mg/day for 8 weeks, then
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Jackson 2012 (Continued)
200 mg/day maintenance dose
Postdiagnosis ART: ART initiated at 4 weeks.
Lumbar puncture schedule: scheduled on days 1, 3, 7, and 14 and as clinically indicated
Laboratory monitoring: CBC, ALT, AST, K, Cr 3 times per week for first 2 weeks
Outcomes Primary outcome
• Rate of CSF fungal clearance in first 2 weeks
Secondary outcomes
• Mortality at 2 and 10 weeks
• Drug safety
• Serious adverse events
Outcome assessment schedule: daily while hospitalized, then scheduled for visit at 4
weeks to initiate ART, then followed until 10 weeks
Notes Date of study: 2009 to 2010
Funding:Medical Research Council (UK); Department for International Development
in Malawi (UK)
Declaration of conflict of interest by authors: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1 randomization stratified by GCS < 15
using random computer-generated list
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Vital status known for most participants
(39/40) at 10 weeks
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk None noted.
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Jarvis 2012
Methods Study type: unblinded RCT
Setting: 1 hospital in South Africa
Participants Inclusion criteria: HIV infected; ART-naive; ≥ 21 years of age; positive CSF India ink
or CrAg test
Exclusion criteria: pregnant or breastfeeding; previous cryptococcal meningitis; ALT
> 200 IU/mL; ANC < 500 x 106 cells/L; platelets < 50 x 106 cells/L; previous serious
reaction to study drugs or contraindication to study drugs
Number randomized: 90 (2 excluded after randomization due to prior episode of cryp-
tococcal meningitis and low platelets)
Age: median 32 years
Gender: 44% male
CD4 T-cell count: median 27 cells/µL
Baseline ART: none (excluded if prior ART)
Baseline GCS/AMS: GCS < 15 in 37% of participants
Interventions Intervention
1. AmBd 1.0 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks
2. AmBd 1.0 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks with interferon
gamma 100 µg days 1 and 3
3. AmBd 1.0 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks with interferon
gamma 100 µg days 1, 3, 5, 8, 10, and 12
Consolidation: fluconazole 400 mg/day up to 8 weeks, then 200 mg/day maintenance
dose
Postdiagnosis ART: protocol for ART initiation between 2 and 4 weeks
Lumbar puncture schedule: scheduled days 1, 3, 7, and 14 and as clinically indicated
Laboratory monitoring: alternate-day renal function and electrolyte testing and twice-
weekly CBC and LFTs during first 2 weeks
Outcomes Primary outcome
• Rate of CSF fungal clearance in the first 2 weeks
Secondary outcomes
• (Mortality at 2 and 10 weeks
• Serious adverse events
• Laboratory toxicities
Outcome assessment schedule: daily while hospitalized, then up to 1 year after enrol-
ment
Notes Date of study: 2007 to 2010
Funding: Wellcome Trust
Declaration of conflict of interest by authors: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1 randomization with random com-
puter-generated lists with block sizes of 8,
stratified by GCS of 15 or GCS < 15
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Jarvis 2012 (Continued)
Allocation concealment (selection bias) Low risk Numbers maintained in sealed envelopes
prepared by independent individuals
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Vital status at 10 weeks complete in all
groups
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk None noted.
Jarvis 2018
Methods Study type: unblinded RCT
Setting: 1 referral hospital in Botswana and 2 in Tanzania
Participants Inclusion criteria: ≥ 18 years of age; positive CSF India ink or cryptococcal antigen
Exclusion criteria: pregnant or breastfeeding; prior cryptococcal meningitis or more
than 48 hours of antifungal treatment; previous serious reaction to study drugs
Number randomized: 81 (1 participant excluded after randomization due to prior
episode of cryptococcal meningitis)
Age: median 38 years
Gender: 54% male
CD4 T-cell count: median 32 cells/µL
Baseline ART: 32% on ART at enrolment
Baseline GCS/AMS: 28% with GCS < 15
Interventions Intervention
1. Liposomal AmB 10 mg/kg day 1 with fluconazole 1200 mg/day for 2 weeks
2. Liposomal AmB 10 mg/kg day 1 and 5 mg/kg day 3 with fluconazole 1200 mg/
day for 2 weeks
3. Liposomal AmB 10 mg/kg day 1 and 5 mg/kg days 3 and 7 with fluconazole
1200 mg/day for 2 weeks
4. Liposomal AmB 3 mg/kg/day for 14 days
Consolidation: fluconazole 800 mg/day for 8 weeks then 200 mg/day maintenance
Postdiagnosis ART: initiated at 4 to 6 weeks in ART-naive participants
Lumbar puncture schedule: scheduled at days 3, 7, 14, and 21; additional therapeutic
LP if CSF opening pressure > 30 cm H2O or symptoms of raised intracranial pressure
Laboratory monitoring: alternate day renal function and electrolyte assessment and
twice-weekly CBC and ALT for first 2 weeks
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Jarvis 2018 (Continued)
Outcomes Primary outcome
• Mean rate of decrease in CSF cryptococcal colony forming units
Secondary outcomes
• Mortality at 2 and 10 weeks
• Pharmacokinetic/pharmacodynamic parameters
• DAIDS grade 3/4 adverse events
Outcome assessment schedule: clinical monitoring daily for first 2 weeks or until
discharge (whichever was later); clinic follow-up visits weeks 3, 4, 6, and 10
Notes Date of study: 2014 to 2016
Funding: Gilead investigator-initiated award
Declaration of conflict of interest by authors: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomized by means of random com-
puter-generated lists with allocation ratio
of 1:1 andblock sizes of 8; stratified byGCS
< 15 and ART status
Allocation concealment (selection bias) Low risk Randomization lists were accessible to
an independent statistician who prepared
sealed envelopes thatwere sent to study sites
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk Research funded by a pharmaceutical
company through an investigator-initiated
grant; sponsors played no part in the de-
sign, conduct, data analysis, or publication
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Leenders 1997
Methods Study type: unblinded RCT
Setting: academic hospitals in the Netherlands and Australia
Participants Inclusion criteria: HIV infected; ≥ 18 years of age; positive CSF India ink or CrAg
with confirmation by positive CSF culture or CSF CrAg with positive blood culture
Exclusion criteria: previous cryptococcal meningitis; Cr > 250 µmol/L
Number randomized: 30 (2 excluded after randomization including comatose patient
without written informed consent from family and patient with negative CSF culture)
Age: median 41 years (AmBd); 40 years (liposomal AmB)
Gender: not specified
CD4 T-cell count: median 35 cells/µL (AmBd); 35 cells/µL (liposomal AmB)
Baseline ART: 85% (AmBd); 47% (liposomal AmB)
Baseline GCS/AMS: altered mental status 15% (AmBd); 40% (liposomal AmB)
Interventions Intervention
1. AmBd 0.7 mg/kg/day for 3 weeks
2. Liposomal AmB (AmBisome) 4 mg/kg/day for 3 weeks
Consolidation: fluconazole 400 mg/day up to 10 weeks, then 200 mg/day maintenance
dose
Postdiagnosis ART: not specified
Lumbar puncture schedule: scheduled days 7, 14, and 21, after 10 weeks, and as
clinically indicated
Laboratory monitoring: twice-weekly BUN, Cr, and K; weekly CBC and LFTs
Outcomes Primary outcome
• Clinical and mycological response at the completion of 10 weeks (including
mortality and sterile CSF culture)
Secondary outcomes
• Mortality up to 6 months
Outcome assessment schedule: daily for first 3 weeks, then at least every 2 weeks until
10 weeks, with further follow-up until 6 months
Notes Date of study: 1992 to 1995
Funding: NeXstar Pharmaceuticals
Declaration of conflict of interest by authors: industry-sponsored (role of pharma-
ceutical company, which manufactured study drug AmBisome, not specified)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1 randomization stratified by clinical site;
performed by means of sealed envelopes
generated centrally atDutch andAustralian
co-ordination sites
Allocation concealment (selection bias) Low risk Used sealed envelopes maintained sepa-
rately at study co-ordinating centres
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Leenders 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Little loss to follow-up in (1 of 25 partici-
pants)
Selective reporting (reporting bias) Unclear risk Primary and secondary outcomes not spe-
cific, reported on multiple clinical and my-
cological outcomes
Other bias Unclear risk Sponsored by drug manufacturer, involve-
ment in study not clearly stated
Loyse 2012
Methods Study type: unblinded RCT
Setting: 2 hospitals in South Africa
Participants Inclusion criteria: HIV infected; ART-naive; ≥ 18 years of age; positive CSF India ink
confirmed by culture
Exclusion criteria: pregnant or breastfeeding; previous cryptococcal meningitis; ALT
> 200 IU/mL; ANC < 500 x 106 cells/L; platelets < 50 x 106 cells/L; previous serious
reaction to study drugs or contraindication to study drugs
Number randomized: 80 (1 excluded after randomization for prior history of crypto-
coccal meningitis)
Age: median 34 years
Gender: 49% male
CD4 T-cell count: median 37 cells/µL
Baseline ART: none (excluded if prior ART)
Baseline GCS/AMS: GCS < 15 in 15% of participants
Interventions Intervention
1. AmBd 0.7 to 1.0 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks
2. AmBd 0.7 to 1.0 mg/kg/day and fluconazole 800 mg/day for 2 weeks
3. AmBd 0.7 to 1.0 mg/kg/day and fluconazole 1200 mg/day for 2 weeks
4. AmBd 0.7 to 1.0 mg/kg/day and voriconazole 600 mg/day for 2 weeks
Consolidation: fluconazole 400 mg/day up to 8 weeks, then 200 mg/day maintenance
dose
Postdiagnosis ART: protocol for ART initiation > 2 weeks after starting antifungal
therapy
Lumbar puncture schedule: scheduled days 3, 7, and 14 and as clinically indicated
Laboratory monitoring: alternate-day renal function, twice-weekly CBC and LFTs
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Loyse 2012 (Continued)
Outcomes Primary outcome
• Rate of CSF fungal clearance in the first 2 weeks
Secondary outcomes
• Mortality at 2 and 10 weeks
• Drug-related clinical and laboratory adverse events
Outcome assessment schedule: daily while hospitalized, started on ART at 2 weeks,
and followed up to 6 months from enrolment
Notes Date of study: 2006 to 2008
Funding: Wellcome Trust; Medical Research Council (UK)
Declaration of conflict of interest by authors: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1:1 randomization using computer-
generated sequence, stratified by baseline
altered mental status
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Vital status at 10 weeks in most (75/79)
participants
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk None noted.
Mayanja-Kizza 1998
Methods Study type: unblinded RCT
Setting: 1 hospital in Uganda
Participants Inclusion criteria: HIV infected; ≥ 16 years of age; positive CSF India ink or CrAg
Exclusion criteria: pregnant; antifungal therapy in the previous month; comatose
Number randomized: 58
Age: median 34 years
Gender: 43% male
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Mayanja-Kizza 1998 (Continued)
CD4 T-cell count: mean 77 cells/µL
Baseline ART: no
Baseline GCS/AMS: excluded if comatose; 52% of participants noted to have normal
sensorium (no stupor or somnolence)
Interventions Intervention
• Fluconazole 200 mg/day and flucytosine 150 mg/kg/day for 2 months
• Fluconazole 200 mg/day for 2 months
Consolidation: fluconazole 200 mg 3 times weekly
Postdiagnosis ART: no
Lumbar puncture schedule: scheduled after 2 months and 6 months
Laboratory monitoring: laboratory monitoring schedule not specified
Outcomes Primary outcome
• Participant improved clinically or complete resolution of symptoms after 2
months
Secondary outcome
• Mortality up to 6 months
Outcome assessment schedule: Participants assessed by primary medicine service while
hospitalized, with clinic follow-up at 2, 4, 8, and 10 weeks, then monthly up to 3 years
Notes Date of study: 1994
Funding: Pfizer; Japanese Ministry of Education, Science, and Culture
Declaration of conflict of interest by authors: Not specified; role of pharmaceutical
sponsor not specified
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk 1:1 randomization; method of randomiza-
tion not specified
Allocation concealment (selection bias) Low risk Used sealed envelopes for allocation con-
cealment
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
High risk Attrition of 8/58 participants by 6 months
Selective reporting (reporting bias) Low risk Authors reported on primary and sec-
ondary outcome measures.
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Mayanja-Kizza 1998 (Continued)
Other bias Unclear risk Sponsored by pharmaceutical company;
role of company in conduct of study not
specified
Molloy 2018
Methods Study type: unblinded RCT
Setting: 9 hospitals in Malawi, Zambia, Tanzania, and Cameroon
Participants Inclusion criteria: ≥ 18 years of age; positive CSF India ink or cryptococcal antigen
Exclusion criteria: pregnant or breastfeeding; prior cryptococcal meningitis; > 1 dose of
AmBd or > 1 treatment dose (1200 mg) or > 7 low doses (200 mg) of fluconazole in the 2
weeks before screening; previous adverse reaction to study drugs; taking contraindicated
concomitant drugs; ALT > 5 times upper limit of normal or ANC< 500 x 106/L included
as late exclusion criteria after screening; patients with elevated creatinine > 220 µmol/L
the day after enrolment despite hydration were withdrawn from the study
Number randomized: 721 (43 excluded from all analyses because of predefined late
exclusion criteria (30), immediately withdrew consent (3), cryptococcal meningitis neg-
ative (7), or prior cryptococcal meningitis (3))
Age: median 36 years (fluconazole and flucytosine), 38 years (combined 1-week AmBd
arms), 37 years (combined 2-week AmBd arms)
Gender: 53% male (fluconazole and flucytosine), 61% (combined 1-week AmBd arms)
, 58% (combined 2-week AmBd arms)
CD4 T-cell count:median 25 cells/µL (fluconazole and flucytosine), 26 cells/µL (com-
bined 1-week AmBd arms), 26 cells/µL (combined 2-week AmBd arms)
Baseline ART: 59% were taking or had previously taken ART overall
BaselineGCS/AMS:24%withGCS<15 (fluconazole and flucytosine), 20% (combined
1-week AmBd arms), 28% (combined 2-week AmBd arms)
Interventions Intervention
1. Fluconazole 1200 mg/day and flucytosine 100 mg/kg/day for 2 weeks
2. AmBd 1 mg/kg/day for 1 week and fluconazole 1200 mg/day for 2 weeks
3. AmBd 1 mg/kg/day and flucytosine 100 mg/kg/day for 7 days with fluconazole
1200 mg/day on days 8 to 14
4. AmBd 1 mg/kg/day and fluconazole 1200 mg/day for 2 weeks
5. AmBd 1 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks
Consolidation: fluconazole 800 mg/day for 4 weeks then 400 mg/day for 4 weeks then
200 mg/day thereafter
Postdiagnosis ART: initiated at 4 weeks in ART-naive participants or participants who
had discontinued therapy
Lumbar puncture schedule: scheduled at days 7 and 14; additional daily therapeutic
LPs for participants with high CSF pressure until pressure was controlled
Laboratory monitoring: laboratory blood tests monitored regularly during the first 2
weeks
Outcomes Primary outcome
• 10-week mortality
Secondary outcomes
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Molloy 2018 (Continued)
• Mortality at 2 and 4 weeks
• Rate of decrease in log CSF fungal counts over 2 weeks
• DAIDS grade 3/4 adverse events
Outcome assessment schedule: participants were followed daily in hospital and up to
10 weeks
Notes Date of study: 2013 to 2016
Funding: Medical Research Council (UK); France REcherche Nord & Sud Sida-HIV
et Hépatites (France)
Declaration of conflict of interest by authors: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Block randomization in 2:1:1:1:1 ratio (2
for fluconazole and flucytosine arm) using
computer-generated randomization with
block sizes of 18, 24, and 30 at each site
Allocation concealment (selection bias) Low risk Trial pharmacist and clinician responsi-
ble for randomising participants by tak-
ing sealed envelopes containing random-
ized treatment sequentially
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Unblinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low loss to follow-up (4/678)
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk No other bias
Nussbaum 2010
Methods Study type: unblinded RCT
Setting: 1 referral hospital in Malawi
Participants Inclusion criteria: HIV infected; ART-naive; diagnosed by CSF India ink or CrAg test
Exclusion criteria: pregnant or breastfeeding; previous cryptococcal meningitis; ALT >
200 IU/mL; ANC < 500 x 106/L; platelets < 50 x 106/L; contraindication to any study
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Nussbaum 2010 (Continued)
medication
Number randomized: 43 (3 excluded after randomization for breastfeeding, false diag-
nosis due to sampling error, and positive CSF CrAg but negative confirmatory culture)
Age: median 36 years
Gender: 66% male
CD4 T-cell count: median 21 cells/µL
Baseline ART: none (excluded if prior ART)
Baseline GCS/AMS: GCS < 15 in 39% of participants
Interventions Intervention
• Fluconazole 1200 mg/day for 2 weeks
• Fluconazole 1200 mg/day and flucytosine 100 mg/kg/day for 2 weeks
Consolidation: fluconazole 800 mg/day for 2 weeks, then 400 mg/day for 8 weeks, then
200 mg/day maintenance dose
Postdiagnosis ART: ART initiated at 4 weeks.
Lumbar puncture schedule: scheduled on days 1, 3, 7, and 14 and as clinically indicated
Laboratorymonitoring: at least 3 blood counts per week and AST, ALT, and chemistries
once weekly for 2 weeks, with ALT and AST repeated at weeks 4, 6, and 10
Outcomes Primary outcome
• Rate of CSF fungal clearance in first 2 weeks
Secondary outcomes
• Mortality at 2 and 10 weeks
• Drug safety
• Serious adverse events
Outcome assessment schedule: daily while hospitalized, then scheduled for visit at 4
weeks to initiate ART, then followed until 10 weeks
Notes Date of study: 2008 (study terminated early when data safety monitoring committee
found primary endpoint was reached in interim analysis)
Funding: Medical Research Council (UK); UNC Center for AIDS Research
Declaration of conflict of interest by authors: none reported.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1 randomization stratified by GCS < 15
using randomcomputer-generated list with
block size of 8
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Treatment was not blinded.
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Nussbaum 2010 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Outcomes unblinded by assessors
Incomplete outcome data (attrition bias)
All outcomes
Low risk Vital status known for most participants
(39/40) at 10 weeks
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Low risk None noted.
Pappas 2009
Methods Study type: unblinded RCT
Setting: 8 hospitals in the USA and 5 hospitals in Thailand
Participants Inclusion criteria: ≥ 13 years of age; positive CSF culture
Exclusion criteria: pregnant or breastfeeding; prior cryptococcal meningitis; concomi-
tant CNS illness that would interfere with assessment of response; creatinine clearance <
50 mL/min; ALT > 5 x ULN; coma; anticipated survival < 14 days; previous antifungal
therapy > 3 days; untreated active tuberculosis
Number randomized: 143 (8 excluded for negative CSF culture, withdrawal of consent
before treatment, poor renal function, prior episode of cryptococcosis, or receipt of
substantial antifungal therapy or rifampicin before study enrolment)
Age:mean 37 years (AmBd); 36 years (AmBd and fluconazole 400 mg); 36 years (AmBd
and fluconazole 800 mg)
Gender: 65% male (AmBd); 65% male (AmBd and fluconazole 400 mg); 64% male
(AmBd and fluconazole 800 mg)
CD4 T-cell count: median 18 cells/µL (AmBd); 17 cells/µL (AmBd and fluconazole
400 mg/day); 15 cells/µL (AmBd and fluconazole 800 mg/day)
Baseline ART: 8% of participants on ART at baseline
Baseline GCS/AMS: excluded if in coma
Interventions Intervention
• AmBd 0.7 mg/kg/day for 2 weeks
• AmBd 0.7 mg/kg/day and fluconazole 400 mg/day for 2 weeks
• AmBd 0.7 mg/kg/day and fluconazole 800 mg/day for 2 weeks
Consolidation: fluconazole 400 mg/day for 8 weeks in intervention 1 and intervention
2; fluconazole 800 mg/day for 8 weeks in intervention 3
Postdiagnosis ART: participants on baseline ART continued; investigators discouraged
initiation of ART before 42 days; at day 42, 17% (AmBd), 4% (AmBd and fluconazole
400 mg/day), and 22% (AmBd and fluconazole 800 mg/day) had initiated ART
Lumbar puncture schedule: encouraged aggressive management of raised intracranial
pressure with LP; scheduled on days 14 and, if still positive, repeated on days 42 or 70
Laboratory monitoring: monitoring schedule not specified
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Pappas 2009 (Continued)
Outcomes Primary outcomes
• Composite of survival, neurological stability, and negative CSF culture at 2 weeks
• Severe or life-threatening treatment-related toxicities by day 100
Secondary outcomes: none
Outcome assessment schedule: participants evaluated regularly while hospitalized, then
followed through 100 days
Notes Date of study: 2005 to 2007
Funding: National Institutes of Health (USA); fluconazole donated by Pfizer
Declaration of conflict of interest by authors: Authors declared research support from
several pharmaceutical companies including manufacturer of study drug
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk 1:1:1 randomization via adaptive random-
ization system stratified by country and
CSF opening pressures (≤ 250 mm versus
> 250 mm)
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Unblinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blindeddata review committee adjudicated
study data related to clinical and safety out-
comes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Low risk Authors reported on all primary clinical
and safety outcomes
Other bias Unclear risk Several authors received research support
frompharmaceutical companies, including
manufacturer of study drug
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van der Horst 1997
Methods Study type: 2-step, double-blinded RCT
Setting: Multiple hospitals in the USA
Participants Inclusion criteria: ≥ 13 years of age; positive CSF culture
Exclusion criteria: pregnant or breastfeeding; prior cryptococcal meningitis or more
than 1 mg/kg amphotericin B or 1200 mg fluconazole, itraconazole, or ketoconazole for
current episode; taking medications that affected metabolism or decreased absorption
of itraconazole; receiving ≥ 50 mg/day hydrocortisone; history of acute hepatitis or
moderate-to-severe haematologic, renal, or hepatic dysfunction; comatose; unable to
take medications by mouth or nasogastric tube; had a history of other opportunistic
infections requiring treatment during the first 2 weeks
Number randomized: 408 randomized in step 1 randomization to AmBd and flucyto-
sine or AmBd (27 ineligible due to negative CSF culture (19), receiving corticosteroids
or rifampicin (4), prior cryptococcal disease (2), HIV-negative (1), or pregnant (1)); 306
randomized in step 2 to fluconazole or itraconazole maintenance of stable or improved
in step 1, receipt minimal dose of 7.5 mg/kg AmBd, ability to take oral medications,
hepatic enzymes less than 10 times ULN and bilirubin less than 2 times ULN
Age: median 37 years
Gender: 87% male (AmBd and flucytosine); 91% male (AmBd)
CD4 T-cell count: median 20 cells/µL (AmBd and flucytosine); 18 cells/µL (AmBd)
Baseline ART: 27% (AmBd and flucytosine); 26% (AmBd)
Baseline GCS/AMS: 89% with normal mental status
Interventions Step 1 induction
1. AmBd 0.7 mg/kg/day and flucytosine 100 mg/kg/day for 2 weeks
2. AmBd 0.7 mg/kg/day
Step 2 consolidation
1. Fluconazole 400 mg/day for 8 weeks with 800 mg/day loading dose for first 2 days
2. Itraconazole 400 mg/day for 8 weeks with 600 mg/day loading dose for first 3 days
Postdiagnosis ART: not specified
Lumbar puncture schedule: scheduled lumbar punctures at weeks 2, 4, and 10
Laboratory monitoring:monitoring twice weekly for 2 weeks; weekly for next 2 weeks;
then every 2 weeks until 10 weeks
Outcomes Primary outcomes
• Negative CSF culture at 2 weeks and 10 weeks
• Stable or improved fever, headache, and meningismus at 2 weeks and 10 weeks
Secondary outcome
• Drug toxicity
Outcome assessment schedule: clinical monitoring twice weekly for 2 weeks; weekly
for next 2 weeks; then every 2 weeks until 10 weeks
Notes Date of study: 1991 to 1994
Funding: National Institute of Allergy and Infectious Diseases, AIDS Clinical Trial
Group, National Center for Research Services, and Janssen Research Foundation; drugs
provided by Bristol-Myers Squibb (AmBd), Roche Laboratories (flucytosine), Roerig-
Pfizer (fluconazole), and Janssen Research Foundation (itraconazole)
Declaration of conflict of interest by authors: research supported by several pharma-
ceutical companies as well as public sources
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van der Horst 1997 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomization not specified;
stratified by altered mental status and insti-
tution in step 1 and baseline mental status
and therapy received in step 2
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcomes reported for all participants.
Selective reporting (reporting bias) Low risk Authors reported on all primary and sec-
ondary outcomes.
Other bias Unclear risk Research funded in part by pharmaceuti-
cal companies, including manufacturer of
study drug
Abbreviations: ALT: alanine aminotransferase; AmBd: amphotericin B deoxycholate; AMS: altered mental status; ANC: absolute
neutrophil count; ART: antiretroviral therapy; AST: aspartate aminotransferase; BUN: blood urea nitrogen; CBC: complete blood
count; CD4: cluster of differentiation 4; CNS: central nervous system;CrAg: cryptococcal antigen; Cr: creatinine; CSF: cerebrospinal
fluid; DAIDS: Division of AIDS; GCS: Glasgow coma scale; K: potassium; LFT: liver function test; LP: lumbar puncture; Na:
sodium; RCT: randomized controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Bicanic 2008 Compared 2 interventions of the same combination antifungal drugs, 2 weeks of AmBd 0.7 mg/kg/day
or AmBd 1 mg/kg/day both combined with flucytosine 100 mg/kg/day
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(Continued)
Bisson 2013 Small trial evaluating early (within 7 days) versus delayed (after 4weeks) ART initiation following diagnosis
of cryptococcal meningitis; all participants received standard induction treatment of AmBd 0.7 mg/kg/
day for 2 weeks
Boulware 2014b RCT comparing early versus delayed ART initiation in participants treated with AmBd and fluconazole;
patients were enrolled 1 week after initiating therapy, before which an estimated 12% of patients had
already died
Bozzette 1991 RCT with participants randomized to maintenance therapy
Brouwer 2007 Subanalysis of included RCT, Brouwer 2004, comparing participants treated with IV versus oral formu-
lations of flucytosine
Chariyalertsak 2002 RCT with participants randomized to consolidation therapy, not induction therapy
Chetchotisakd 2004 RCT of primary prophylaxis against cryptococcal meningitis, not induction therapy
Chotmongkol 1997 RCT of consolidation therapy with itraconazole versus no therapy after CSF culture clearance
Chotmongkol 2005 Small study of 40 participants in which participants in study arms were not well matched for severity
of disease (45% in AmBd plus rifampicin arm versus 0% in AmBd arm had positive Cryptococcus blood
cultures at baseline); important baseline characteristics including CD4 T-cell count were not described
de Gans 1992 Small study of 25 participants randomized to itraconazole versus AmBd and flucytosine for induction
therapy where 2/14 participants in itraconazole group crossed over within 4 hours and an additional 2
participants were lost to follow-up
Hamill 2010 Included re-treatment cases of cryptococcal meningitis
Jadhav 2010 Excluded patients who had not received a minimum of 8 doses of liposomal amphotericin treatment,
introducing immortality bias
Joly 1996a Included patients with relapsed cryptococcal meningitis
Joly 1996b Included patients with relapsed cryptococcal meningitis
Larsen 1990 Small study of 20 participants comparing fluconazole to AmBd and flucytosine, which was excluded for
several reasons: did not do intention-to-treat analysis; excluded significant number of participants (6/
26) from analysis after enrolment; enrolled non-HIV-positive patient; final comparison groups poorly
matched on CD4 count
Makadzange 2010 Evaluated timing of ART (within 72 hours of cryptococcal meningitis diagnosis or after 10 weeks); all
participants received fluconazole induction therapy; a large proportion of patients died before enrolment,
introducing a risk of immortality bias
Mfinanga 2015 RCT with participants randomized to intervention including cryptococcal antigen screening for preven-
tion of cryptococcal meningitis
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Mootsikapun 2003 RCT with participants randomized to consolidation therapy, not induction therapy
Newton 2002 Small RCT of adjunctive acetazolamide that did not limit inclusion to patients with HIV-associated
cryptococcal meningitis
Pappas 2004 Included patients with relapsed cryptococcal meningitis
Powderly 1992 RCT of secondary prophylaxis for prevention of recurrent cryptococcal meningitis
Powderly 1995 RCT of primary prophylaxis for fungal infections
Rhein 2016 Initially was a dose escalation study of adjunctive sertraline as therapy for cryptococcal meningitis; inves-
tigators compared outcomes to historic controls
Saag 1991 RCT that included patients with relapsed cryptococcal meningitis
Saag 1999 RCT of consolidation therapy for cryptococcal meningitis
Sharkey 1996 Small RCT comparing AmBd with different doses of liposomal amphotericin B in which CD4 count and
other baseline characteristics were not well matched between groups
Tansuphaswadikul 2006 Small RCT comparing 1-week and 2-week induction therapy with AmBd with very high loss to follow-
up (33%) by 10 weeks, which could bias mortality results
Techapornroong 2007 Small RCT comparing daily and alternate-day AmBd induction therapy with very high loss to follow-up
(25%) by 3 months, which could bias mortality results
Vaidhya 2015 RCT comparing AmBd with AmBd and fluconazole that did not include any primary or secondary
outcomes (mortality, early fungicidal activity, or adverse events)
Vibhagool 2003 RCT of secondary prophylaxis for cryptococcal meningitis
Villanueva-Lozano 2018 Small RCT of 12 participants comparing amphotericin and fluconazole with adjunctive sertraline and
amphotericin and fluconazole with placebo that had significant imbalance in CD4 count between treat-
ment arms; also excluded one patient from analysis for not receiving per-protocol treatment
Abbreviations: AmBd: amphotericin B deoxycholate; ART: antiretroviral therapy; CD4: cluster of differentiation 4; CSF: cerebrospinal
fluid; IV: intravenous; RCT: randomized controlled trial
78Treatment for HIV-associated cryptococcal meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Characteristics of ongoing studies [ordered by study ID]
ISRCTN72509687
Trial name or title High dose AMBISOME on a fluconazole backbone for cryptococcal meningitis induction therapy in sub-
Saharan Africa
Methods Phase 3 non-inferiority RCT from 6 sites in South Africa, Botswana, Zimbabwe, Malawi, and Uganda with
planned enrolment of 850 participants
Participants Age ≥ 18 years with first episode of HIV-associated cryptococcal meningitis
Interventions (i) Single dose of 10 mg/kg IV liposomal AmB with 2 weeks 5FC 100 mg/kg/day and FLU 1200 mg/day
(ii) 1 week of AmBd 1 mg/kg/day and 5FC 100 mg/kg/day followed by FLU 1200 mg/day days 8 to 14
Outcomes Primary: 10-week mortality
Starting date 2017
Contact information joseph.jarvis@lshtm.ac.uk
Notes Original protocol was to compare short-course L-AmB and 2 weeks of AmBd with FLU as a second drug
for both regimens; however, protocol was modified after results from Molloy 2018 study became available
showing mortality benefit with 1 week of AmBd and 5FC followed by FLU days 8 to 14
NCT00885703
Trial name or title High-dose fluconazole for the treatment of cryptococcal meningitis in HIV-positive individuals
Methods Phase 1/2 dose-finding RCT of high-dose fluconazole for HIV-associated cryptococcal meningitis with or
without AmBd 0.7 to 1.0 mg/kg/day
Participants Age ≥ 16 years with HIV-associated cryptococcal meningitis
Interventions Multistage study of high-dose FLU with or without AmBd
Outcomes Primary: discontinuation of study-provided FLU or AmBd; qualitative and quantitative CSF culture results
at entry, 2 weeks, and through 24 weeks; survival up to 24 weeks
Starting date 2010
Contact information umeshlalloo@gmail.com
Notes Completed study with results not published in peer-reviewed journal but presented at Conference on Retro-
viruses and Opportunistic Infections 2018
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NCT01802385
Trial name or title Adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis (ASTRO-CM)
Methods Phase 3 RCT
Participants ≥ 18 years of age with HIV-associated cryptococcal meningitis
Interventions 2 weeks of AmBd 0.7 to 1.0 mg/kg/day and FLU 800 to 1200 mg/day plus sertraline 400 mg/day for 2 weeks
then sertraline 200 mg/day for 12 weeks then tapered over 3 weeks versus 2 weeks of AmBd 0.7 to 1.0 mg/
kg/day and FLU 800 to 1200 mg/day
Outcomes Primary: 18-week survival
Starting date 2015
Contact information david.meya@gmail.com
Notes Study terminated during interim monitoring for futility, results not published in peer-reviewed journal but
presented at Conference on Retroviruses and Opportunistic Infections 2018
Abbreviations: 5FC: flucytosine; AmBd: amphotericin B deoxycholate; CSF: cerebrospinal fluid; FLU: fluconazole; IV: intravenous;
L-AmB: liposomal amphotericin; RCT: randomized controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. One week of AmBd + 5FC versus two weeks of AmBd + 5FC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 228 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.30, 1.03]
1.2 10 weeks 1 228 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.42, 0.93]
2 Early fungicidal activity 1 186 Mean Difference (IV, Random, 95% CI) 0.05 [-0.02, 0.12]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 228 Risk Ratio (M-H, Random, 95% CI) 0.31 [0.16, 0.60]
3.2 Renal dysfunction 1 228 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.18, 1.93]
3.3 Neutropenia 1 228 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.43, 2.03]
3.4 Hypokalaemia 1 228 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.50, 3.39]
3.5 ALT abnormality 1 228 Risk Ratio (M-H, Random, 95% CI) 3.05 [0.63, 14.81]
Comparison 2. One week of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 227 Risk Ratio (M-H, Random, 95% CI) 0.52 [0.28, 0.97]
1.2 10 weeks 1 227 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.39, 0.86]
2 Early fungicidal activity 1 192 Mean Difference (IV, Random, 95% CI) -0.07 [-0.14, -0.00]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 227 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.18, 0.71]
3.2 Renal dysfunction 1 227 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.10, 0.85]
3.3 Neutropenia 1 227 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.49, 2.51]
3.4 Hypokalaemia 1 227 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.42, 2.45]
3.5 LFT abnormality 1 227 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.34, 3.03]
Comparison 3. One week of AmBd + 5FC versus one week of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 224 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.20, 0.63]
1.2 10 weeks 1 224 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.34, 0.72]
2 Early fungicidal activity 1 179 Mean Difference (IV, Random, 95% CI) -0.08 [-0.15, -0.01]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 224 Risk Ratio (M-H, Random, 95% CI) 0.41 [0.21, 0.82]
81Treatment for HIV-associated cryptococcal meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
3.2 Renal dysfunction 1 224 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.12, 1.09]
3.3 Neutropenia 1 224 Risk Ratio (M-H, Random, 95% CI) 1.54 [0.62, 3.84]
3.4 Hypokalaemia 1 224 Risk Ratio (M-H, Random, 95% CI) 1.77 [0.61, 5.11]
3.5 ALT abnormality 1 224 Risk Ratio (M-H, Random, 95% CI) 2.95 [0.61, 14.29]
Comparison 4. One week of AmBd + 5FC versus two weeks of 5FC + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 338 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.35, 1.13]
1.2 10 weeks 1 338 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.47, 0.99]
2 Early fungicidal activity 1 280 Mean Difference (IV, Random, 95% CI) -0.18 [-0.24, -0.12]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 338 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.79, 4.13]
3.2 Renal dysfunction 1 338 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.24, 2.22]
3.3 Neutropenia 1 338 Risk Ratio (M-H, Random, 95% CI) 0.95 [0.48, 1.88]
3.4 Hypokalaemia 1 338 Risk Ratio (M-H, Random, 95% CI) 5.97 [1.65, 21.63]
3.5 ALT abnormality 1 338 Risk Ratio (M-H, Random, 95% CI) 1.99 [0.66, 6.03]
Comparison 5. Two weeks of 5FC + FLU versus two weeks of AmBd + 5FC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 340 Risk Ratio (M-H, Random, 95% CI) 0.87 [0.56, 1.37]
1.2 10 weeks 1 340 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.69, 1.23]
2 Early fungicidal activity 1 270 Mean Difference (IV, Random, 95% CI) 0.23 [0.17, 0.29]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 340 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.09, 0.32]
3.2 Renal dysfunction 1 340 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.32, 2.02]
3.3 Neutropenia 1 340 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.51, 1.90]
3.4 Hypokalaemia 1 340 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.06, 0.83]
3.5 ALT abnormality 1 340 Risk Ratio (M-H, Random, 95% CI) 1.53 [0.31, 7.48]
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Comparison 6. Two weeks of 5FC + FLU versus two weeks of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 339 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.53, 1.29]
1.2 10 weeks 1 339 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.64, 1.13]
2 Early fungicidal activity 1 276 Mean Difference (IV, Random, 95% CI) 0.11 [0.05, 0.17]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 339 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.10, 0.39]
3.2 Renal dysfunction 1 339 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.19, 0.85]
3.3 Neutropenia 1 339 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.57, 2.36]
3.4 Hypokalaemia 1 339 Risk Ratio (M-H, Random, 95% CI) 0.17 [0.05, 0.61]
3.5 ALT abnormality 1 339 Risk Ratio (M-H, Random, 95% CI) 0.51 [0.17, 1.54]
Comparison 7. Two weeks of AmBd + 5FC versus two weeks of AmBd
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 3 612 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.44, 1.11]
1.2 10 weeks 2 231 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.46, 0.95]
1.3 6 months 1 199 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.46, 0.88]
2 Early fungicidal activity 2 225 Mean Difference (IV, Random, 95% CI) -0.15 [-0.26, -0.04]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 199 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.54, 1.06]
3.2 Renal dysfunction 1 199 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.14, 6.89]
3.3 Neutropenia 1 199 Risk Ratio (M-H, Random, 95% CI) 4.46 [0.99, 20.10]
3.4 Hypokalaemia 1 199 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.64, 1.87]
Comparison 8. Two weeks of AmBd + FLU versus two weeks of AmBd
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 3 371 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.45, 1.77]
1.2 10 weeks 3 371 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.55, 1.62]
1.3 6 months 1 198 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.64, 1.13]
2 Early fungicidal activity 2 223 Mean Difference (IV, Random, 95% CI) -0.02 [-0.06, 0.02]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 198 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.43, 0.91]
3.2 Renal dysfunction 1 198 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.14, 6.96]
3.3 Neutropenia 1 198 Risk Ratio (M-H, Random, 95% CI) 4.5 [1.00, 20.30]
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3.4 Hypokalaemia 1 198 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.34, 1.23]
Comparison 9. Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 4 538 Risk Ratio (M-H, Random, 95% CI) 0.80 [0.55, 1.16]
1.2 10 weeks 4 538 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.69, 1.17]
1.3 6 months 1 199 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.53, 1.06]
2 Early fungicidal activity 4 474 Mean Difference (IV, Random, 95% CI) -0.09 [-0.14, -0.05]
3 DAIDS grade 3/4 toxicities 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 3 507 Risk Ratio (M-H, Random, 95% CI) 1.17 [0.89, 1.55]
3.2 Renal dysfunction 3 507 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.31, 1.37]
3.3 Neutropenia 3 507 Risk Ratio (M-H, Random, 95% CI) 1.10 [0.61, 1.98]
3.4 Hypokalaemia 3 507 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.63, 2.27]
3.5 ALT abnormality 2 308 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.07, 1.60]
Comparison 10. Two weeks of AmBd + FLU + steroids versus two weeks of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 450 Risk Ratio (M-H, Random, 95% CI) 0.84 [0.57, 1.23]
1.2 10 weeks 1 450 Risk Ratio (M-H, Random, 95% CI) 1.15 [0.93, 1.42]
1.3 6 months 1 450 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.99, 1.41]
2 Early fungicidal activity 1 450 Mean Difference (IV, Random, 95% CI) 0.1 [0.06, 0.14]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 450 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.90, 1.29]
3.2 Renal dysfunction 1 450 Risk Ratio (M-H, Random, 95% CI) 1.59 [1.18, 2.16]
3.3 Neutropenia 1 450 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.51, 1.02]
3.4 Hypokalaemia 1 450 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.69, 0.98]
3.5 ALT abnormality 1 450 Risk Ratio (M-H, Random, 95% CI) 3.36 [0.94, 12.06]
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Comparison 11. One week of AmBd + FLU versus two weeks of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 225 Risk Ratio (M-H, Random, 95% CI) 1.48 [0.95, 2.29]
1.2 10 weeks 1 225 Risk Ratio (M-H, Random, 95% CI) 1.18 [0.88, 1.58]
2 Early fungicidal activity 1 175 Mean Difference (IV, Random, 95% CI) 0.01 [-0.06, 0.08]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 225 Risk Ratio (M-H, Random, 95% CI) 0.88 [0.55, 1.42]
3.2 Renal dysfunction 1 225 Risk Ratio (M-H, Random, 95% CI) 0.81 [0.38, 1.70]
3.3 Neutropenia 1 225 Risk Ratio (M-H, Random, 95% CI) 0.72 [0.28, 1.82]
3.4 Hypokalaemia 1 225 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.20, 1.65]
3.5 ALT abnormality 1 225 Risk Ratio (M-H, Random, 95% CI) 0.34 [0.07, 1.66]
Comparison 12. One week of AmBd + FLU versus two weeks of AmBd + 5FC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 226 Risk Ratio (M-H, Random, 95% CI) 1.55 [1.00, 2.43]
1.2 10 weeks 1 226 Risk Ratio (M-H, Random, 95% CI) 1.27 [0.94, 1.72]
2 Early fungicidal activity 1 169 Mean Difference (IV, Random, 95% CI) 0.13 [0.06, 0.20]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 226 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.48, 1.19]
3.2 Renal dysfunction 1 226 Risk Ratio (M-H, Random, 95% CI) 1.63 [0.65, 4.05]
3.3 Neutropenia 1 226 Risk Ratio (M-H, Random, 95% CI) 0.60 [0.25, 1.48]
3.4 Hypokalaemia 1 226 Risk Ratio (M-H, Random, 95% CI) 0.74 [0.24, 2.26]
3.5 ALT abnormality 1 226 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.15, 7.23]
Comparison 13. One week of AmBd + FLU versus two weeks of 5FC + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 336 Risk Ratio (M-H, Random, 95% CI) 1.78 [1.21, 2.62]
1.2 10 weeks 1 336 Risk Ratio (M-H, Random, 95% CI) 1.39 [1.07, 1.80]
2 Early fungicidal activity 1 263 Mean Difference (IV, Random, 95% CI) -0.10 [-0.16, -0.04]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 336 Risk Ratio (M-H, Random, 95% CI) 4.42 [2.25, 8.70]
3.2 Renal dysfunction 1 336 Risk Ratio (M-H, Random, 95% CI) 2.03 [0.91, 4.53]
3.3 Neutropenia 1 336 Risk Ratio (M-H, Random, 95% CI) 0.62 [0.27, 1.39]
3.4 Hypokalaemia 1 336 Risk Ratio (M-H, Random, 95% CI) 3.38 [0.82, 13.88]
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3.5 ALT abnormality 1 336 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.14, 3.29]
Comparison 14. Two weeks of FLU versus two weeks of 5FC + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 2 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 2 98 Risk Ratio (M-H, Random, 95% CI) 3.04 [1.31, 7.06]
1.2 10 weeks 2 98 Risk Ratio (M-H, Random, 95% CI) 1.46 [0.96, 2.23]
2 Early fungicidal activity 1 37 Mean Difference (IV, Random, 95% CI) 0.17 [0.08, 0.26]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 40 Risk Ratio (M-H, Random, 95% CI) 1.11 [0.07, 16.47]
3.2 Renal dysfunction 1 40 Risk Ratio (M-H, Random, 95% CI) 2.21 [0.22, 22.47]
3.3 Neutropenia 1 40 Risk Ratio (M-H, Random, 95% CI) 0.22 [0.03, 1.73]
3.4 ALT abnormality 1 40 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 15. Two weeks of L-AmB versus two weeks of AmBd
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 28 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
1.2 10 weeks 1 28 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.04, 4.25]
1.3 6 months 1 28 Risk Ratio (M-H, Random, 95% CI) 0.58 [0.11, 2.94]
Comparison 16. Short-course L-AmB + FLU versus two weeks of L-AmB + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 79 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.43, 7.59]
1.2 10 weeks 1 79 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.47, 2.25]
2 Early fungicidal activity 1 67 Mean Difference (IV, Random, 95% CI) -0.10 [-0.21, 0.01]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 79 Risk Ratio (M-H, Random, 95% CI) 1.81 [0.22, 14.61]
3.2 Renal dysfunction 1 79 Risk Ratio (M-H, Random, 95% CI) 4.10 [0.24, 71.15]
3.3 Neutropenia 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.4 Hypokalaemia 1 79 Risk Ratio (M-H, Random, 95% CI) 0.07 [0.01, 0.58]
3.5 ALT abnormality 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 17. Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + 5FC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 31 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.06, 13.68]
1.2 10 weeks 1 31 Risk Ratio (M-H, Random, 95% CI) 2.81 [0.33, 24.16]
2 Early fungicidal activity 1 27 Mean Difference (IV, Random, 95% CI) 0.16 [0.03, 0.29]
Comparison 18. Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 32 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.03, 1.53]
1.2 10 weeks 1 32 Risk Ratio (M-H, Random, 95% CI) 0.43 [0.13, 1.37]
2 Early fungicidal activity 1 26 Mean Difference (IV, Random, 95% CI) 0.01 [-0.10, 0.12]
Comparison 19. Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 32 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.05, 4.98]
1.2 10 weeks 1 32 Risk Ratio (M-H, Random, 95% CI) 1.0 [0.24, 4.23]
2 Early fungicidal activity 1 29 Mean Difference (IV, Random, 95% CI) -0.07 [-0.18, 0.04]
Comparison 20. One week of AmBd + 5FC + FLU versus one week of AmBd + FLU
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 40 Risk Ratio (M-H, Random, 95% CI) 0.5 [0.10, 2.43]
1.2 10 weeks 1 40 Risk Ratio (M-H, Random, 95% CI) 0.86 [0.35, 2.10]
2 Early fungicidal activity 1 37 Mean Difference (IV, Random, 95% CI) -0.12 [-0.23, -0.01]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 40 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.20, 1.65]
3.2 Renal dysfunction 1 40 Risk Ratio (M-H, Random, 95% CI) 0.8 [0.25, 2.55]
3.3 Neutropenia 1 40 Risk Ratio (M-H, Random, 95% CI) 1.25 [0.39, 3.99]
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3.4 Hypokalaemia 1 40 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.12, 3.57]
Comparison 21. Two weeks of AmBd + 5FC + IFNg versus two weeks of AmBd + 5FC
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 2 weeks 1 88 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.28, 1.90]
1.2 10 weeks 1 88 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.48, 1.77]
2 Early fungicidal activity 1 88 Mean Difference (IV, Random, 95% CI) -0.15 [-0.24, -0.06]
3 DAIDS grade 3/4 toxicities 1 Risk Ratio (M-H, Random, 95% CI) Subtotals only
3.1 Anaemia 1 88 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.62, 2.11]
3.2 Renal dysfunction 1 88 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.37, 1.98]
3.3 Neutropenia 1 88 Risk Ratio (M-H, Random, 95% CI) 1.36 [0.28, 6.60]
3.4 Hypokalaemia 1 88 Risk Ratio (M-H, Random, 95% CI) 3.86 [0.21, 72.44]
3.5 ALT abnormality 1 88 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 One week of AmBd + 5FC versus two weeks of AmBd + 5FC, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 1 One week of AmBd + 5FC versus two weeks of AmBd + 5FC
Outcome: 1 Mortality
Study or subgroup short AmBd+5FC AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 13/113 24/115 100.0 % 0.55 [ 0.30, 1.03 ]
Subtotal (95% CI) 113 115 100.0 % 0.55 [ 0.30, 1.03 ]
Total events: 13 (short AmBd+5FC), 24 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.87 (P = 0.061)
2 10 weeks
Molloy 2018 27/113 44/115 100.0 % 0.62 [ 0.42, 0.93 ]
Subtotal (95% CI) 113 115 100.0 % 0.62 [ 0.42, 0.93 ]
Total events: 27 (short AmBd+5FC), 44 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 2.29 (P = 0.022)
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Analysis 1.2. Comparison 1 One week of AmBd + 5FC versus two weeks of AmBd + 5FC, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 1 One week of AmBd + 5FC versus two weeks of AmBd + 5FC
Outcome: 2 Early fungicidal activity
Study or subgroup short AmBd+5FC AmBd+5FC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 98 -0.44 (0.25) 88 -0.49 (0.26) 100.0 % 0.05 [ -0.02, 0.12 ]
Total (95% CI) 98 88 100.0 % 0.05 [ -0.02, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours short AmBd+5FC Favours AmBd+5FC
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Analysis 1.3. Comparison 1 One week of AmBd + 5FC versus two weeks of AmBd + 5FC, Outcome 3
DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 1 One week of AmBd + 5FC versus two weeks of AmBd + 5FC
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short AmBd+5FC AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 10/113 33/115 100.0 % 0.31 [ 0.16, 0.60 ]
Subtotal (95% CI) 113 115 100.0 % 0.31 [ 0.16, 0.60 ]
Total events: 10 (short AmBd+5FC), 33 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 3.50 (P = 0.00046)
2 Renal dysfunction
Molloy 2018 4/113 7/115 100.0 % 0.58 [ 0.18, 1.93 ]
Subtotal (95% CI) 113 115 100.0 % 0.58 [ 0.18, 1.93 ]
Total events: 4 (short AmBd+5FC), 7 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
3 Neutropenia
Molloy 2018 11/113 12/115 100.0 % 0.93 [ 0.43, 2.03 ]
Subtotal (95% CI) 113 115 100.0 % 0.93 [ 0.43, 2.03 ]
Total events: 11 (short AmBd+5FC), 12 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
4 Hypokalaemia
Molloy 2018 9/113 7/115 100.0 % 1.31 [ 0.50, 3.39 ]
Subtotal (95% CI) 113 115 100.0 % 1.31 [ 0.50, 3.39 ]
Total events: 9 (short AmBd+5FC), 7 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
5 ALT abnormality
Molloy 2018 6/113 2/115 100.0 % 3.05 [ 0.63, 14.81 ]
Subtotal (95% CI) 113 115 100.0 % 3.05 [ 0.63, 14.81 ]
Total events: 6 (short AmBd+5FC), 2 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.17)
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Analysis 2.1. Comparison 2 One week of AmBd + 5FC versus two weeks of AmBd + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 2 One week of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup short AmBd+5FC AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 13/113 25/114 100.0 % 0.52 [ 0.28, 0.97 ]
Subtotal (95% CI) 113 114 100.0 % 0.52 [ 0.28, 0.97 ]
Total events: 13 (short AmBd+5FC), 25 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.041)
2 10 weeks
Molloy 2018 27/113 47/114 100.0 % 0.58 [ 0.39, 0.86 ]
Subtotal (95% CI) 113 114 100.0 % 0.58 [ 0.39, 0.86 ]
Total events: 27 (short AmBd+5FC), 47 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0068)
Test for subgroup differences: Chi2 = 0.07, df = 1 (P = 0.79), I2 =0.0%
0.05 0.2 1 5 20
Favours short AmBd+5FC Favours AmBd+FLU
91Treatment for HIV-associated cryptococcal meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 2.2. Comparison 2 One week of AmBd + 5FC versus two weeks of AmBd + FLU, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 2 One week of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup short AmBd+5FC AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 98 -0.44 (0.25) 94 -0.37 (0.24) 100.0 % -0.07 [ -0.14, 0.00 ]
Total (95% CI) 98 94 100.0 % -0.07 [ -0.14, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours short AmBd+5FC Favours AmBd+FLU
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Analysis 2.3. Comparison 2 One week of AmBd + 5FC versus two weeks of AmBd + FLU, Outcome 3
DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 2 One week of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short AmBd+5FC AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 10/113 28/114 100.0 % 0.36 [ 0.18, 0.71 ]
Subtotal (95% CI) 113 114 100.0 % 0.36 [ 0.18, 0.71 ]
Total events: 10 (short AmBd+5FC), 28 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.97 (P = 0.0030)
2 Renal dysfunction
Molloy 2018 4/113 14/114 100.0 % 0.29 [ 0.10, 0.85 ]
Subtotal (95% CI) 113 114 100.0 % 0.29 [ 0.10, 0.85 ]
Total events: 4 (short AmBd+5FC), 14 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
3 Neutropenia
Molloy 2018 11/113 10/114 100.0 % 1.11 [ 0.49, 2.51 ]
Subtotal (95% CI) 113 114 100.0 % 1.11 [ 0.49, 2.51 ]
Total events: 11 (short AmBd+5FC), 10 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
4 Hypokalaemia
Molloy 2018 9/113 9/114 100.0 % 1.01 [ 0.42, 2.45 ]
Subtotal (95% CI) 113 114 100.0 % 1.01 [ 0.42, 2.45 ]
Total events: 9 (short AmBd+5FC), 9 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
5 LFT abnormality
Molloy 2018 6/113 6/114 100.0 % 1.01 [ 0.34, 3.03 ]
Subtotal (95% CI) 113 114 100.0 % 1.01 [ 0.34, 3.03 ]
Total events: 6 (short AmBd+5FC), 6 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Test for subgroup differences: Chi2 = 8.29, df = 4 (P = 0.08), I2 =52%
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Analysis 3.1. Comparison 3 One week of AmBd + 5FC versus one week of AmBd + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 3 One week of AmBd + 5FC versus one week of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup short AmBd+5FC short AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 13/113 36/111 100.0 % 0.35 [ 0.20, 0.63 ]
Subtotal (95% CI) 113 111 100.0 % 0.35 [ 0.20, 0.63 ]
Total events: 13 (short AmBd+5FC), 36 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 3.52 (P = 0.00044)
2 10 weeks
Molloy 2018 27/113 54/111 100.0 % 0.49 [ 0.34, 0.72 ]
Subtotal (95% CI) 113 111 100.0 % 0.49 [ 0.34, 0.72 ]
Total events: 27 (short AmBd+5FC), 54 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 3.66 (P = 0.00025)
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Analysis 3.2. Comparison 3 One week of AmBd + 5FC versus one week of AmBd + FLU, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 3 One week of AmBd + 5FC versus one week of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup short AmBd+5FC short AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 98 -0.44 (0.25) 81 -0.36 (0.23) 100.0 % -0.08 [ -0.15, -0.01 ]
Total (95% CI) 98 81 100.0 % -0.08 [ -0.15, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 One week of AmBd + 5FC versus one week of AmBd + FLU, Outcome 3 DAIDS
grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 3 One week of AmBd + 5FC versus one week of AmBd + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short AmBd+5FC short AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 10/113 24/111 100.0 % 0.41 [ 0.21, 0.82 ]
Subtotal (95% CI) 113 111 100.0 % 0.41 [ 0.21, 0.82 ]
Total events: 10 (short AmBd+5FC), 24 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
2 Renal dysfunction
Molloy 2018 4/113 11/111 100.0 % 0.36 [ 0.12, 1.09 ]
Subtotal (95% CI) 113 111 100.0 % 0.36 [ 0.12, 1.09 ]
Total events: 4 (short AmBd+5FC), 11 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.070)
3 Neutropenia
Molloy 2018 11/113 7/111 100.0 % 1.54 [ 0.62, 3.84 ]
Subtotal (95% CI) 113 111 100.0 % 1.54 [ 0.62, 3.84 ]
Total events: 11 (short AmBd+5FC), 7 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.93 (P = 0.35)
4 Hypokalaemia
Molloy 2018 9/113 5/111 100.0 % 1.77 [ 0.61, 5.11 ]
Subtotal (95% CI) 113 111 100.0 % 1.77 [ 0.61, 5.11 ]
Total events: 9 (short AmBd+5FC), 5 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
5 ALT abnormality
Molloy 2018 6/113 2/111 100.0 % 2.95 [ 0.61, 14.29 ]
Subtotal (95% CI) 113 111 100.0 % 2.95 [ 0.61, 14.29 ]
Total events: 6 (short AmBd+5FC), 2 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
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Analysis 4.1. Comparison 4 One week of AmBd + 5FC versus two weeks of 5FC + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 4 One week of AmBd + 5FC versus two weeks of 5FC + FLU
Outcome: 1 Mortality
Study or subgroup short AmBd+5FC 5FC+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 13/113 41/225 100.0 % 0.63 [ 0.35, 1.13 ]
Subtotal (95% CI) 113 225 100.0 % 0.63 [ 0.35, 1.13 ]
Total events: 13 (short AmBd+5FC), 41 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
2 10 weeks
Molloy 2018 27/113 79/225 100.0 % 0.68 [ 0.47, 0.99 ]
Subtotal (95% CI) 113 225 100.0 % 0.68 [ 0.47, 0.99 ]
Total events: 27 (short AmBd+5FC), 79 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.044)
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Analysis 4.2. Comparison 4 One week of AmBd + 5FC versus two weeks of 5FC + FLU, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 4 One week of AmBd + 5FC versus two weeks of 5FC + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup short AmBd+5FC 5FC+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 98 -0.44 (0.25) 182 -0.26 (0.18) 100.0 % -0.18 [ -0.24, -0.12 ]
Total (95% CI) 98 182 100.0 % -0.18 [ -0.24, -0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.30 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 One week of AmBd + 5FC versus two weeks of 5FC + FLU, Outcome 3 DAIDS
grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 4 One week of AmBd + 5FC versus two weeks of 5FC + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short AmBd+5FC 5FC+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 10/113 11/225 100.0 % 1.81 [ 0.79, 4.13 ]
Subtotal (95% CI) 113 225 100.0 % 1.81 [ 0.79, 4.13 ]
Total events: 10 (short AmBd+5FC), 11 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.41 (P = 0.16)
2 Renal dysfunction
Molloy 2018 4/113 11/225 100.0 % 0.72 [ 0.24, 2.22 ]
Subtotal (95% CI) 113 225 100.0 % 0.72 [ 0.24, 2.22 ]
Total events: 4 (short AmBd+5FC), 11 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
3 Neutropenia
Molloy 2018 11/113 23/225 100.0 % 0.95 [ 0.48, 1.88 ]
Subtotal (95% CI) 113 225 100.0 % 0.95 [ 0.48, 1.88 ]
Total events: 11 (short AmBd+5FC), 23 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
4 Hypokalaemia
Molloy 2018 9/113 3/225 100.0 % 5.97 [ 1.65, 21.63 ]
Subtotal (95% CI) 113 225 100.0 % 5.97 [ 1.65, 21.63 ]
Total events: 9 (short AmBd+5FC), 3 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.72 (P = 0.0065)
5 ALT abnormality
Molloy 2018 6/113 6/225 100.0 % 1.99 [ 0.66, 6.03 ]
Subtotal (95% CI) 113 225 100.0 % 1.99 [ 0.66, 6.03 ]
Total events: 6 (short AmBd+5FC), 6 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
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Analysis 5.1. Comparison 5 Two weeks of 5FC + FLU versus two weeks of AmBd + 5FC, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 5 Two weeks of 5FC + FLU versus two weeks of AmBd + 5FC
Outcome: 1 Mortality
Study or subgroup 5FC+FLU AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 41/225 24/115 100.0 % 0.87 [ 0.56, 1.37 ]
Subtotal (95% CI) 225 115 100.0 % 0.87 [ 0.56, 1.37 ]
Total events: 41 (5FC+FLU), 24 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.56)
2 10 weeks
Molloy 2018 79/225 44/115 100.0 % 0.92 [ 0.69, 1.23 ]
Subtotal (95% CI) 225 115 100.0 % 0.92 [ 0.69, 1.23 ]
Total events: 79 (5FC+FLU), 44 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
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Analysis 5.2. Comparison 5 Two weeks of 5FC + FLU versus two weeks of AmBd + 5FC, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 5 Two weeks of 5FC + FLU versus two weeks of AmBd + 5FC
Outcome: 2 Early fungicidal activity
Study or subgroup 5FC+FLU AmBd+5FC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 182 -0.26 (0.18) 88 -0.49 (0.26) 100.0 % 0.23 [ 0.17, 0.29 ]
Total (95% CI) 182 88 100.0 % 0.23 [ 0.17, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.48 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.3. Comparison 5 Two weeks of 5FC + FLU versus two weeks of AmBd + 5FC, Outcome 3 DAIDS
grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 5 Two weeks of 5FC + FLU versus two weeks of AmBd + 5FC
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup 5FC+FLU AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 11/225 33/115 100.0 % 0.17 [ 0.09, 0.32 ]
Subtotal (95% CI) 225 115 100.0 % 0.17 [ 0.09, 0.32 ]
Total events: 11 (5FC+FLU), 33 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 5.38 (P < 0.00001)
2 Renal dysfunction
Molloy 2018 11/225 7/115 100.0 % 0.80 [ 0.32, 2.02 ]
Subtotal (95% CI) 225 115 100.0 % 0.80 [ 0.32, 2.02 ]
Total events: 11 (5FC+FLU), 7 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Neutropenia
Molloy 2018 23/225 12/115 100.0 % 0.98 [ 0.51, 1.90 ]
Subtotal (95% CI) 225 115 100.0 % 0.98 [ 0.51, 1.90 ]
Total events: 23 (5FC+FLU), 12 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
4 Hypokalaemia
Molloy 2018 3/225 7/115 100.0 % 0.22 [ 0.06, 0.83 ]
Subtotal (95% CI) 225 115 100.0 % 0.22 [ 0.06, 0.83 ]
Total events: 3 (5FC+FLU), 7 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.026)
5 ALT abnormality
Molloy 2018 6/225 2/115 100.0 % 1.53 [ 0.31, 7.48 ]
Subtotal (95% CI) 225 115 100.0 % 1.53 [ 0.31, 7.48 ]
Total events: 6 (5FC+FLU), 2 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 6.1. Comparison 6 Two weeks of 5FC + FLU versus two weeks of AmBd + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 6 Two weeks of 5FC + FLU versus two weeks of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup 5FC+FLU AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 41/225 25/114 100.0 % 0.83 [ 0.53, 1.29 ]
Subtotal (95% CI) 225 114 100.0 % 0.83 [ 0.53, 1.29 ]
Total events: 41 (5FC+FLU), 25 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
2 10 weeks
Molloy 2018 79/225 47/114 100.0 % 0.85 [ 0.64, 1.13 ]
Subtotal (95% CI) 225 114 100.0 % 0.85 [ 0.64, 1.13 ]
Total events: 79 (5FC+FLU), 47 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
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Analysis 6.2. Comparison 6 Two weeks of 5FC + FLU versus two weeks of AmBd + FLU, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 6 Two weeks of 5FC + FLU versus two weeks of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup 5FC+FLU AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 182 -0.26 (0.18) 94 -0.37 (0.24) 100.0 % 0.11 [ 0.05, 0.17 ]
Total (95% CI) 182 94 100.0 % 0.11 [ 0.05, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.91 (P = 0.000092)
Test for subgroup differences: Not applicable
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Analysis 6.3. Comparison 6 Two weeks of 5FC + FLU versus two weeks of AmBd + FLU, Outcome 3 DAIDS
grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 6 Two weeks of 5FC + FLU versus two weeks of AmBd + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup 5FC+FLU AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 11/225 28/114 100.0 % 0.20 [ 0.10, 0.39 ]
Subtotal (95% CI) 225 114 100.0 % 0.20 [ 0.10, 0.39 ]
Total events: 11 (5FC+FLU), 28 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 4.79 (P < 0.00001)
2 Renal dysfunction
Molloy 2018 11/225 14/114 100.0 % 0.40 [ 0.19, 0.85 ]
Subtotal (95% CI) 225 114 100.0 % 0.40 [ 0.19, 0.85 ]
Total events: 11 (5FC+FLU), 14 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
3 Neutropenia
Molloy 2018 23/225 10/114 100.0 % 1.17 [ 0.57, 2.36 ]
Subtotal (95% CI) 225 114 100.0 % 1.17 [ 0.57, 2.36 ]
Total events: 23 (5FC+FLU), 10 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
4 Hypokalaemia
Molloy 2018 3/225 9/114 100.0 % 0.17 [ 0.05, 0.61 ]
Subtotal (95% CI) 225 114 100.0 % 0.17 [ 0.05, 0.61 ]
Total events: 3 (5FC+FLU), 9 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0068)
5 ALT abnormality
Molloy 2018 6/225 6/114 100.0 % 0.51 [ 0.17, 1.54 ]
Subtotal (95% CI) 225 114 100.0 % 0.51 [ 0.17, 1.54 ]
Total events: 6 (5FC+FLU), 6 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
0.01 0.1 1 10 100
Favours 5FC+FLU Favours AmBd+FLU
105Treatment for HIV-associated cryptococcal meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 7.1. Comparison 7 Two weeks of AmBd + 5FC versus two weeks of AmBd, Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 7 Two weeks of AmBd + 5FC versus two weeks of AmBd
Outcome: 1 Mortality
Study or subgroup AmBd +5FC AmBd Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Brouwer 2004 1/16 2/16 4.1 % 0.50 [ 0.05, 4.98 ]
Day 2013 15/100 25/99 64.8 % 0.59 [ 0.33, 1.06 ]
van der Horst 1997 10/179 11/202 31.1 % 1.03 [ 0.45, 2.36 ]
Subtotal (95% CI) 295 317 100.0 % 0.70 [ 0.44, 1.11 ]
Total events: 26 (AmBd +5FC), 38 (AmBd)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.21, df = 2 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
2 10 weeks
Brouwer 2004 1/16 3/16 2.9 % 0.33 [ 0.04, 2.87 ]
Day 2013 30/100 44/99 97.1 % 0.68 [ 0.47, 0.98 ]
Subtotal (95% CI) 116 115 100.0 % 0.66 [ 0.46, 0.95 ]
Total events: 31 (AmBd +5FC), 47 (AmBd)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
3 6 months
Day 2013 34/100 53/99 100.0 % 0.64 [ 0.46, 0.88 ]
Subtotal (95% CI) 100 99 100.0 % 0.64 [ 0.46, 0.88 ]
Total events: 34 (AmBd +5FC), 53 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0068)
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Analysis 7.2. Comparison 7 Two weeks of AmBd + 5FC versus two weeks of AmBd, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 7 Two weeks of AmBd + 5FC versus two weeks of AmBd
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd +5FC AmBd
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brouwer 2004 12 -0.54 (0.19) 14 -0.31 (0.18) 32.7 % -0.23 [ -0.37, -0.09 ]
Day 2013 100 -0.42 (0.1008) 99 -0.31 (0.1504) 67.3 % -0.11 [ -0.15, -0.07 ]
Total (95% CI) 112 113 100.0 % -0.15 [ -0.26, -0.04 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 2.65 (P = 0.0080)
Test for subgroup differences: Not applicable
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Analysis 7.3. Comparison 7 Two weeks of AmBd + 5FC versus two weeks of AmBd, Outcome 3 DAIDS
grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 7 Two weeks of AmBd + 5FC versus two weeks of AmBd
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup AmBd +5FC AmBd Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Day 2013 35/100 46/99 100.0 % 0.75 [ 0.54, 1.06 ]
Subtotal (95% CI) 100 99 100.0 % 0.75 [ 0.54, 1.06 ]
Total events: 35 (AmBd +5FC), 46 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 1.63 (P = 0.10)
2 Renal dysfunction
Day 2013 2/100 2/99 100.0 % 0.99 [ 0.14, 6.89 ]
Subtotal (95% CI) 100 99 100.0 % 0.99 [ 0.14, 6.89 ]
Total events: 2 (AmBd +5FC), 2 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
3 Neutropenia
Day 2013 9/100 2/99 100.0 % 4.46 [ 0.99, 20.10 ]
Subtotal (95% CI) 100 99 100.0 % 4.46 [ 0.99, 20.10 ]
Total events: 9 (AmBd +5FC), 2 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
4 Hypokalaemia
Day 2013 22/100 20/99 100.0 % 1.09 [ 0.64, 1.87 ]
Subtotal (95% CI) 100 99 100.0 % 1.09 [ 0.64, 1.87 ]
Total events: 22 (AmBd +5FC), 20 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
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Analysis 8.1. Comparison 8 Two weeks of AmBd + FLU versus two weeks of AmBd, Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 8 Two weeks of AmBd + FLU versus two weeks of AmBd
Outcome: 1 Mortality
Study or subgroup AmBd+FLU AmBd Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Brouwer 2004 5/16 2/16 17.6 % 2.50 [ 0.57, 11.05 ]
Day 2013 20/99 25/99 66.3 % 0.80 [ 0.48, 1.34 ]
Pappas 2009 3/96 3/45 16.2 % 0.47 [ 0.10, 2.23 ]
Subtotal (95% CI) 211 160 100.0 % 0.90 [ 0.45, 1.77 ]
Total events: 28 (AmBd+FLU), 30 (AmBd)
Heterogeneity: Tau2 = 0.11; Chi2 = 2.64, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.32 (P = 0.75)
2 10 weeks
Brouwer 2004 7/16 3/16 16.9 % 2.33 [ 0.73, 7.45 ]
Day 2013 33/99 44/99 56.7 % 0.75 [ 0.53, 1.07 ]
Pappas 2009 13/96 7/45 26.4 % 0.87 [ 0.37, 2.03 ]
Subtotal (95% CI) 211 160 100.0 % 0.94 [ 0.55, 1.62 ]
Total events: 53 (AmBd+FLU), 54 (AmBd)
Heterogeneity: Tau2 = 0.10; Chi2 = 3.39, df = 2 (P = 0.18); I2 =41%
Test for overall effect: Z = 0.21 (P = 0.84)
3 6 months
Day 2013 45/99 53/99 100.0 % 0.85 [ 0.64, 1.13 ]
Subtotal (95% CI) 99 99 100.0 % 0.85 [ 0.64, 1.13 ]
Total events: 45 (AmBd+FLU), 53 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
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Analysis 8.2. Comparison 8 Two weeks of AmBd + FLU versus two weeks of AmBd, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 8 Two weeks of AmBd + FLU versus two weeks of AmBd
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd+FLU AmBd
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brouwer 2004 11 -0.39 (0.15) 14 -0.31 (0.18) 8.9 % -0.08 [ -0.21, 0.05 ]
Day 2013 99 -0.32 (0.1003) 99 -0.31 (0.1504) 91.1 % -0.01 [ -0.05, 0.03 ]
Total (95% CI) 110 113 100.0 % -0.02 [ -0.06, 0.02 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 8.3. Comparison 8 Two weeks of AmBd + FLU versus two weeks of AmBd, Outcome 3 DAIDS
grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 8 Two weeks of AmBd + FLU versus two weeks of AmBd
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup AmBd+FLU AmBd Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Day 2013 29/99 46/99 100.0 % 0.63 [ 0.43, 0.91 ]
Subtotal (95% CI) 99 99 100.0 % 0.63 [ 0.43, 0.91 ]
Total events: 29 (AmBd+FLU), 46 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 2.43 (P = 0.015)
2 Renal dysfunction
Day 2013 2/99 2/99 100.0 % 1.00 [ 0.14, 6.96 ]
Subtotal (95% CI) 99 99 100.0 % 1.00 [ 0.14, 6.96 ]
Total events: 2 (AmBd+FLU), 2 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
3 Neutropenia
Day 2013 9/99 2/99 100.0 % 4.50 [ 1.00, 20.30 ]
Subtotal (95% CI) 99 99 100.0 % 4.50 [ 1.00, 20.30 ]
Total events: 9 (AmBd+FLU), 2 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
4 Hypokalaemia
Day 2013 13/99 20/99 100.0 % 0.65 [ 0.34, 1.23 ]
Subtotal (95% CI) 99 99 100.0 % 0.65 [ 0.34, 1.23 ]
Total events: 13 (AmBd+FLU), 20 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 9.1. Comparison 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup AmBd+5FC AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Brouwer 2004 1/15 5/16 3.4 % 0.21 [ 0.03, 1.62 ]
Day 2013 15/100 20/99 37.2 % 0.74 [ 0.40, 1.37 ]
Loyse 2012 1/21 8/58 3.4 % 0.35 [ 0.05, 2.60 ]
Molloy 2018 24/115 25/114 56.0 % 0.95 [ 0.58, 1.56 ]
Subtotal (95% CI) 251 287 100.0 % 0.80 [ 0.55, 1.16 ]
Total events: 41 (AmBd+5FC), 58 (AmBd+FLU)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.88, df = 3 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
2 10 weeks
Brouwer 2004 1/15 7/16 1.8 % 0.15 [ 0.02, 1.10 ]
Day 2013 30/100 33/99 35.3 % 0.90 [ 0.60, 1.35 ]
Loyse 2012 6/21 16/58 10.7 % 1.04 [ 0.47, 2.29 ]
Molloy 2018 44/115 47/114 52.2 % 0.93 [ 0.67, 1.28 ]
Subtotal (95% CI) 251 287 100.0 % 0.90 [ 0.69, 1.17 ]
Total events: 81 (AmBd+5FC), 103 (AmBd+FLU)
Heterogeneity: Tau2 = 0.01; Chi2 = 3.35, df = 3 (P = 0.34); I2 =10%
Test for overall effect: Z = 0.78 (P = 0.43)
3 6 months
Day 2013 34/100 45/99 100.0 % 0.75 [ 0.53, 1.06 ]
Subtotal (95% CI) 100 99 100.0 % 0.75 [ 0.53, 1.06 ]
Total events: 34 (AmBd+5FC), 45 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
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Analysis 9.2. Comparison 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd+5FC AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brouwer 2004 12 -0.54 (0.19) 11 -0.39 (0.15) 8.4 % -0.15 [ -0.29, -0.01 ]
Day 2013 100 -0.42 (0.1) 99 -0.32 (0.1) 50.8 % -0.10 [ -0.13, -0.07 ]
Loyse 2012 19 -0.41 (0.11) 51 -0.4 (0.26) 18.0 % -0.01 [ -0.10, 0.08 ]
Molloy 2018 88 -0.49 (0.26) 94 -0.37 (0.24) 22.8 % -0.12 [ -0.19, -0.05 ]
Total (95% CI) 219 255 100.0 % -0.09 [ -0.14, -0.05 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.84, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 4.19 (P = 0.000028)
Test for subgroup differences: Not applicable
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Analysis 9.3. Comparison 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU, Outcome 3
DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 9 Two weeks of AmBd + 5FC versus two weeks of AmBd + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup AmBd+5FC AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Day 2013 35/100 29/99 46.7 % 1.19 [ 0.80, 1.79 ]
Loyse 2012 6/21 15/58 11.9 % 1.10 [ 0.49, 2.47 ]
Molloy 2018 33/115 28/114 41.3 % 1.17 [ 0.76, 1.80 ]
Subtotal (95% CI) 236 271 100.0 % 1.17 [ 0.89, 1.55 ]
Total events: 74 (AmBd+5FC), 72 (AmBd+FLU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
2 Renal dysfunction
Day 2013 2/100 2/99 14.8 % 0.99 [ 0.14, 6.89 ]
Loyse 2012 2/21 7/58 25.0 % 0.79 [ 0.18, 3.50 ]
Molloy 2018 6/115 11/114 60.2 % 0.54 [ 0.21, 1.41 ]
Subtotal (95% CI) 236 271 100.0 % 0.65 [ 0.31, 1.37 ]
Total events: 10 (AmBd+5FC), 20 (AmBd+FLU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
3 Neutropenia
Day 2013 9/100 9/99 45.1 % 0.99 [ 0.41, 2.39 ]
Loyse 2012 0/21 0/58 Not estimable
Molloy 2018 12/115 10/114 54.9 % 1.19 [ 0.54, 2.64 ]
Subtotal (95% CI) 236 271 100.0 % 1.10 [ 0.61, 1.98 ]
Total events: 21 (AmBd+5FC), 19 (AmBd+FLU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
4 Hypokalaemia
Day 2013 22/100 13/99 61.0 % 1.68 [ 0.90, 3.14 ]
Loyse 2012 0/21 3/58 4.6 % 0.38 [ 0.02, 7.12 ]
Molloy 2018 7/115 9/114 34.4 % 0.77 [ 0.30, 2.00 ]
Subtotal (95% CI) 236 271 100.0 % 1.20 [ 0.63, 2.27 ]
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(. . . Continued)
Study or subgroup AmBd+5FC AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total events: 29 (AmBd+5FC), 25 (AmBd+FLU)
Heterogeneity: Tau2 = 0.07; Chi2 = 2.47, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.56 (P = 0.58)
5 ALT abnormality
Loyse 2012 0/21 0/58 Not estimable
Molloy 2018 2/115 6/114 100.0 % 0.33 [ 0.07, 1.60 ]
Subtotal (95% CI) 136 172 100.0 % 0.33 [ 0.07, 1.60 ]
Total events: 2 (AmBd+5FC), 6 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.37 (P = 0.17)
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Analysis 10.1. Comparison 10 Two weeks of AmBd + FLU + steroids versus two weeks of AmBd + FLU,
Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 10 Two weeks of AmBd + FLU + steroids versus two weeks of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup AmBd+FLU+steroids AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Beardsley 2016 39/224 47/226 100.0 % 0.84 [ 0.57, 1.23 ]
Subtotal (95% CI) 224 226 100.0 % 0.84 [ 0.57, 1.23 ]
Total events: 39 (AmBd+FLU+steroids), 47 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.36)
2 10 weeks
Beardsley 2016 106/224 93/226 100.0 % 1.15 [ 0.93, 1.42 ]
Subtotal (95% CI) 224 226 100.0 % 1.15 [ 0.93, 1.42 ]
Total events: 106 (AmBd+FLU+steroids), 93 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
3 6 months
Beardsley 2016 128/224 109/226 100.0 % 1.18 [ 0.99, 1.41 ]
Subtotal (95% CI) 224 226 100.0 % 1.18 [ 0.99, 1.41 ]
Total events: 128 (AmBd+FLU+steroids), 109 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.88 (P = 0.060)
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Analysis 10.2. Comparison 10 Two weeks of AmBd + FLU + steroids versus two weeks of AmBd + FLU,
Outcome 2 Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 10 Two weeks of AmBd + FLU + steroids versus two weeks of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd+FLU+steroids AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Beardsley 2016 224 -0.21 (0.2278) 226 -0.31 (0.2289) 100.0 % 0.10 [ 0.06, 0.14 ]
Total (95% CI) 224 226 100.0 % 0.10 [ 0.06, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.64 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 10.3. Comparison 10 Two weeks of AmBd + FLU + steroids versus two weeks of AmBd + FLU,
Outcome 3 DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 10 Two weeks of AmBd + FLU + steroids versus two weeks of AmBd + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup AmBd+FLU+steroids AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Beardsley 2016 120/224 112/226 100.0 % 1.08 [ 0.90, 1.29 ]
Subtotal (95% CI) 224 226 100.0 % 1.08 [ 0.90, 1.29 ]
Total events: 120 (AmBd+FLU+steroids), 112 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.39)
2 Renal dysfunction
Beardsley 2016 79/224 50/226 100.0 % 1.59 [ 1.18, 2.16 ]
Subtotal (95% CI) 224 226 100.0 % 1.59 [ 1.18, 2.16 ]
Total events: 79 (AmBd+FLU+steroids), 50 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
3 Neutropenia
Beardsley 2016 42/224 59/226 100.0 % 0.72 [ 0.51, 1.02 ]
Subtotal (95% CI) 224 226 100.0 % 0.72 [ 0.51, 1.02 ]
Total events: 42 (AmBd+FLU+steroids), 59 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.85 (P = 0.064)
4 Hypokalaemia
Beardsley 2016 108/224 132/226 100.0 % 0.83 [ 0.69, 0.98 ]
Subtotal (95% CI) 224 226 100.0 % 0.83 [ 0.69, 0.98 ]
Total events: 108 (AmBd+FLU+steroids), 132 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
5 ALT abnormality
Beardsley 2016 10/224 3/226 100.0 % 3.36 [ 0.94, 12.06 ]
Subtotal (95% CI) 224 226 100.0 % 3.36 [ 0.94, 12.06 ]
Total events: 10 (AmBd+FLU+steroids), 3 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.86 (P = 0.063)
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Analysis 11.1. Comparison 11 One week of AmBd + FLU versus two weeks of AmBd + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 11 One week of AmBd + FLU versus two weeks of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup short AmBd+FLU AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 36/111 25/114 100.0 % 1.48 [ 0.95, 2.29 ]
Subtotal (95% CI) 111 114 100.0 % 1.48 [ 0.95, 2.29 ]
Total events: 36 (short AmBd+FLU), 25 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.75 (P = 0.080)
2 10 weeks
Molloy 2018 54/111 47/114 100.0 % 1.18 [ 0.88, 1.58 ]
Subtotal (95% CI) 111 114 100.0 % 1.18 [ 0.88, 1.58 ]
Total events: 54 (short AmBd+FLU), 47 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
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Analysis 11.2. Comparison 11 One week of AmBd + FLU versus two weeks of AmBd + FLU, Outcome 2
Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 11 One week of AmBd + FLU versus two weeks of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup short AmBd+FLU AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 81 -0.36 (0.23) 94 -0.37 (0.24) 100.0 % 0.01 [ -0.06, 0.08 ]
Total (95% CI) 81 94 100.0 % 0.01 [ -0.06, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 11.3. Comparison 11 One week of AmBd + FLU versus two weeks of AmBd + FLU, Outcome 3
DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 11 One week of AmBd + FLU versus two weeks of AmBd + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short AmBd+FLU AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 24/111 28/114 100.0 % 0.88 [ 0.55, 1.42 ]
Subtotal (95% CI) 111 114 100.0 % 0.88 [ 0.55, 1.42 ]
Total events: 24 (short AmBd+FLU), 28 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
2 Renal dysfunction
Molloy 2018 11/111 14/114 100.0 % 0.81 [ 0.38, 1.70 ]
Subtotal (95% CI) 111 114 100.0 % 0.81 [ 0.38, 1.70 ]
Total events: 11 (short AmBd+FLU), 14 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
3 Neutropenia
Molloy 2018 7/111 10/114 100.0 % 0.72 [ 0.28, 1.82 ]
Subtotal (95% CI) 111 114 100.0 % 0.72 [ 0.28, 1.82 ]
Total events: 7 (short AmBd+FLU), 10 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.49)
4 Hypokalaemia
Molloy 2018 5/111 9/114 100.0 % 0.57 [ 0.20, 1.65 ]
Subtotal (95% CI) 111 114 100.0 % 0.57 [ 0.20, 1.65 ]
Total events: 5 (short AmBd+FLU), 9 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.04 (P = 0.30)
5 ALT abnormality
Molloy 2018 2/111 6/114 100.0 % 0.34 [ 0.07, 1.66 ]
Subtotal (95% CI) 111 114 100.0 % 0.34 [ 0.07, 1.66 ]
Total events: 2 (short AmBd+FLU), 6 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
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Analysis 12.1. Comparison 12 One week of AmBd + FLU versus two weeks of AmBd + 5FC, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 12 One week of AmBd + FLU versus two weeks of AmBd + 5FC
Outcome: 1 Mortality
Study or subgroup short AmBd+FLU AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 36/111 24/115 100.0 % 1.55 [ 1.00, 2.43 ]
Subtotal (95% CI) 111 115 100.0 % 1.55 [ 1.00, 2.43 ]
Total events: 36 (short AmBd+FLU), 24 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.053)
2 10 weeks
Molloy 2018 54/111 44/115 100.0 % 1.27 [ 0.94, 1.72 ]
Subtotal (95% CI) 111 115 100.0 % 1.27 [ 0.94, 1.72 ]
Total events: 54 (short AmBd+FLU), 44 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
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Analysis 12.2. Comparison 12 One week of AmBd + FLU versus two weeks of AmBd + 5FC, Outcome 2
Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 12 One week of AmBd + FLU versus two weeks of AmBd + 5FC
Outcome: 2 Early fungicidal activity
Study or subgroup short AmBd+FLU AmBd+5FC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 81 -0.36 (0.23) 88 -0.49 (0.26) 100.0 % 0.13 [ 0.06, 0.20 ]
Total (95% CI) 81 88 100.0 % 0.13 [ 0.06, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.45 (P = 0.00056)
Test for subgroup differences: Not applicable
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Analysis 12.3. Comparison 12 One week of AmBd + FLU versus two weeks of AmBd + 5FC, Outcome 3
DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 12 One week of AmBd + FLU versus two weeks of AmBd + 5FC
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short AmBd+FLU AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 24/111 33/115 100.0 % 0.75 [ 0.48, 1.19 ]
Subtotal (95% CI) 111 115 100.0 % 0.75 [ 0.48, 1.19 ]
Total events: 24 (short AmBd+FLU), 33 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
2 Renal dysfunction
Molloy 2018 11/111 7/115 100.0 % 1.63 [ 0.65, 4.05 ]
Subtotal (95% CI) 111 115 100.0 % 1.63 [ 0.65, 4.05 ]
Total events: 11 (short AmBd+FLU), 7 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
3 Neutropenia
Molloy 2018 7/111 12/115 100.0 % 0.60 [ 0.25, 1.48 ]
Subtotal (95% CI) 111 115 100.0 % 0.60 [ 0.25, 1.48 ]
Total events: 7 (short AmBd+FLU), 12 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
4 Hypokalaemia
Molloy 2018 5/111 7/115 100.0 % 0.74 [ 0.24, 2.26 ]
Subtotal (95% CI) 111 115 100.0 % 0.74 [ 0.24, 2.26 ]
Total events: 5 (short AmBd+FLU), 7 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
5 ALT abnormality
Molloy 2018 2/111 2/115 100.0 % 1.04 [ 0.15, 7.23 ]
Subtotal (95% CI) 111 115 100.0 % 1.04 [ 0.15, 7.23 ]
Total events: 2 (short AmBd+FLU), 2 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi2 = 2.84, df = 4 (P = 0.58), I2 =0.0%
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Analysis 13.1. Comparison 13 One week of AmBd + FLU versus two weeks of 5FC + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 13 One week of AmBd + FLU versus two weeks of 5FC + FLU
Outcome: 1 Mortality
Study or subgroup short AmBd+FLU 5FC+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Molloy 2018 36/111 41/225 100.0 % 1.78 [ 1.21, 2.62 ]
Subtotal (95% CI) 111 225 100.0 % 1.78 [ 1.21, 2.62 ]
Total events: 36 (short AmBd+FLU), 41 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.93 (P = 0.0034)
2 10 weeks
Molloy 2018 54/111 79/225 100.0 % 1.39 [ 1.07, 1.80 ]
Subtotal (95% CI) 111 225 100.0 % 1.39 [ 1.07, 1.80 ]
Total events: 54 (short AmBd+FLU), 79 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
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Analysis 13.2. Comparison 13 One week of AmBd + FLU versus two weeks of 5FC + FLU, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 13 One week of AmBd + FLU versus two weeks of 5FC + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup short AmBd+FLU 5FC+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Molloy 2018 81 -0.36 (0.23) 182 -0.26 (0.18) 100.0 % -0.10 [ -0.16, -0.04 ]
Total (95% CI) 81 182 100.0 % -0.10 [ -0.16, -0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.47 (P = 0.00052)
Test for subgroup differences: Not applicable
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Analysis 13.3. Comparison 13 One week of AmBd + FLU versus two weeks of 5FC + FLU, Outcome 3
DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 13 One week of AmBd + FLU versus two weeks of 5FC + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short AmBd+FLU 5FC+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Molloy 2018 24/111 11/225 100.0 % 4.42 [ 2.25, 8.70 ]
Subtotal (95% CI) 111 225 100.0 % 4.42 [ 2.25, 8.70 ]
Total events: 24 (short AmBd+FLU), 11 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 4.31 (P = 0.000017)
2 Renal dysfunction
Molloy 2018 11/111 11/225 100.0 % 2.03 [ 0.91, 4.53 ]
Subtotal (95% CI) 111 225 100.0 % 2.03 [ 0.91, 4.53 ]
Total events: 11 (short AmBd+FLU), 11 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
3 Neutropenia
Molloy 2018 7/111 23/225 100.0 % 0.62 [ 0.27, 1.39 ]
Subtotal (95% CI) 111 225 100.0 % 0.62 [ 0.27, 1.39 ]
Total events: 7 (short AmBd+FLU), 23 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
4 Hypokalaemia
Molloy 2018 5/111 3/225 100.0 % 3.38 [ 0.82, 13.88 ]
Subtotal (95% CI) 111 225 100.0 % 3.38 [ 0.82, 13.88 ]
Total events: 5 (short AmBd+FLU), 3 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
5 ALT abnormality
Molloy 2018 2/111 6/225 100.0 % 0.68 [ 0.14, 3.29 ]
Subtotal (95% CI) 111 225 100.0 % 0.68 [ 0.14, 3.29 ]
Total events: 2 (short AmBd+FLU), 6 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.63)
0.01 0.1 1 10 100
Favours short AmBd+FLU Favours 5FC+FLU
127Treatment for HIV-associated cryptococcal meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Analysis 14.1. Comparison 14 Two weeks of FLU versus two weeks of 5FC + FLU, Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 14 Two weeks of FLU versus two weeks of 5FC + FLU
Outcome: 1 Mortality
Study or subgroup FLU 5FC+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Mayanja-Kizza 1998 10/28 4/30 65.9 % 2.68 [ 0.95, 7.57 ]
Nussbaum 2010 7/19 2/21 34.1 % 3.87 [ 0.91, 16.39 ]
Subtotal (95% CI) 47 51 100.0 % 3.04 [ 1.31, 7.06 ]
Total events: 17 (FLU), 6 (5FC+FLU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.0098)
2 10 weeks
Mayanja-Kizza 1998 16/28 11/30 54.7 % 1.56 [ 0.88, 2.75 ]
Nussbaum 2010 11/19 9/21 45.3 % 1.35 [ 0.72, 2.52 ]
Subtotal (95% CI) 47 51 100.0 % 1.46 [ 0.96, 2.23 ]
Total events: 27 (FLU), 20 (5FC+FLU)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
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Analysis 14.2. Comparison 14 Two weeks of FLU versus two weeks of 5FC + FLU, Outcome 2 Early
fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 14 Two weeks of FLU versus two weeks of 5FC + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup FLU 5FC+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nussbaum 2010 17 -0.11 (0.095) 20 -0.28 (0.17) 100.0 % 0.17 [ 0.08, 0.26 ]
Total (95% CI) 17 20 100.0 % 0.17 [ 0.08, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.82 (P = 0.00013)
Test for subgroup differences: Not applicable
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Analysis 14.3. Comparison 14 Two weeks of FLU versus two weeks of 5FC + FLU, Outcome 3 DAIDS grade
3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 14 Two weeks of FLU versus two weeks of 5FC + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup FLU 5FC+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Nussbaum 2010 1/19 1/21 100.0 % 1.11 [ 0.07, 16.47 ]
Subtotal (95% CI) 19 21 100.0 % 1.11 [ 0.07, 16.47 ]
Total events: 1 (FLU), 1 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.94)
2 Renal dysfunction
Nussbaum 2010 2/19 1/21 100.0 % 2.21 [ 0.22, 22.47 ]
Subtotal (95% CI) 19 21 100.0 % 2.21 [ 0.22, 22.47 ]
Total events: 2 (FLU), 1 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 Neutropenia
Nussbaum 2010 1/19 5/21 100.0 % 0.22 [ 0.03, 1.73 ]
Subtotal (95% CI) 19 21 100.0 % 0.22 [ 0.03, 1.73 ]
Total events: 1 (FLU), 5 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.44 (P = 0.15)
4 ALT abnormality
Nussbaum 2010 0/19 0/21 Not estimable
Subtotal (95% CI) 19 21 Not estimable
Total events: 0 (FLU), 0 (5FC+FLU)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.1. Comparison 15 Two weeks of L-AmB versus two weeks of AmBd, Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 15 Two weeks of L-AmB versus two weeks of AmBd
Outcome: 1 Mortality
Study or subgroup L-AmBd AmB Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Leenders 1997 0/15 0/13 Not estimable
Subtotal (95% CI) 15 13 Not estimable
Total events: 0 (L-AmBd), 0 (AmB)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 10 weeks
Leenders 1997 1/15 2/13 100.0 % 0.43 [ 0.04, 4.25 ]
Subtotal (95% CI) 15 13 100.0 % 0.43 [ 0.04, 4.25 ]
Total events: 1 (L-AmBd), 2 (AmB)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
3 6 months
Leenders 1997 2/15 3/13 100.0 % 0.58 [ 0.11, 2.94 ]
Subtotal (95% CI) 15 13 100.0 % 0.58 [ 0.11, 2.94 ]
Total events: 2 (L-AmBd), 3 (AmB)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 16.1. Comparison 16 Short-course L-AmB + FLU versus two weeks of L-AmB + FLU, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 16 Short-course L-AmB + FLU versus two weeks of L-AmB + FLU
Outcome: 1 Mortality
Study or subgroup short L-Amb+FLU L-AmB+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Jarvis 2018 10/58 2/21 100.0 % 1.81 [ 0.43, 7.59 ]
Subtotal (95% CI) 58 21 100.0 % 1.81 [ 0.43, 7.59 ]
Total events: 10 (short L-Amb+FLU), 2 (L-AmB+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 10 weeks
Jarvis 2018 17/58 6/21 100.0 % 1.03 [ 0.47, 2.25 ]
Subtotal (95% CI) 58 21 100.0 % 1.03 [ 0.47, 2.25 ]
Total events: 17 (short L-Amb+FLU), 6 (L-AmB+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
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Analysis 16.2. Comparison 16 Short-course L-AmB + FLU versus two weeks of L-AmB + FLU, Outcome 2
Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 16 Short-course L-AmB + FLU versus two weeks of L-AmB + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup short L-Amb+FLU L-AmB+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jarvis 2018 50 -0.51 (0.35) 17 -0.41 (0.11) 100.0 % -0.10 [ -0.21, 0.01 ]
Total (95% CI) 50 17 100.0 % -0.10 [ -0.21, 0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
Test for subgroup differences: Not applicable
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Analysis 16.3. Comparison 16 Short-course L-AmB + FLU versus two weeks of L-AmB + FLU, Outcome 3
DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 16 Short-course L-AmB + FLU versus two weeks of L-AmB + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup short L-Amb+FLU L-AmB+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Jarvis 2018 5/58 1/21 100.0 % 1.81 [ 0.22, 14.61 ]
Subtotal (95% CI) 58 21 100.0 % 1.81 [ 0.22, 14.61 ]
Total events: 5 (short L-Amb+FLU), 1 (L-AmB+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
2 Renal dysfunction
Jarvis 2018 5/58 0/21 100.0 % 4.10 [ 0.24, 71.15 ]
Subtotal (95% CI) 58 21 100.0 % 4.10 [ 0.24, 71.15 ]
Total events: 5 (short L-Amb+FLU), 0 (L-AmB+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
3 Neutropenia
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (short L-Amb+FLU), 0 (L-AmB+FLU)
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Hypokalaemia
Jarvis 2018 1/58 5/21 100.0 % 0.07 [ 0.01, 0.58 ]
Subtotal (95% CI) 58 21 100.0 % 0.07 [ 0.01, 0.58 ]
Total events: 1 (short L-Amb+FLU), 5 (L-AmB+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
5 ALT abnormality
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (short L-Amb+FLU), 0 (L-AmB+FLU)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 17.1. Comparison 17 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + 5FC,
Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 17 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + 5FC
Outcome: 1 Mortality
Study or subgroup AmBd+5FC+FLU AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Brouwer 2004 1/16 1/15 100.0 % 0.94 [ 0.06, 13.68 ]
Subtotal (95% CI) 16 15 100.0 % 0.94 [ 0.06, 13.68 ]
Total events: 1 (AmBd+5FC+FLU), 1 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 10 weeks
Brouwer 2004 3/16 1/15 100.0 % 2.81 [ 0.33, 24.16 ]
Subtotal (95% CI) 16 15 100.0 % 2.81 [ 0.33, 24.16 ]
Total events: 3 (AmBd+5FC+FLU), 1 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 17.2. Comparison 17 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + 5FC,
Outcome 2 Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 17 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + 5FC
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd+5FC+FLU AmBd+5FC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brouwer 2004 15 -0.38 (0.13) 12 -0.54 (0.19) 100.0 % 0.16 [ 0.03, 0.29 ]
Total (95% CI) 15 12 100.0 % 0.16 [ 0.03, 0.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
Test for subgroup differences: Not applicable
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Analysis 18.1. Comparison 18 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + FLU,
Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 18 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup AmBd+5FC+FLU AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Brouwer 2004 1/16 5/16 100.0 % 0.20 [ 0.03, 1.53 ]
Subtotal (95% CI) 16 16 100.0 % 0.20 [ 0.03, 1.53 ]
Total events: 1 (AmBd+5FC+FLU), 5 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
2 10 weeks
Brouwer 2004 3/16 7/16 100.0 % 0.43 [ 0.13, 1.37 ]
Subtotal (95% CI) 16 16 100.0 % 0.43 [ 0.13, 1.37 ]
Total events: 3 (AmBd+5FC+FLU), 7 (AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
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Analysis 18.2. Comparison 18 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + FLU,
Outcome 2 Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 18 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd+5FC+FLU AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brouwer 2004 15 -0.38 (0.13) 11 -0.39 (0.15) 100.0 % 0.01 [ -0.10, 0.12 ]
Total (95% CI) 15 11 100.0 % 0.01 [ -0.10, 0.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
Test for subgroup differences: Not applicable
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Analysis 19.1. Comparison 19 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd, Outcome 1
Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 19 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd
Outcome: 1 Mortality
Study or subgroup AmBd+5FC+FLU AmBd Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Brouwer 2004 1/16 2/16 100.0 % 0.50 [ 0.05, 4.98 ]
Subtotal (95% CI) 16 16 100.0 % 0.50 [ 0.05, 4.98 ]
Total events: 1 (AmBd+5FC+FLU), 2 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 10 weeks
Brouwer 2004 3/16 3/16 100.0 % 1.00 [ 0.24, 4.23 ]
Subtotal (95% CI) 16 16 100.0 % 1.00 [ 0.24, 4.23 ]
Total events: 3 (AmBd+5FC+FLU), 3 (AmBd)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 19.2. Comparison 19 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd, Outcome 2
Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 19 Two weeks of AmBd + 5FC + FLU versus two weeks of AmBd
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd+5FC+FLU AmBd
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brouwer 2004 15 -0.38 (0.13) 14 -0.31 (0.18) 100.0 % -0.07 [ -0.18, 0.04 ]
Total (95% CI) 15 14 100.0 % -0.07 [ -0.18, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
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Analysis 20.1. Comparison 20 One week of AmBd + 5FC + FLU versus one week of AmBd + FLU, Outcome
1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 20 One week of AmBd + 5FC + FLU versus one week of AmBd + FLU
Outcome: 1 Mortality
Study or subgroup
short
AmBd+5FC+FLU short AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Jackson 2012 2/20 4/20 100.0 % 0.50 [ 0.10, 2.43 ]
Subtotal (95% CI) 20 20 100.0 % 0.50 [ 0.10, 2.43 ]
Total events: 2 (short AmBd+5FC+FLU), 4 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
2 10 weeks
Jackson 2012 6/20 7/20 100.0 % 0.86 [ 0.35, 2.10 ]
Subtotal (95% CI) 20 20 100.0 % 0.86 [ 0.35, 2.10 ]
Total events: 6 (short AmBd+5FC+FLU), 7 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
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Analysis 20.2. Comparison 20 One week of AmBd + 5FC + FLU versus one week of AmBd + FLU, Outcome
2 Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 20 One week of AmBd + 5FC + FLU versus one week of AmBd + FLU
Outcome: 2 Early fungicidal activity
Study or subgroup
short
AmBd+5FC+FLU short AmBd+FLU
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jackson 2012 18 -0.5 (0.15) 19 -0.38 (0.19) 100.0 % -0.12 [ -0.23, -0.01 ]
Total (95% CI) 18 19 100.0 % -0.12 [ -0.23, -0.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.14 (P = 0.033)
Test for subgroup differences: Not applicable
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Analysis 20.3. Comparison 20 One week of AmBd + 5FC + FLU versus one week of AmBd + FLU, Outcome
3 DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 20 One week of AmBd + 5FC + FLU versus one week of AmBd + FLU
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup
short
AmBd+5FC+FLU short AmBd+FLU Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Jackson 2012 4/20 7/20 100.0 % 0.57 [ 0.20, 1.65 ]
Subtotal (95% CI) 20 20 100.0 % 0.57 [ 0.20, 1.65 ]
Total events: 4 (short AmBd+5FC+FLU), 7 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
2 Renal dysfunction
Jackson 2012 4/20 5/20 100.0 % 0.80 [ 0.25, 2.55 ]
Subtotal (95% CI) 20 20 100.0 % 0.80 [ 0.25, 2.55 ]
Total events: 4 (short AmBd+5FC+FLU), 5 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
3 Neutropenia
Jackson 2012 5/20 4/20 100.0 % 1.25 [ 0.39, 3.99 ]
Subtotal (95% CI) 20 20 100.0 % 1.25 [ 0.39, 3.99 ]
Total events: 5 (short AmBd+5FC+FLU), 4 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.71)
4 Hypokalaemia
Jackson 2012 2/20 3/20 100.0 % 0.67 [ 0.12, 3.57 ]
Subtotal (95% CI) 20 20 100.0 % 0.67 [ 0.12, 3.57 ]
Total events: 2 (short AmBd+5FC+FLU), 3 (short AmBd+FLU)
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
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Analysis 21.1. Comparison 21 Two weeks of AmBd + 5FC + IFNg versus two weeks of AmBd + 5FC,
Outcome 1 Mortality.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 21 Two weeks of AmBd + 5FC + IFNg versus two weeks of AmBd + 5FC
Outcome: 1 Mortality
Study or subgroup AmBd+5FC+IFNg AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 2 weeks
Jarvis 2012 8/57 6/31 100.0 % 0.73 [ 0.28, 1.90 ]
Subtotal (95% CI) 57 31 100.0 % 0.73 [ 0.28, 1.90 ]
Total events: 8 (AmBd+5FC+IFNg), 6 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
2 10 weeks
Jarvis 2012 17/57 10/31 100.0 % 0.92 [ 0.48, 1.77 ]
Subtotal (95% CI) 57 31 100.0 % 0.92 [ 0.48, 1.77 ]
Total events: 17 (AmBd+5FC+IFNg), 10 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
0.2 0.5 1 2 5
Favours AmBd+5FC+IFNg Favours AmBd+5FC
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Analysis 21.2. Comparison 21 Two weeks of AmBd + 5FC + IFNg versus two weeks of AmBd + 5FC,
Outcome 2 Early fungicidal activity.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 21 Two weeks of AmBd + 5FC + IFNg versus two weeks of AmBd + 5FC
Outcome: 2 Early fungicidal activity
Study or subgroup AmBd+5FC+IFNg AmBd+5FC
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Jarvis 2012 57 -0.64 (0.24) 31 -0.49 (0.17) 100.0 % -0.15 [ -0.24, -0.06 ]
Total (95% CI) 57 31 100.0 % -0.15 [ -0.24, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.40 (P = 0.00067)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
Favours AmBd+5FC+IFNg Favours AmBd+5FC
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Analysis 21.3. Comparison 21 Two weeks of AmBd + 5FC + IFNg versus two weeks of AmBd + 5FC,
Outcome 3 DAIDS grade 3/4 toxicities.
Review: Treatment for HIV-associated cryptococcal meningitis
Comparison: 21 Two weeks of AmBd + 5FC + IFNg versus two weeks of AmBd + 5FC
Outcome: 3 DAIDS grade 3/4 toxicities
Study or subgroup AmBd+5FC+IFNg AmBd+5FC Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Anaemia
Jarvis 2012 21/57 10/31 100.0 % 1.14 [ 0.62, 2.11 ]
Subtotal (95% CI) 57 31 100.0 % 1.14 [ 0.62, 2.11 ]
Total events: 21 (AmBd+5FC+IFNg), 10 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
2 Renal dysfunction
Jarvis 2012 11/57 7/31 100.0 % 0.85 [ 0.37, 1.98 ]
Subtotal (95% CI) 57 31 100.0 % 0.85 [ 0.37, 1.98 ]
Total events: 11 (AmBd+5FC+IFNg), 7 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
3 Neutropenia
Jarvis 2012 5/57 2/31 100.0 % 1.36 [ 0.28, 6.60 ]
Subtotal (95% CI) 57 31 100.0 % 1.36 [ 0.28, 6.60 ]
Total events: 5 (AmBd+5FC+IFNg), 2 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.38 (P = 0.70)
4 Hypokalaemia
Jarvis 2012 3/57 0/31 100.0 % 3.86 [ 0.21, 72.44 ]
Subtotal (95% CI) 57 31 100.0 % 3.86 [ 0.21, 72.44 ]
Total events: 3 (AmBd+5FC+IFNg), 0 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
5 ALT abnormality
Jarvis 2012 0/57 0/31 Not estimable
Subtotal (95% CI) 57 31 Not estimable
Total events: 0 (AmBd+5FC+IFNg), 0 (AmBd+5FC)
Heterogeneity: not applicable
Test for overall effect: not applicable
0.01 0.1 1 10 100
Favours AmBd+5FC+IFNg Favours AmBd+5FC
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A D D I T I O N A L T A B L E S
Table 1. Overview of drugs evaluated for the treatment of HIV-associated cryptococcal meningitis
Class Mechanism of action Drug examples for cryptococ-
cal meningitis therapy
Major class side effects
Polyenes Disrupt cell membranes Amphotericin B (liposomal or
non-liposomal formulations)
Nephrotoxicity, electrolyte ab-
normalities, anaemia
Azoles Inhibit ergosterol biosynthesis Fluconazole, voriconazole, itra-
conazole
Hepatotoxicity, drug-drug in-
teractions, GI symptoms, rash
Pyrimidine analogue Inhibit fungal RNAandprotein
biosynthesis
Flucytosine Bone marrow suppression, hep-
atotoxicity, GI symptoms
Glucocorticoids Various anti-inflammatory ef-
fects
Dexamethasone Hyperglycaemia, bleeding, psy-
chiatric effects, secondary hy-
poaldosteronism, immunosup-
pression
Selective serotonin reuptake in-
hibitor (SSRI)
5-hydroxytryptamine
transporter inhibitor, antifun-
gal mechanism of action un-
clear
Sertraline Neurocognitive effects, GI
symptoms
Carbonic anhydrase inhibitor Reduces in-
tracranial pressure by reducing
cerebrospinal fluid production,
likely through multiple mecha-
nisms
Acetazolamide Metabolic aci-
dosis, nephrolithiasis, aplastic
anaemia, GI symptoms, paraes-
thesias
Abbreviations: GI: gastrointestinal; RNA: ribonucleic acid
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A P P E N D I C E S
Appendix 1. Search strategy
PubMed
No. Query
#4 Search (#1 AND #2 AND #3)
#3 Search (Antifungal agents[mh] OR azole*[tiab] OR fluconazole[tiab] OR amphotericin[tiab] OR flucytosine[tiab] OR sertra-
line[tiab] OR dexamethasone[tiab] OR voriconazole[tiab] OR acetazolamide[tiab] OR diflucan[tiab] OR itraconazole[tiab]
OR rifampin[tiab] OR 5-FC[tiab])
#2 Search (“Meningitis, Cryptococcal”[Mesh] OR cryptococcal meningitis[tiab] OR cryptococcal meningitis[tiab] OR crypto-
coccal meningitides[tiab] OR cerebral cryptococcosis[tiab] OR cerebral cryptococcoses[tiab] OR toruloma*[tiab] OR cryp-
tococcus neoforman[mh] OR cryptococcus neoforman[tiab] OR ((cryptococcal[tiab] OR cryptococcal[tiab] OR cyptococco-
sis[tiab] OR cryptococcoses[tiab] OR Cryptococcus[tiab]) AND (meningitis[tiab]))
#1 Search (HIV Infections[MeSH] ORHIV[MeSH] OR hiv[tiab] OR hiv-1*[tiab] OR hiv-2*[tiab] OR hiv1[tiab] OR hiv2[tiab]
ORhiv infect*[tiab] ORhuman immunodeficiency virus[tiab] ORhuman immunedeficiency virus[tiab] ORhuman immuno-
deficiency virus[tiab] OR human immune-deficiency virus[tiab] OR ((human immun*[tiab]) AND (deficiency virus[tiab])
) OR acquired immunodeficiency syndrome[tiab] OR acquired immunedeficiency syndrome[tiab] OR acquired immuno-
deficiency syndrome[tiab] OR acquired immune-deficiency syndrome[tiab] OR ((acquired immun*[tiab]) AND (deficiency
syndrome[tiab]))
Embase
No. Query
#11 #1 AND #7 AND #8 AND #9 AND [1980-2017]/py
#10 #1 AND #7 AND #8 AND #9
#9 ‘antifungal agent’/syn OR azole*:ab,ti OR fluconazole:ab,ti OR amphotericin:ab,ti OR flucytosine:ab,ti OR sertraline:ab,ti
OR dexamethasone:ab,ti OR voriconazole:ab,ti OR acetazolamide:ab,ti OR diflucan:ab,ti OR itraconazole:ab,ti OR rifampin:
ab,ti OR ‘5-fc’:ab,ti
#8 ‘cryptococcal meningitis’/de OR ‘cryptococcal meningitis’:ab,ti OR ‘cryptococcus meningitis’:ab,ti OR ‘cryptococcal menin-
gitis’:ab,ti OR ‘cryptococcal meningitides’:ab,ti OR ‘cerebral cryptococcosis’:ab,ti OR ‘cerebral cryptococcoses’:ab,ti OR toru-
loma*:ab,ti OR ‘cryptococcus neoforman’:ab,ti OR (cryptococcal:ab,ti OR cryptococcal:ab,ti OR cryptococcosis:ab,ti OR
cryptococcoses:ab,ti AND meningitis:ab,ti)
#7 #2 NOT #6
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(Continued)
#6 #3 NOT #5
#5 #3 AND #4
#4 ‘human’/de OR ‘normal human’/de OR ‘human cell’/de
#3 ‘animal’/de OR ‘animal experiment’/de OR ‘invertebrate’/de OR ‘animal tissue’/de OR ‘animal cell’/de OR ‘nonhuman’/de
#2 ‘randomised controlled trial’/deOR ‘randomised controlled trial’ OR random*:ab,tiOR trial:tiOR allocat*:ab,tiOR factorial*:
ab,ti OR placebo*:ab,ti OR assign*:ab,ti OR volunteer*:ab,ti OR ‘crossover procedure’/de OR ‘crossover procedure’ OR
‘double-blind procedure’/de OR ‘double-blind procedure’ OR ‘single-blind procedure’/de OR ‘single-blind procedure’ OR
(doubl* NEAR/3 blind*):ab,ti OR (singl*:ab,ti AND blind*:ab,ti) OR crossover*:ab,ti OR cross+over*:ab,ti OR (cross NEXT/
1 over*):ab,ti
#1 ‘human immunodeficiency virus infection’/expOR ‘human immunodeficiency virus infection’ OR ‘human immunodeficiency
virus’/exp OR ‘human immunodeficiency virus’ OR ‘human immunodeficiency virus’:ab,ti OR ‘human immuno+deficiency
virus’:ab,ti OR ‘human immunedeficiency virus’:ab,ti OR ‘human immune+deficiency virus’:ab,ti OR hiv:ab,ti OR ‘hiv-1’:
ab,ti OR ‘hiv-2’:ab,ti OR ‘acquired immunodeficiency syndrome’:ab,ti OR ‘acquired immuno+deficiency syndrome’:ab,ti OR
‘acquired immunedeficiency syndrome’:ab,ti OR ‘acquired immune+deficiency syndrome’:ab,ti
CENTRAL
ID Search
#1 MeSH descriptor: [HIV Infections] explode all trees
#2 MeSH descriptor: [HIV] explode all trees
#3 hiv or hiv-1* or hiv-2* or hiv1 or hiv2 or (hiv near infect*) or (human immunodeficiency virus) or (human immunedeficiency
virus) or (human immune-deficiency virus) or (human immuno-deficiency virus) or (human immune deficiency virus) or (hu-
man immuno deficiency virus) or (acquired immunodeficiency syndrome) or (acquired immunedeficiency syndrome) or (ac-
quired immuno-deficiency syndrome) or (acquired immune-deficiency syndrome) or (acquired immun* deficiency syndrome)
#4 MeSH descriptor: [Lymphoma, AIDS-Related] this term only
#5 MeSH descriptor: [Sexually Transmitted Diseases, Viral] this term only
#6 #1 or #2 or #3 or #4 or #5
#7 [mh “meningitis, cryptococcal”] or “cryptococcal meningitis”:ti,ab,kw or “cryptococcal meningitis”:ti,ab,kw or “cryptococcal
meningitides”:ti,ab,kw or “cerebral cryptococcosis”:ti,ab,kw or “cerebral cryptococcoses”:ti,ab,kw or toruloma*:ti,ab,kw or
[mh “cryptococcus neoforman”] or “cryptococcus neoforman”:ti,ab,kw or ((cryptococcal:ti,ab,kw or cryptococcal:ti,ab,kw or
cyptococcosis:ti,ab,kw or cryptococcoses:ti,ab,kw or Cryptococcus:ti,ab,kw) and meningitis:ti,ab,kw) (Word variations have
been searched)
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(Continued)
#8 [mh “antifungal agents”] or azole*:ti,ab,kw or fluconazole:ti,ab,kw or amphotericin:ti,ab,kw or flucytosine:ti,ab,kw or sertraline:
ti,ab,kw or dexamethasone:ti,ab,kw or voriconazole:ti,ab,kw or acetazolamide:ti,ab,kw or diflucan:ti,ab,kw or itraconazole:ti,
ab,kw or rifampin:ti,ab,kw or “5-FC”:ti,ab,kw (Word variations have been searched)
#9 #6 and #7 and #8 in Trials
LILACS, IMSEAR, African Medicus Index
cryptococc$ [Words] and meningitis or brain or menin$ [Words] and randomised or trial or controlled or placebo or double-blind$
or single-blind$ [Words]
Appendix 2. Sample study eligibility form
Review title Treatment of HIV-associated cryptococcal meningitis
Reviewer ID
Study ID (first author sur-
name and year of publication)
Study characteristics Review inclusion criteria Yes/No/Unclear Location in text
(pg & ¶/fig/table)
1. Type of study Randomized trial
Non-randomized trial
Cohort study
Quasi-experimental study
Other design (specify):
2. Participants HIV-
infected with initial episode of
cryptococcal meningitis?
3. Diagnosis Diagnosis confirmed by CSF
India ink stain, fungal culture,
or CrAg testing?
4. Types of intervention Two or more treatments com-
pared?
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(Continued)
5. Types of outcome measures Included mortality, safety, or
microbiological outcome(s)?
6. Decision: (For inclusion, must answer
YES for RCT for item 1 and
YES for items 2-6)
7. Reason for exclusion
8. Notes:
Appendix 3. Data extraction form
Methods Study design:
Randomization method:
Blinding:
Participants Country/countries:
Inclusion criteria:
Exclusion criteria:
Number of participants:
Number dropped out:
Age:
Gender:
Number on ART:
Baseline CD4 count:
Baseline Glasgow coma scale (GCS) score or altered mental status:
Intervention For each intervention group
Specific intervention
• Number of participants:
• Drug(s) and dose(s):
• Duration of induction therapy:
• Maintenance therapy and duration:
General to all intervention groups
Protocol for LP after diagnostic LP:
Toxicity monitoring:
ART started after initiation of treatment for CM:
Timing of ART initiation:
Outcomes Intention-to-treat or per-protocol outcomes:
Mortality
• Up to two weeks:
• Up to 10 weeks:
• Up to six months:
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(Continued)
Early fungicidal activity:
Serious adverse events:
Missing participant data:
Notes Years study conducted:
Sources of funding:
Conflicts of interest:
Potentially relevant studies in references:
WH A T ’ S N E W
Last assessed as up-to-date: 9 July 2018.
Date Event Description
24 July 2018 New search has been performed This is an update of a review last published in 2011 (Sloan
2011). The review author team updated the protocol ex-
tensively, and differences are highlighted in the ‘Differences
between protocol and review’ section.
24 July 2018 New citation required and conclusions have changed We included 13 eligible studies that enrolled 2426 partici-
pants and compared 21 interventions. Using random-effects
models we determined pooled risk ratio (RR) and 95% con-
fidence interval (CI) for dichotomous outcomes and mean
differences (MD) and 95% CI for continuous outcomes. We
performed a network meta-analysis using multivariate meta-
regression. We modelled treatment differences (RR and 95%
CI) and determined treatment rankings for two-week and
10-week mortality outcomes using surface under the cumu-
lative ranking curve (SUCRA). We assessed the certainty of
the evidence using the GRADE approach
C O N T R I B U T I O N S O F A U T H O R S
Mark W Tenforde contributed to study design and protocol writing, performed literature reviews and data extraction, data analysis
and interpretation, and wrote the first draft of the manuscript.
Adrienne E Shapiro contributed to study design and protocol writing, performed literature reviews and data extraction, and provided
input on the manuscript.
Benjamin Rouse contributed to study design and protocol writing, performed data analysis for the network meta-analysis, and provided
input on the manuscript.
Joseph N Jarvis provided data interpretation and collection and provided input on the manuscript.
Tianjing Li contributed to study design, supervised data analysis for the network meta-analysis, and provided input on the manuscript.
152Treatment for HIV-associated cryptococcal meningitis (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Ingrid Eshun-Wilson contributed to study design, data interpretation, and provided input on the manuscript.
Nathan Ford contributed to study design and protocol writing, data and interpretation, and and provided input on the manuscript.
D E C L A R A T I O N S O F I N T E R E S T
Mark W Tenforde declares no relevant conflicts of interest.
Adrienne E Shapiro has received salary compensation from the University of Washington, as a trainee postdoctoral fellow in Infectious
Diseases. A portion of the salary derives from an NIH T32 training grant.
Benjamin Rouse declares no relevant conflicts of interest.
Joseph N Jarvis has been an investigator in several clinical trials of therapies for HIV-associated cryptococcal meningitis. He has
previously received grant support through his institution from Gilead Sciences Europe (investigator initiated award for the Ambition
Phase II Trial)
Tianjing Li declares no relevant conflicts of interest.
Ingrid Eshun-Wilson declares no relevant conflicts of interest.
Nathan Ford declares no relevant conflicts of interest.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development, UK.
Grant: 5242
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is an update of a published Cochrane review (Sloan 2011). The new review author team extensively revised the protocol, which
is available on the CIDG website at cidg.cochrane.org/our-reviews under the subheading ‘Related content’.
Differences between the revised protocol (10 August 2017) and review update
Types of studies
The protocol stated that, in addition to comparing different treatment regimens, we would also make comparisons between different
doses of a single agent or the same induction therapywith different timing of antiretroviral therapy.However, as timing of ART initiation
for HIV-associated cryptococcal meningitis is a distinct clinical question, we excluded studies on timing of ART from our review
(Makadzange 2010; Bisson 2013; Boulware 2014b). Additionally, we excluded one RCT that compared different doses of amphotericin
B deoxycholate (0.7 mg/kg/day or 1 mg/kg/day) with flucytosine, as this RCT was not subject to analysis in either pairwise comparison
or NMA (Bicanic 2008).
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Types of participants
The protocol stated that studies with a significant amount of missing outcomes data would either be excluded or presented with
sensitivity analyses. Out of concern that participants lost to follow-up were not missing at random and were more likely to have died
compared to participants with complete follow-up, in the review we instead excluded any study with missing outcomes data within six
months on more than 20% of participants.
Methods
Secondary outcomes
For our secondary outcome of serious adverse events, the protocol did not provide the specific laboratory toxicities we would compare
between induction regimens. In the review, we limited these to common toxicities from antifungal therapies used for the treatment
of cryptococcal meningitis, including anaemia, renal dysfunction, neutropenia, hypokalaemia, and liver function test abnormalities
(specifically alanine aminotransferase).
Dealing with missing data
The protocol stated that we would perform sensitivity analyses for studies with significant missingness of outcomes data. Because we
believed that missingness of outcomes data was unlikely to be missing at random, we excluded any study with missing outcomes data
within six months on more than 20% of participants
Presentation of results
The protocol stated that we would perform GRADE assessments for pairwise meta-analysis and modified GRADE assessment for the
network meta-analysis but did not state at which mortality time point (2 weeks, 10 weeks, or 6 months) assessments would be made.
In the review, we limited GRADE assessment to 10-week mortality, as we believed this was the most clinically relevant time point,
and all included studies followed participants at both two-week and 10-week mortality endpoints (with 10-week mortality for one
study excluded due to secondary randomization after two weeks) (van der Horst 1997). Few studies followed participants up to six
months, so we did not perform GRADE assessment at this time point or six-month network meta-analysis due to the limited number
of network comparisons. Additionally, although not explicitly stated in the protocol, in the review we downgraded for imprecision
studies with fewer than 200 deaths overall in pairwise comparisons. Most studies were at high risk of performance and detection bias
according to the Cochrane ‘Risk of bias’ assessment. However, we decided not to downgrade studies in the GRADE risk of bias domain
for performance and detection bias, as we believed that our primary outcome of interest, death, was unlikely to be influenced by
performance or detection bias.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Acetazolamide [adverse effects]; Acute Disease; Amphotericin B [supply & distribution; therapeutic use]; Antifungal Agents [supply &
distribution; ∗therapeutic use]; Antihypertensive Agents [adverse effects]; Developing Countries; Fluconazole [supply & distribution;
therapeutic use]; Flucytosine [supply & distribution; therapeutic use]; HIV Infections [∗complications]; Health Resources [∗supply &
distribution]; Intracranial Hypertension [drug therapy]; Meningitis, Cryptococcal [∗drug therapy]
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MeSH check words
Adult; Humans
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